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Many nanomaterials have been synthesized and explored for 
potential use in consumer and medical products. Majority of the 
commercial products incorporated with nanomaterials exist in the 
areas of skin care and cosmetics, but interests of using 
nanomaterials in various applications related to electronics, food 
additives and biomedical products are increasing. The prevalent of 
nanomaterials applications has attracted researchers’ attention on 
their health and environmental safety concerns. Previous studies in 
nanotoxicology demonstrated adverse health effects of many 
nanomaterials. The toxicity of new nanomaterials could not be 
deduced from earlier knowledge and results, as small differences in 
composition and properties of nanomaterials could induce large 
changes in toxicity. Thus detailed studies of toxicity of all 
nanomaterials need to be carefully investigated and documented. 
In this thesis, we are focusing on the toxicity studies of two 
nanomaterials: silver (Ag) and gold (Au) nanoparticles. Particularly, 
Ag nanoparticles are incorporated in many commercial products 
such as sunscreens, cosmetics, wound dressings, surgical tools, 
detergents and automotive paints because of their antibacterial 
effects. Au nanoparticles have attracted significant scientific and 
technological interest owing to their ease of synthesis, chemical 
XIII 
 
stability and unique optical properties.  
In Chapter 1, a brief introduction is given to discuss the 
development of nanotechnology and its potential impact on health 
and environmental safety. In Chapter 2, the materials and methods 
used were discussed in detail. Nanomaterials used in this thesis 
were characterized with multiple different techniques.  
In Chapter 3, the cytotoxicity of Ag nanoparticles with plant 
extracts as capping agents was examined using human tumor cells. 
The results demonstrated that Ag nanoparticles with different 
capping agents induced different toxicities. In Chapter 4, 
shape-dependent toxicity of Ag nanoparticles in human skin 
fibroblast cells is discussed in detail. Ag nanocube, Ag truncated 
nanocube and Ag nanowire were used for the investigation. Among 
the three Ag nanomaterials, Ag nanocubes were the most toxic as 
compared to other particles, which could be attributed to their 
relatively sharp angles and high instability. The confocal 
microscope images showed that Ag nanomaterials penetrated inside 
the cytoplasm but not entered the nucleus of cells. In Chapter 5, 
shape-dependent toxicity of Au nanoplates (Au hexagon, Au 
pentagon and Au triangle) is discussed with details. Among three 
Au nanoplates investigated, Au triangle nanoplates were the most 
toxic. The relatively sharp angles and high surface potential energy 
XIV 
 
of Au triangle nanoplates enabled them to penetrate cell membrane 
more easily. Transmission electron microscope images of the thin 
section of cells indicated that Au nanomaterials were distributed in 
both cytoplasm and nucleus of cells.  
In Chapter 6, the cytotoxicity and genotoxicity of Ag and Au 
nanoparticles were explored using human colon cancer stem cells 
and embryonic stem cells. The results showed that Ag and Au 
nanoparticles did not cause cytotoxicity to colon cancer stem cells 
at low concentrations. Similarly, Ag nanoparticles did not cause 
adverse effect to both undifferentiated cells and differentiated cells 
at low concentrations. In conclusion, the toxicity of nanomaterials 
is influenced by composition, surface functional group, size, shape 
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FTIR Fourier transform infrared spectroscopy 
G1 gap1 
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H2O2 hydrogen peroxide 
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HAuNPs gold hexagon nanoplates  
HDF human dermal fibroblast 
HeLa human cervical cancer cells 
XXXVI 
 
HepG2 hepatocellular liver carcinoma cells 
HESCs human embryonic stem cells 
IC50 half maximal inhibitory concentration 
ICP Inductively-coupled plasma 
ICP-MS inductively coupled plasma-mass spectrometry 
ICP-OES 
inductively coupled plasma optical emission 
spectroscopy 
ICP-RIE inductively coupled plasma reactive ion etching 
IMR90 lung fibroblast cells 
JNK c-Jun NH2-terminal kinase 
KAuCl4 potassium gold (III) chloride 
LD50 lethal dose fifty 
LDH lactate dehydrogenase 
MAPK mitogen activate protein kinase 
MCF7 breast cancer cells 
MEF mouse embryonic fibroblasts 
MEM minimum essential medium 
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MWCNTs multiwalled carbon nanotubes 
NEAA non-essential amino acids 
NIR near-infrared region 
NLS nuclear location sequence 
NMR nuclear magnetic resonance 
NNI National Nanotechnology Initiative 
OA oleic acid 
PAuNPs gold pentagon nanoplates 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PEDT Poly(3,4-ethylenedioxythiophene) 
PEG polyethylene glycol 
PI propidium iodide 
PMAA poly(methacrylic acid) 
PS phosphotidyl serine 
PVP polyvinylpyrrolidone 
R&D research and development 
RGD arginine-glycine-aspartic acid 
ROS reactive oxygen species 
RPA ribonuclease protection assay 
RT-PCR reverse transcriptase- polymerase chain reaction  
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S DNA synthesis  
SAXS small-angle X-ray scattering 
SCI science citation index 
SEM scanning electron microscopy 
SGC-7901 human stomach cancer cells 
siRNA small interfering RNA 
SPR surface plasmon resonance 
TAuNPs triangle nanoplates  
TEM  transmission electron microscope 
TGA ultraviolet–visible 
TiO2 titanium dioxide 
UV-Vis ultraviolet–visible 
XAS X-ray absorption spectroscopy 
XPS X-ray photoemission spectroscopy 
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1.1 Overview of nanotechnology 
Nano, originated from Greek words, means “one billionth” (10-9). 
Nanoscale is normally defined as smaller than 100 nanometers in at least one 
dimension, although sometimes it may be used to describe even smaller 
materials. Nanotechnology is the term used to describe areas of science and 
engineering of design, characterization, production and application of 
materials, structures, devices and systems at nanoscale dimensions. 
Nanomaterials which have at least one dimension in the range 1 - 100 nm, 
exhibit interesting properties that differ from the bulk materials. Early 
example of use of nanostructured materials can be back dated to 4th century, 
the Lycurgus Cup (Rome), made of colloidal gold and silver, looks opaque 
green when lit from outside but translucent red when light shines from inside.1 
During the 9th and 17th century, glowing and glittering polychrome lustreware 
bowl which was used in the Islamic world and later in Europe, contained 
either silver or copper or other metallic nanoparticles.2  
Concepts of nanotechnology became more popular after the talk given by 
physicist Richard Feynman at an American Physical Society meeting in 1959.3 
Feynman suggested that a process to manipulate individual atoms and 
molecules might be developed, using one set of precise tools to build and 
operate another proportionally smaller set, down to the needed scale. The term 
"nanotechnology" was first used in 1974 by Norio Taniguchi,4 and defined as 
follows: “Nanotechnology mainly consists of the processing of, separation, 
consolidation, and deformation of materials by one atom or by one molecule. ” 
The book ‘Engines of Creation: The Coming Era of Nanotechnology’ written 
by Dr. K. Eric Drexler (1986),5 is considered as the first book on the topic of 
nanotechnology. Nanotechnology and nanoscience started in the early 1980s 
with two major developments. One major development is the birth of cluster 
science and the invention of the scanning tunneling microscope (1981)6 while 
the other is the synthesis and properties of semiconductor nanocrystals (1981, 




1985).7,8 Later, Don Eigler and Erhard Schweizer of the IBM's Almaden 
Research Center, manipulated 35 individual xenon atoms to spell out the IBM 
logo in 1989.6 In 1990s, early nanotechnology companies began to operate, e.g. 
Nanophase Technologies in 1989, Helix Energy Solutions Group in 1990, 
Zyvex in 1997, and Nano-Tex in 1998. Consumer products making use of 
nanotechnology, such as nano-silver antibacterial socks, clear sunscreens and 
deep-penetrating therapeutic cosmetics, began appearing in the marketplace in 
1999–early 2000’s.  
The world’s first national nanotechnology program – the U.S.’s National 
Nanotechnology Initiative (NNI) – was launched by President Clinton in 2000. 
From 2001 through 2012, the U.S. government invested approximately $15.6 
billion in nanoscience, engineering and technology through NNI and $1.8 
billion in NNI funding has requested by President Obama for 2013.9 In 2004, 
the European Commission adopted the Communication “Towards a European 
Strategy for Nanotechnology,” COM (2004) 338, which proposed an 
integrated and responsible approach to institutionalize European nanoscience 
and nanotechnology research and development (R&D).  
Inventions related to nanotechnology are reflected by the number of 
patent applications filed in the top 15 repositories, which increased from 1,200 
in 2000 (of which 405 were filed at the US Patent and Trade Office, 
USPTO)10,11 to about 13,000 in 2008 (of which 3,729 were filed at USPTO), 
with an annual growth rate of about 35%, as shown in Figure 1.1.12,13 As 
products incorporating nanotechnology commercialized, investments in 
nanotechnology have already begun to yield economic benefits. The value of 
these products reached about $200 billion worldwide in 2008.12 The 
estimation made by Roco and Bainbridge14 for a product value of $1 trillion 
by 2015 still appears to hold (Figure 1.2).12 Owing to successive introduction 
of new products, the market increase with an annual speed 25% and nearly 
double in every 3 years.  





Figure 1.1: Longitudinal evolution of the total number of nanotechnology 
patent applications in the 15 repositories per year (‘‘title abstract,’’ 
1991–2008). (Adapted from Ref12, 13) 
 
Figure 1.2: Market timeline: projection for the worldwide market of final 
products that incorporate nanotechnology. (Adapted from Ref 12) 
1.2 Classification of nanoparticles  
There are various approaches for classification of nanoparticles. Generally 
nanoparticles can be classified by their composition and morphology.15  
As to compositions, nanoparticles can be composed of a single constituent 




material or be a composite of several materials. The nanoparticles found in 
nature are often agglomerations with various compositions, while pure 
single-composition materials are normally synthesized in labs. In detail, 
nanoparticles can be further divided into metals (gold, silver, platinum), metal 
oxides (zinc oxide, titanium dioxide, iron oxide, aluminium oxide), 
carbon-based nanoparticles (fullerenes, carbon nanotubes) nanomaterials, 
organic (e.g. dendrimer, micelle) and hybrid structures such as quantum dots, 
core-shell structures.  
Based on the shape of particles, nanoparticles could be classified into 
different groups, such as, nanosphere, nanocube, hexagon, pentagon, triangle, 
nanoflower, nanowire and octahedral structures. Different morphological 
variants of nanoparticles are represented in Figure 1.3. 
1.3 Synthesis of nanomaterials 
In general, nanomaterials may be separated into two classes based on the 
method of fabrication: bottom up or top down methods.16,17 Top-down 
methods seek to create smaller devices by slicing or successive cutting of a 
bulk material, on the other hand, bottom up methods refer to building up of a 
material from the bottom: atom by atom or molecule by molecule (Figure 1.4). 
Attrition or milling is a typical top down method in making nanomaterials, 
whereas synthesis of colloidal dispersion via reducing of metal salts is a good 
example of bottom up approach for the synthesis of nanomaterials.  





Figure 1.3: Morphological variant of inorganic Au nps: sperical (A), cube (B), 
hexagon (C), pentagon (D), triangle (E) and nanoflower (F).  
In the top-down approaches, large starting material is reduced to small 
size by using mechanical or chemical methods. The most commonly used top 
down fabrication techniques include silicon micro-fabrication and 
photolithography.18 Advantages of this method are the possibility of mass 
production in the industrial setting and place different materials next to each 
other.19 The major disadvantages of the top-down approach include time 
consuming processes, high deployment costs, low impact to overall 
organization, generation of a broad feature size distribution and imperfections 
or defects of the surface morphology generated. The production of 
monodispersed spherical colloids from metals with relatively low melting 
points such as bismuth, lead, indium, tin and cadmium, can be realized by 
emulsifying molten drops of bismuth in boiling di(ethylene glycol), followed 
by quenching with cold ethanol.16 ZnO nanowire devices could be fabricated 
by using optical lithography20 and semiconductor nanowires such as InP and 
InGaAsP/InP nanowires could be fabricated by using inductively coupled 
plasma reactive ion etching from their respective wafers.21 Surface 




deformations were reported to have a significant impact on its physical 
properties and surface chemistry of the nanoparticles.22 In pyrolysis, an 
organic precursor was burnt after forcing through an orifice at high pressure 
and the resulting ash was processed to recover the oxidized nanoparticles with 
a wide particle size distribution.22 This process consumed enormous amounts 
of energy to sustain the high pressure and temperature. On the contrary, the 
bottom-up approaches normally operate under ambient conditions which leads 
to high energy savings.  
 
Figure 1.4: Nanomaterials of different sizes and morphologies (such as 
nanosphere, nanopyramid and nanowire) can be fabricated via either top-down 
mechanical methods or bottom-up approaches. 




A variety of bottom-up approaches exist, comprising precipitation from 
solution, co-precipitation, complex coacervation of two oppositely-charged 
polyelectrolytes, salting-out from an aqueous–organic mixture, 
nanoprecipitation or solvent displacement, chemical vapor deposition, gas 
condensation, solvent emulsification–diffusion using an oil–water emulsion, 
high-temperature decomposition of organic precursors, laser ablation, 
radiolytic methods, vacuum evaporation of metal, the Svedberg method of 
electrocondensation and using supercritical fluids.23-25 These techniques can 
be used to generate a variety of nanomaterials which include metal 
nanoparticles (magnetic or Ag nps), liposomes, nanoemulsions, polymeric 
micelles, polymeric nanoparticles, protein nanoparticles, solid lipid 
nanoparticles and carbohydrate (chitosan, alginate, hyaluronic acid, dextran) 
nanoparticles.25-27 The most commonly employed method is wet chemical 
synthesis method, where metal ions were reduced to yield the corresponding 
metal particles by a suitable reducing agent in the presence of capping agent(s). 
The growth of the metal particle is controlled by the addition of capping 
agents, which works either by conferring a charge (carboxylic acids for 
negative charge and amines for positive charge) on the surface to help repel 
neighbouring nanoparticles, or by sterically preventing the agglomeration of 
two nanoparticles.28 Apart from preventing nanoparticles from precipitation, 
capping agents also serve other important functions such as controlling 
particle size, shape, surface charge, solubility and surface functionality which 
can confer special properties.29  
Recently, there has been a growing interest in biological synthesis of 
metallic nanoparticles using bacteria,30 yeast,31 fungi, plants and algae.22 As 
compared to conventional chemical methods, these methods offer advantages 
such as avoiding the use of toxic organic solvents and reagents, generation of 
hazardous side-products, high cost and energy consumption as well as 
producing nanoparticles which are relatively non-toxic and biocompatible. 




During the synthesis, biomaterials extracts can be used as both reducing agents 
and capping agents.32 Extracts from biomaterials such as coffee,33 tea,33 garlic, 
jatropha seeds,34 plant leaf,35 rosa rugosa leaf,36 lemongrass,37 aloevera,38 
alfalfa,39 neem,40 tamarind41 have been used for the synthesis of nanomaterials. 
Different nanoparticles from Ag, Au, CdS, magnetite and uranium were 
reported to be synthesized through biological processes.42 A similar method 
for synthesis of Ag nps using fungal cell filtrate was also reported.43 
1.4 Characterization of nanoparticles  
Nanoparticles exhibit entirely different properties from their bulk 
materials, which offer them special advantages in many commercial products 
such as fillers, catalysts, semiconductors, cosmetics, microelectronics, and 
drug carriers.44 Important factors such as size, morphology, composition, 
surface area, surface chemistry and aggregation of nanoparticles in solution 
affect their properties.44 The need to characterize nanomaterials before  
incorporating them into applications is a high priority. Many techniques are 
often complementary and used together to fully characterize nanomaterials. 
For example, the transmission electron microscope (TEM) is used to image 
nanomaterials, which provides the information of nanomaterials morphology 
and size distribution. However, this technique is limited to materials with high 
electron density, organic capping agents or uncrystallized surface matter 
cannot be seen clearly. Dynamic light scattering (DLS), which could detect the 
hydrodynamic size of nanoparticles including the contribution from the 
ligands and the hydration shell in a solvent, can be used in conjunction with 
TEM to support the data obtained from each other. A systematic 
characterization for nanomaterials has been recommended by Sayeset al.:45 
Primary characterization is performed on dry nanomaterials to get the 
basic characterization parameters of nanomaterials. These parameters include 
chemical composition, crystal structure, size and morphology, which can be 
measured with multiple techniques (Table 1.1).46,47 For example, the size and 




morphology of nanomaterials can be detected by TEM,48 scanning electron 
microscopy (SEM)49 and atomic force microscopy (AFM).50 The chemical 
composition of nanomaterials can be analyzed by both elemental analysis 
(ICP-MS) and X-ray photoemission spectroscopy (XPS).51 Moreover, XPS is a 
surface chemical analysis technique which can be used to analyze the surface 
chemistry of nanomaterials.52 Crystal structure of nanomaterials is detected by 
X-ray diffraction (XRD)53 and specific surface area evaluation of 
nanomaterials is measured by Brunauer, Emmett and Teller (BET) method.54 
Fourier transform infrared spectroscopy (FTIR) is used to detect infrared 
spectrum of nanomaterials.55  
Secondary characterization of nanomaterials is done in solution or 
suspension form. Parameters such as size distribution, concentration, purity, 
solubility, stability, agglomeration/aggregation, surface charge, surface activity 
and presence of other reactive species are investigated.56 Additional 
experiments which could be carried out are DLS, zeta potential and nuclear 
magnetic resonance (NMR) (Table 1.1).  


















poor contrast no ultra-high 
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SEM bulk to 2 
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matching 
functional groups yes solution 
XPS indirect 
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BET surface area −  yes solid 
DLS 10−3000 nm 
sensitive to 
aggregation 
−  − solution 
XRD bulk to 1 nm lattice 
parameter 
crystal only − solid 
SAXS 1−100 nm − intermediate 
contrast 
− solid or 
solution 
a TGA: thermal gravimetric analysis and SAXS: small-angle X-ray scattering. 
Hybrid structures are those with a significant organic and inorganic structure 
that need differentiation. Organic impurities are low Z small molecules that 
need detection or purification. Sample state is the necessary condition for 
measurement. No experiment captures the entire description of the particle, 
and many aspects require more than one experiment. (Adapted from Ref 47) 
Generally, primary and secondary characterization should be used 
together to fully characterize nanomaterials. Typically, only a fraction of these 
techniques are accessible or usable. Moreover, multiple techniques required 
for characterization may slow down or limit complete execution progress. For 
example, purified Au nps can be fully characterized by using a reduced set of 




techniques:57 1H NMR to identify ligands and organic impurities; UV−Vis 
spectroscopy to verify the optical properties and estimate sizes from the 
plasmon spectral shifts; TEM/EDX to determine geometry, core size and 
elemental composition. In addition, some concerns involving nanomaterials 
purity, equipment sensitivity and sample state associated with current available 
methods are also highlighted in Table 1.1.47 
1.5 Silver and gold nanoparticles 
Nanomaterials with different characteristics are designed and 
manufactured for specific applications; metallic nanoparticles especially silver 
and gold are largely used in multidisciplinary areas.  
1.5.1 Silver nanoparticles (Ag nps) 
Silver metal has been used by mankind for thousands of years in the area 
such as coins, jewelry or dental alloy. Silver is well known by its antibacterial 
property. In ancient time as early as 1000 BC, the Greeks and others used 
silver containers for the conservation of water and food to prevent bacterial 
overgrowth.58 In 8th century, the first medicinal record was using silver as a 
treatment to cure blood-related disorders and heart palpitations.58 Silver nitrate 
was used to treat ulcers in 17th and 18th century and further used in the 
standard surgical operation in the 19th century.59 In addition, silver has also 
been used for treating burn infections for a long time.60-64 After the emergence 
of nanotechnology, commercialized products incorporated with nanosilver 
have invaded the market, owing to the antimicrobial activity of silver. These 
products include wide ranges such as wound and burn dressings, cosmetics, 
household detergents, refrigerators, mobile phones or clothes. Sometimes Ag 
nps have also been proposed for medical applications such as imaging, drug 
delivery, disinfection and tissue repair.65-67 
It is estimated that today about 320 tons/year of Ag nps are produced for 
use in commercial or industrial products68 and the number is expected to reach 




1,120 tons by 2015.69 Further, the number of nanosilver-containing products 
has increased from less than 30 in 2006 to over 300 at the beginning of 2011.69 
Lem et al.70 conducted a market based intellectual property study to examine 
the current global patent landscape of companies using Ag nps in their 
consumer product development and production from 1980 to 2010. As shown 
in Figure 1.5A, a growing patent publication trend in commercial products 
was observed, especially for the last decade from 2001 to 2010, the number 
reached 1199 in 2010. Figure 1.5B gives an overall patent publication of the 
consumer products that contains Ag nps. Similar to the patent publication 
numbers in commercial products, the patent publication in consumer products 
peaked at 162 in 2010. Moreover, among 932 publications in consumer 
products, cosmetics, personal care, medical and health care were reported to 
occupy more than 70% of the application areas as shown in Figure 1.6.70 
 
Figure 1.5: Patent publication trend of nanosilver-containing commercial 
products (A) and the consumer products that contains Ag nps (B) from January 




1, 1980 to December 31, 2010. (Adapted from Ref 70) 
 
Figure 1.6: Nanosilver in various application of consumer products. (Adapted 
from Ref 70) 
1.5.2 Gold nanoparticles (Au nps)  
Gold was used in decorative objects in Eastern Europe in 4000 BC and 
gold jewelries were found in the tomb of Djer, King of the first Egyptian 
Dynasty (2500 BC).71 The earliest records of the use of gold for medicinal and 
healing purposes can be traced back to the Chinese in 2500 BC.72 Over 5000 
years ago the Egyptians ingested gold for mental and bodily purification. Gold 
was mainly used in medicine for its magico-religious powers throughout the 
ancient world from Egypt to India.73 For a long time, gold was used as a drug 
called “nervin” for the revitalization of people suffering from nervous 
disorders.74 In the beginning of the 19th century, gold was used to treat 
syphilis75 and later gold complexes were introduced for the treatment for 
rheumatoid arthritis.72 However, the modern scientific study of colloidal gold 
commenced in 1857, when Michael Faraday proved that the color of gold 
solutions was attributed to the small size of gold particles.76 Due to their 
unique properties, Au nps have been used as an additive to various drugs. In 
1971, Au nps used as labels in immunostaining considered as the beginning of 
their biological applications.77 Over the past decades, Au nps have been 




extensively studied for biological and medical applications such as 
colorimetric biosensors,78,79 drug delivery,80,81 cancer imaging82-84 and cancer 
therapies,85-87 due to their good biocompatibility, monodispersity, easy 
synthesis and ready functionalization. For example, Au NMs can resonantly 
absorb and scatter incident light upon excitation of their surface plasmon 
oscillations typically in the near- infrared region (NIR)88 and photon energies 
that are absorbed by Au NMs can be efficiently converted into heat on a 
picosecond time scale, as a result of electron-phonon and phonon-phonon 
processes. Therefore, Au NMs can be a highly potent photothermal therapeutic 
agent, by exploiting their strong absorptions and efficient heat 
conversions.88-90 In addition, Guo et al.81 first developed charge-reversal 
functional Au nps prepared by layer-by- layer technique to deliver small 
interfering RNA (siRNA) and plasmid DNA into cancer cells. 
1.6 Safety concern of nanoparticles 
Nanotechnology may be able to create many new functional materials and 
devices with a vast range of applications; however, it also raises important 
issues on living systems, environmental adverse impact of nanomaterials and 
their potential negative effects on global economy. As nanomaterials are 
increasingly prevalent, the chance of human exposure to nanoparticles has 
increased. In 2004, “Nanoscience and Nanotechnologies: Opportunities and 
Uncertainties” published Britain’s Royal Society and the Royal Academy of 
Engineering, which advocate the need to address potential health and 
environmental effects of nanoparticles. It also makes recommendations on 
regulatory issues associated with nanotechnology. In 2008, the first official 
NNI Strategy for Nanotechnology-Related Environmental, Health, and Safety 
(EHS) Research was published, which was updated in 2011.  
Earlier studies have shown the association of air pollution with lung 
diseases such as asthma, lung cancer and cardiovascular diseases such as 
myocardial infarction.91-93 Evidences suggest that exposure to the 




nanoparticles induced adverse effects to human health.94 More research must 
be done to provide a complete understanding of biological responses of 
nanoparticles at the cellular level. The current pool of data available in the 
literature was gathered from the bioactivity studies of nanoparticles such as 
titanium dioxide (TiO2),
95,96 zinc oxide (ZnO)97 or silver (Ag)98,99 
nanoparticles, several of the earliest commercialised nanomaterials. The data 
obtained from such studies offers much valuable information and sheds light 
to the mechanisms of nanoparticle toxicity.  
1.7 Exposure of nanoparticles to living systems 
Many factors such as manufacturing conditions, volume of production, 
industrial applications, usage of consumer products, distribution, stability, 
behavior and environmental fate could affect the outcome of human exposure 
to nanomaterials. Living organisms are exposed to nanomaterials through 
active routes which include work and lifestyle related activities or passive 
exposure through living in contaminated areas or ingesting of contaminated 
water or food. External exposure routes for humans comprise inhalation (e.g. 
as aerosols), absorption through the skin and gastrointestinal tract. After the 
entry, absorption, distribution, metabolism and excretion of particles inside the 
body will depend on the size, chemical nature and stability of the 
nanomaterials. Nanomaterials could reach various organs through blood 
circulation and may accumulate inside the body as well.100 Detailed 
information of portals of nanoparticle entry into living systems is summarized 
in the following sections.  
1.7.1 Inhalation 
The lungs are the most likely route of exposure to nanomaterials. Particle 
deposition and retention in the different pulmonary compartments is 
determined by many factors such as respiratory tract anatomy, breathing 
pattern, the exposure time and concentration, method of particle 
administration, particle size and agglomeration state.101,102 Ultrafine particles 




with size less than 100 nm were the crucial cause of respiratory disorders; 
these particles were more toxic and caused greater inflammation than larger 
particles.103 Small particles were found to penetrate deeper as compared to 
larger ones.104 Multiwalled carbon nanotubes reach the subpleura in mice after 
a single inhalation exposure of 30 mg/L for 6 h.105 Nanoparticles can enter in 
the lung-epithelium and depth translocate beyond the epithelial barrier106 or be 
cleared by macrophages.107 This process is influenced by the size and shape of 
nanomaterials.108 Nanoparticles with size below 400 nm have a high chance to 
cross the epithelial barrier, enter the blood or lymphatic systems and 
subsequently transport to different organs.109 Inhalation experiments of 
Au107,110 and Ag111 nanoparticles in animal models resulted in systemic 
distribution and subsequent deposition in various organs.  
1.7.2 Skin absorption  
The human skin is one of the major entry routes for external substances,112 
owing to its large surface area and accessibility to environmental exposure. 
Nanomaterials contact with human skin may happen not only accidentally but 
also intentionally due to their presence in clothing, drugs, cosmetics, and other 
skin care products. Healthy skin is an efficient barrier to nanoparticles and 
other chemicals. The strongly keratinized stratum corneum (10 mm) is the 
main skin barrier which expels foreign bodies effectively.113 However, the 
sweat glands and hair follicles on the skin could make this barrier vulnerable 
and facilitate nanoparticles entry. Most of the studies assessing the skin 
penetration of nanoparticles (such as titanium dioxide (TiO2),
114 ZnO,115,116 Ag 
nps117 or quantum dots118) have shown penetration of particles into upper 
layers of the stratum corneum, occasionally reaching the viable epidermis.119 
Smaller iron nanoparticles (10 nm) accumulated in hair follicle orifices and 
penetrated through the lipid matrix of the stratum corneum but not deeper than 
the uppermost strata of the epidermis.119 Ag nps exhibited low penetration 
through intact and damaged human skin, but in the case of damaged skin, an 




increased absorption of Ag nps was observed.117 Rancan et al.120 reported that 
the skin penetration and cellular uptake of amorphous silica nanoparticles 
were size-dependent. These nanoparticles (42, 75 to 290 nm) partially 
disrupted stratum corneum, only small nanoparticles (42 ± 3 nm) were found 
to be associated with epidermal cells and especially dendritic cells, 
independent of their surface charge.120 
1.7.3 Ingestion 
Absorption of nanoparticles through the gastro- intestinal (GI) tract is one 
of the potential exposure routes for the entry of nanoparticles into human body 
owing to their use in food additives and drugs. Multiple parameters such as 
size, shape, composition, surface charge or surface functionalization could 
affect their targeting and absorption in GI tract.121 Ingested nanomaterials may 
agglomerate inside the intestinal tract due to pH changes. These agglomerates 
can get expelled through feces if they are small enough or induced obstruction 
of GI tract and death if they are too big.122 Au nps with size of 15 nm showed 
higher penetration rates in rat intestinal models as compared to larger ones 
(102 and 198 nm).123 Internal diffusion and absorption of TiO2 nanoparticles in 
the digestive system of mice explored by Abe et al.124 described that TiO2 fed 
to mice was detected in the lung, liver, and spleen after 10 days of exposure. 
TiO2 nanoparticles were also reported to migrate into other tissues and organs 
(include brain) and induce significant lesions to the liver and kidneys.125 These 
reports indicate that nanomaterials could penetrate the GI tract and result in 
translocation to other organs. 
1.7.4 Translocation 
From the site of entry, nanoparticles can enter multiple organs such as 
brain, spleen, liver, kidney and muscles through the circulatory system.109,126 
Intratracheal- instilled iron oxide nanoparticles passed through the 
alveolar-capillary barrier into systemic circulation within 10 min.127 The 
pulmonary deposition and the translocation to secondary target organs in 




Wistar rats intratracheally instilled with ceria nanoparticles showed that ceria 
nanoparticles could penetrate through the alveolar wall into the systemic 
circulation and accumulate in the extra-pulmonary organs.128 Nanoparticle 
characteristics such as size and composition, surface charge and surface 
structures are vital factors to influence nanoparticle biokinetics, as they 
determined the interactions of nanoparticles with proteins and cellular 
components and thereby the mechanisms for particle translocation and 
accumulation in extra-pulmonary organs.126 Nanoparticles with hydrodynamic 
diameter less than 30 nm and a noncationic surface charge translocate rapidly 
from the lung to mediastinal lymph nodes.129 The individual health status is 
also an important determinant of the response to nanomaterials exposure. 
Significantly higher concentrations of Au were detected in heart and thymus of 
healthy animals, whereas higher concentrations of Au nps were observed in 
spleen in animals with prior lung inflammation.130 
1.7.5 Excretion of nanoparticles 
Excretion of nanomaterials are proposed to be through various routes such 
as urine, feces, sweat, breast milk and saliva.104 Expulsion of nanoparticles is 
dependent on various parameters such as size, agglomeration, surface 
functionality and aspect ratio.122,129 Nanoparticles (< 6 nm) can traffic rapidly 
from the lungs to lymph nodes and the bloodstream, and then be subsequently 
cleared by the kidneys.129 Quantum dots with size less than 5.5 nm were 
rapidly eliminated in the rat model while renal excretion was prevented when 
the hydrodynamic diameter of quantum dots increased to larger than 15 nm 
owing to proteins adsorption on their surface.131 Highly-charged mesoporous 
silica nanoparticles (+34.4 mV at pH 7.4) were rapidly excreted from the liver 
into the gastrointestinal tract as compared to lesser charged particles (+17.6 
mV at pH 7.4), suggesting that charge-dependent adsorption of serum proteins 
greatly facilitates the hepatobiliary excretion of silica nanoparticles.132 Carbon 
nanotubes (with high aspect ratios) that are well individualized and soluble in 




biological milieu can also cross the kidney barrier and be excreted in urine.133 
1.8 Nanotoxicity 
The toxicity of nanomaterials was studied both in vivo and in vitro. In 
vitro studies are usually done with commercially available cell lines while in 
vivo studies are typically performed on rats134 and mice,135,136 some other 
models include zebrafish,137 zebrafish embryos,138 mosquito larvae,139 guinea 
pig,140 fruit fly141 and fruit fly eggs.142 
1.8.1 In vitro and in vivo toxicity testing  
For in vitro studies, cytotoxicity of nanomaterials is performed using 
viability/proliferation assays (MTT/MTS or ATP), cytotoxicity assay (lactate 
dehydrogenase, glyceraldehyde-3-phosphate dehydro-genase (GAPDH), 
adenylate kinase), and necrosis and apoptosis assay.143-146 Genotoxicity of 
nanomaterials were studied using the reverse mutation (Ames) assay,147 
cytokinesis-blocked micronucleus assay (CBMN) and alkaline single-cell gel 
electrophoresis (comet assay)148 while alteration in gene expression were 
examined by northern blot analyses, ribonuclease protection assay (RPA), 
polymerase chain reaction (PCR) and microarray analyses.147 However, 
physicochemical properties of nanomaterials which include high adsorption 
capacity, optical properties, catalytic activity, acidity/alkalinity, magnetic 
properties and dissolution, often limit the use of in vitro toxicity assays.146 
Studies designed to determine nanomaterial toxicity should be performed 
using test systems that cannot be influenced by nanospecific properties.44,146 In 
addition, cellular uptake of nanomaterials can be monitored by confocal 
microscopy149-151 and their exact distribution can be observed by imaging the 
ultrathin cells section using TEM.152-154 Moreover, the quantitative analysis of 
the amount of nanomaterials inside cells is generally detected by ICP-MS.154  
In vivo systems are extremely complicated and the interactions of 
nanomaterials with biological components, such as proteins and cells, could 




lead to unique biodistribution, clearance, immune response, and 
metabolism.155 In vivo studies were generally used to gather information on 
short/long-term effects, tissue localization, biodistribution and 
retention/excretion.156 NM exposure via different pathways such as inhalation 
(lung), dermal (skin), ingestion (GI tract) and intravenous injection can 
provide useful information on toxicity and accumulation of nanomaterials in 
target organs.157 The content of nanomaterials in tissue or blood samples can 
be analyzed by using neutron activation methods (INAA or NAA), inductively 
coupled plasma-mass spectrometry (ICP-MS), and atomic absorption 
spectroscopy (AAS).158,159 In addition, the commonly used methods for 
identification and localization of nanomaterials in tissues include 
autometallography, SEM, and TEM techniques.159,160 Elemental data of 
nanomaterials in tissues could be obtained by combining SEM or TEM 
analysis with energy dispersive X-ray spectroscopy (EDX). Furthermore, 
X-ray absorption spectroscopy (XAS) can be used to obtain structural 
information of nanomaterials in samples under examination.159 
1.8.2 Nanotoxicity - In vitro  
In vitro study suggests that nanomaterials could affect cellular functions at 
molecular levels161 indicated by the depletion of intracellular glutathione.162 
Ag NMs showed significant damages to mammalian germ line stem cells 
through apoptosis,163 anti-platelet properties164 and caused severe damage to 
erythrocytes via lysis, membrane damage, hemagglutination and cytoskeletal 
distortions at a high concentration of 100 µg/mL.165 Nanomaterials are 
reported to have the capability of penetrating the physiological barriers to 
reach vital areas or organs due to their small size. Cellular uptake studies 
showed that nanomaterials could penetrate cell membrane into cytoplasm of 
the cells, sometime even to the nucleus area (Figure 1.7). The toxicity of 
nanomaterials was believed to be caused by oxidative stress resulting from the 
generation of reactive oxygen species (ROS) inside the cells.166 ROS was 




responsible for DNA damage and chromosomal aberrations, which further 
induced cell cycle arrest at G2/M or S stage and caused cell death through 
apoptosis.  
 
Figure 1.7: TEM images of ultrathin section of MCF7 cells treated with Au 
NMs. Untreated cells showed no abnormality (A) while cells treated with Au 
NMs showed aggregate nanomaterials in lysosomes (thick arrows) or scattered 
Au NMs in the cytoplasm (open arrow) inside cells (B). Image also showed 
Au NMs aggregate in the nucleus (diamond arrow) through penetrating the 
nuclear membrane (C).  
Cancer growth is dictated by a small cell population called cancer stem 
cells (CSCs),167 which have been isolated from a variety of tumor types.168 
CSCs have the ability to generate more differentiated tumor cells , the majority 
of a tumor mass.169 Due to this reason, CSCs commonly show resistance to 
conventional cancer therapies and are responsible for tumor 
maintenance.170,171 Since CSCs are the cell populations responsible for the 
development of tumor and have important role in cancer recurrence, these 
cells are of particular importance to explore innovative cancer therapies.  
Multiwalled carbon nanotubes (MWCNTs) were injected into breast tumors, 
followed by heated with a quick, 30-second laser treatment killed breast 
cancer stem cells.172 In addition, Wang et al.173 reported that 
aptamer-conjugated Au nanorods can be used to target and kill both prostate 
cancer cells and cancer stem cells by near- infrared (NIR) laser irradiation. 
However, until recently no studies were reported on cellular responses of Ag 
and Au nps on cancer stem cells. 
Stem cells have attracted particular attention in the field o f regenerative 




medicine because of their pluripotency. Directed differentiation of stem cells 
into certain types of cells is one of the most important issues  in embryonic 
stem cells (ESCs) research, which represent not only theoretical interest, but 
also show potential application on cell or tissue therapy for curing serious 
human diseases.174 Several groups have explored the possibilities of using 
embryonic and fetal stem cells to produce dopaminergic cells for curing 
Parkinson’s disease.175 Mesenchymal stem cells could be implanted locally to 
promote or augment repair or regeneration of a fractured or osteoporotic 
bone.176 Skin stem cells can not only provide hope for the functional repair of 
the skin itself but also offer a potential source of adult stem cells for the 
cell-based therapy of injuries and diseases throughout the body.177 Yi et al.178 
reported that Au nps can promote the differentiation of mesenchymal stem 
cells toward osteoblast cells over adipocyte cells through p38 MAPK Pathway. 
Smith et al.179 proposed that nano-fibrous architecture could enhance the 
osteogenic differentiation of the human ESCs compared to more traditional 
scaffolding architectures. In addition, Greulich et al. found that Ag nps exerted 
cytotoxic effects on human mesenchymal stem cells at high concentrations and 
induced cell activation (as analyzed by the release of IL-8) at high but 
nontoxic concentrations of nanosilver.180 However, cytotoxicity and 
genotoxicity of Ag nps on human ESCs were not fully investigated, especially 
their cellular responses at nontoxic doses.  
1.8.3 Nanotoxicity - In vivo 
Animal study showed that nano-anatase TiO2 at a relative high dose could 
cause serious damage to liver, kidney, and myocardium of mice by disturbing 
the balance of blood sugar and lipid in mice.181 In addition, no pulmonary 
inflammation, DNA damage or hepatic histopathology were observed in mice 
instilled with NanoTiO2 dust from paint while pure NanoTiO2 caused the 
inflammation.182 Research report showed that multiwalled carbon nanotubes 
could easily reach the subpleura tissue in mice after a single inhalation 




exposure and get embedded in the subpleural wall and within subpleural 
macrophages.105 Moreover, it is reported that nanomaterials transferred from 
pregnant mice to their offspring can damage genital and cranial nerve 
systems.100 The biodistribution of Au NMs in vital organs after injected 
intravenously to 6–8-week-old female nu/nu mice bearing orthotopic ovarian 
tumors showed that Au nanorods were taken up to a lesser extent by the liver, 
had longer circulation time in the blood, and higher accumulation in the 
tumors, as compared with their spherical counterparts.183 Huang et al.184 
reported that organ distributions of intravenously administrated mesoporous 
silica nanoparticles (MSNs) were mainly present in the liver, spleen and lung 
(>80%) in mice and there is obvious shape effects on their in vivo behaviors. 
Short-rod MSNs were easily trapped in the liver, while long-rod MSNs 
distributed in the spleen.184 Various routes for excretion of nanomaterials (such 
as through urine, feces, sweat, breast milk and saliva) have been suggested in 
the literature. However, only a few (through urine and feces185) have been 
proven experimentally. Excretion of nano-sized latex particles from medaka 
(Oryzias latipes) embryos and larvae was size-dependent; the smaller particles 
(50 nm) were removed slower than the larger particles (500 nm).186 MSNs are 
found to be mainly excreted by urine and feces, and their clearance rate was 
primarily shape-dependent, where short-rod MSNs showed a more rapid 
clearance rate than long-rod MSNs in both excretion routes.184 Although 
MSNs did not cause significant toxicity in vivo as indicated by hematology, 
serum biochemistry, and histopathology results, MSNs have the potential to 
induce of biliary excretion and glomerular filtration dysfunction in mice.184 
Special design of nanomaterials structure (clustering design of nanorose) 
could enhance the excretion of nanomaterials, which could help to limit the 
potential toxicity of nanomaterials in clinical applications.187 
Recently, use of zebrafish as the animal model has attracted interest owing 
to high degree of homology to the human genome, and the transparency of the 




eggs for easy visualization of embryogenesis.137,188 Zebrafish have become a 
popular organism for the study of vertebrate gene function, and it is reported 
that approximately 70% of human genes have at least one obvious zebrafish 
orthologue.189,190 Further, zebrafish is also proving to be a quick, cheap, and 
facile model to conservatively assess toxicity of nanomaterials.191 Adverse 
effects of nanomaterials exposure on zebrafish embryo can be observed in the 
development of notochord, eye, heart, tail, brain and fish size.192 
1.9 Factors affecting cellular uptake and nanotoxicity  
The cellular uptake and cytotoxicity of nanomaterials can be influenced 
by a few characteristics such as shape, size, stability and surface 
functionalities. Such a high number of variable make the nanoparticles to 
behavior differently from small molecular pollutants.193 The small size of 
nanomaterials (< 100 nm) enables them to interact with biological entities 
such as bacteria, cells, cellular proteins and viruses. Cellular uptake, 
cytotoxicity and innate immune response of nanomaterials depend on size, 
shape, compositions, surface functionalities, chemical nature and cell 
types.194-200  
1.9.1 Size effect 
Earlier reports showed that nanomatrials exhibited size-dependent toxicity 
(Table 1.2).138,201-205 Nanomatrials with smaller size are reported to be more 
toxic than those with the larger size owing to their higher reactive surface area 
for interaction with biomolecules and easy uptake into cells via varied 
mechanisms such as diffusion or endocytosis.138,206-210 Au nps of 1 - 2 nm in 
size were highly toxic and induce cell death via both apoptosis and 
necrosis,194,211 while larger 50 – 100 nm Au particles were comparatively 
nontoxic.194. Cui et al.212 reported that small Au nps could be endocytosed by 
cells resulting in cytotoxicity while large aggregates adhered onto the cell 
surface and increased the growth rate of HeLa cells. In addition, the ultimate 
intracellular destination of Au nps is also determined by the size. The smaller 




Au nps penetrate nucleus and cytoplasm, and some particles remain at the 
membrane, while the larger ones did not enter the cells and were located at the 
cellular periphery.205 
Table 1.2: Summary of literature of nanomaterials with size-dependent 
cellular uptake and toxicitya  
Species Cellular uptake and toxicity Sources 
Au nps 2.4 nm: localize in the nucleus 
5.5 and 8.2 nm: partially delivered into the 
cytoplasm; 
16 nm or larger: not enter the cells and located at the 
cellular periphery 
205 
Au nps  1 - 2 nm: highly toxic  
> 15 nm: comparatively nontoxic 
206 
Au nps  IC50 
0.8 nm: 200 µM 
1.2 nm: 100 µM 
1.4 nm: 80 µM 
1.8 nm: 200-500 µM 




the cell had 1.5 – 2.4-times higher uptake for the 15 




the 33 nm sample showed 1.5 – 4.4-times higher 
uptake than the 45 nm sample 
209 
Ag nps  Human lung adenocarcinoma epithelial (A549) cells: 
EC50 
5 nm: 1 µg/mL 
20 nm: 10 µg/mL 
50 nm: 14 µg/mL 
207 
Ag nps 30 – 50 nm: mitochondrial function was reduced at 10 
– 20 µg/mL, 
 




Species Cellular uptake and toxicity Sources 
necrosis/apoptosis at 2.5 – 15 µg/mL 
Ag nps 79 ± 1 nm, toxic at 15 and 30 µg/mL; 
82 ± 1 nm, toxic at 7.5 and 15 µg/mL (after 4 days); 
toxic at 30 µg/mL (after 2 days); 
88 ± 1 nm, toxic at 7.5 µg/mL (after 4 days), toxic at 
15 and 30 µg/mL (after 2 days), toxic at 15 µg/mL 
(after 4 days); 
94 ± 1 nm, toxic at 7.5 and 15 µg/mL (after 4 days), 
toxic at 30 µg/mL (after 4 days); 
95 ± 1 nm, toxic at 7.5, 15 and 30 µg/mL (after 4 
days); 
99 ± 1 nm, toxic at 7.5, 15 and 30 µg/mL (after 4 
days) 
204 
Ag nps 20 nm, EC20 (WST test)=21 µg/mL; EC20 (LDH 
assay)=3 µg/mL; 
80 nm, EC20 (WST test)=31 µg/mL; EC20 (LDH 
assay)=33 µg/mL; 
113 nm, EC20 (WST test)=29 µg/mL; EC20 (LDH 
assay)=43 µg/mL 
203 
Ag nps 10 nm, cytotoxicity ca. 40% at 25 µg/mL; 
20 nm, cytotoxicity ca. 20% at 25 µg/mL; 
32nm, cytotoxicity ca. 50% at 12.5 µg/mL, ca. 70%at 
25 µg/mL; 
40 nm, not toxic at 25 µg/mL 
138 
Ag nps 25 nm, toxic at 62.5 µg/mL; 
35 nm, toxic at 62.5 µg/mL; 
45 nm, toxic at 62.5 µg/mL; 
60 nm, toxic at 125 µg/mL; 
70 nm, toxic at 125 µg/mL 
201 
Ag nps 4 nm, cell viability 36% at 3.12 µg/mL; 
20 nm, cell viability 6% at 25 µg/mL; 
202 




Species Cellular uptake and toxicity Sources 
70 nm, cell viability 100% at 50 µg/mL 
Ag nps 5 nm, cell viability 50% at 6.25 µg/mL, 0% at > 12.5 
µg/mL; 





Viability at 500 µg/mL: 
25 nm: 68%  
50 nm: 65% 
75 nm:72%  
100 nm: 78% 
213 
SiO2 Human kidney cells (HK-2) at 100 µg/mL 
20 nm, 12% colony formation; 
100 nm, 80% colony formation 
214 
a IC50 = half maximal inhibitory concentration, EC50 = half maximal effective 
concentration 
1.9.2 Shape effect 
Shape is another important factor which affects the responses in living and 
environment.138,215-218 The shape anisotropy and initial orientation of 
nanomaterials play a complicated role in their physical translocation,219 and 
biological outcome depends on the differences in the surface reactivity, 
cellular uptake, biocompatibility of nanomaterials and retention at various 
tissues or organs.220,221 For instance, a recent study showed that dendrimer 
shaped nickel nanoparticles exhibited higher toxicity than spherical 
nanoparticles in zebrafish embryos.222 The shape effect of nanomaterials was 
also observed in bacteria,221,223 human cancer cell lines224 and zebrafish 
embryos.138 Ag nanoplates showed a higher degree of toxicity than Ag sphere 
nanoparticles, owing to surface reactivity resulting from crystal defects.138 
However, until now, no comparison study was reported on Ag NMs with 
different shapes such as Ag nanocubes and truncated nanocubes. Au nanorods 




induced cell apoptosis while Au nanosphere did not induce any such 
detrimental effects to cells.225 In addition, spherical Au nps displayed high 
biocompatibility in mice models, and rod-shaped Au nps were more toxic than 
cube-shaped Au nps.217 Au nanoplates (AuNPs) have attracted great interests 
as they could exhibit a strong plasmon band in the near- infrared region (NIR). 
However, no comparison studies on their shape sensitive effects on cellular 
responses in human cells were reported.  
Table 1.3: Summary of literature on shape-dependent cellular uptake and 
toxicity of nanomaterials a 
Species  Shape dependent effects Sources  
Ag NMs Toxicity: Ag nanoplates > spheres or wires 138 
Ag2O NMs E. coli at 5 µg/mL: 
octahedral particles, 80% viability; 
cubic particles, 10% viabilty 
226 
Au NMs Au nanorods caused significant ROS production 
and up-regulated several genes involved in cellular 
stress and toxicity as compares to Au nanospheres 
225 
Au NMs Cellular uptake on human breast cancer cells 
(SK-BR-3): spherical particles > cubic particles 
(capped with PEG or anti-HER2) 
209 
ZnO NMs EC50: 
Nanorod, 8.5 µg/mL  
Nanosphere, 12.1 µg/mL 
227 
PEDT NMs Toxicity: PEDT-1 (aspect ratio = 1.3) > PEDT-2 
(aspect ratio = 4.5) or PEDT-3(aspect ratio = 25.0). 
215 






the length of carbon nanotubes greatly affected 
their  
toxicity in zebrafish embryos: long nanotubes did 
not induce any obvious toxicity, short nanotubes 
229 




Species  Shape dependent effects Sources  





aspect ratios > 1, highly toxic (LD50 = 110 pg/g 
embryo) and cause embryo deformities; aspect ratio 
= 1 neither toxic nor teratogenic at the same 
concentrations 
230 
TiO2 NMs Long nanobelts, highly toxic, initiates inflammatory 
responses; 
nanospheres and Short nanobelts, not significantly 
cytotoxic 
231 
a Ag2O = silver oxide, PEDT = Poly(3,4-ethylenedioxythiophene), a.r. = aspect 
ratio 
Aspect ratio is also a vital factor to impact the toxicity of nanomaterials. 
Toxicity of nanowires, nanotubes or nanobelts with high aspect ratio was 
summarized here (Table 1.3). As for the polymer nanomaterials such as PEDT 
or polyaniline, the toxicity of nanomaterials increased as decreasing their 
aspect ratios.215,228 Similar results was also reported for multiwalled carbon 
nanotubes, short nanotubes caused severe developmental toxicity whereas 
long nanotubes did not induce any obvious toxicity in the tested developing 
zebrafish embryos.229 On the contrary, silica nanowires with aspect ratios > 1 
showed high toxicity and caused embryo deformities whereas nanowires with 
aspect ratio = 1 were neither toxic nor teratogenic at the same 
concentrations.230 As for TiO2 nanomaterials, long TiO2 nanobelts (> 15 µm) 
interact with lung macrophages while nanospheres (200 nm) and short 
nanobelts (< 5 µm) were not significantly cytotoxic.231 
1.9.3 Surface functionalization effect 
Surface functionalization of nanomaterials cause interesting properties 
such as changes in stability, solubility, surface charge, hydrophilicity or 




hydrophobicity of nanomaterials, which could affect nanomaterials 
biocompatibility, subsequent uptake and downstream processing by cells. 
Various molecules (e.g. polyethylene glycol, polyvinylpyrrolidone (PVP)) 
have been used as capping agents to improve solubility of nanoparticles in 
water. Cetyltrimethylammoniumbromide (CTAB) coated Au nanorods were 
highly toxic while nanorods coated with polymers232 such as 
poly(styrenesulfonate),233 polyethylene glycol (PEG),234,235 
phosphatidylcholine236 or small molecules such as mercaptohexadecanoic acid 
(MHDA)235 could reduce cytotoxicity (Table 1.4). It is reported that surface 
charge plays important roles in nanomaterials toxicity; positively charged 
nanomaterials were much more toxic as compared to negatively charged or 
neutral nanomaterials (Table 1.4).213,237-244 Polymer-coated cerium oxide 
nanoparticles with different surface charges (positive, negative, and neutral) 
showed a surface-charge-dependent cell localization and cytotoxicity in 
normal and cancer cells.244 Similarly, Ag nps also exhibited surface 
charge-dependent toxicity on the bacillus species.241 Charged Au nps induced 
cell death through apoptosis while neutral Au nps led to necrosis.245 Surface 
functionalization of nanomaterials which normally covered the nanomaterials 
surface can influence their intracellular solubility, which further affects their 
cytotoxicity. Copper oxide were reported to be highly cytotoxic, while carbon 
stabilized copper nanoparticles were less cytotoxic and showed no adverse 
effect.246 In addition, cationic and hydrophobic Au nps could penetrate into the 
circulatory system of the fish, leading to widespread distribution in the organs 
of the fish and cause fish mortality in less than 24 h while the hydrophilic 
surface of nanoparticles prevents their accumulation, facilitates clearance and 
minimizes environmental impacts.239 
Cell type is considered as another variable to influence the intracellular 
fate and toxic response to nanomaterials.166 Platinum nanoparticles capped 
with PVP showed higher cellular uptake in human cervical cancer cells (HeLa) 




than in breast cancer cells (MCF7) and lung fibroblast cells (IMR90).247 Au 
sphere nanoparticles induced death response in human carcinoma lung cells 
(A549) but nontoxic to baby hamster kidney cells (BHK21) and human liver 
carcinoma (HepG2).248 In addition, Ag nps also showed different toxicities to 
different cell lines: EC50 of Ag nps (50 nm) in A549 cells is 14 µg/mL, in 
HepG2 34 µg/mL, in MCF7 48 µg/mL and in human stomach cancer cells 
(SGC-7901) 112 µg/mL.207 
Table 1.4: Summary of literature on surface functionalization-dependent 
cellular uptake and toxicity of nanomaterialsa 
Species Functionalization dependent effects Sources 
Au nanorods CTAB coated nanorods are toxic,  
nanorods coated with polymer reduce cytotoxicty 
232 
Au nanorods Toxicity: CTAB coated nanorods more toxic than 
poly(styrenesulfonate) coated 
233 
Au nanorods HeLa cells treated with 0.05 mM:  
CTAB-coated, 80% cell death  
PEG-coated: 10% cell death  
234 
Au nanorods Au-PEG and Au-MHDA nanorods exhibited 
minimal effects on cell proliferation,  
Au-CTAB reduced cell proliferation significantly,  
low cellular uptake for Au-PEG, 
high uptake for Au-MHDA 
235 
Au nanorods Toxicity to HeLa cells: 
phosphatidylcholine-modified nanorods < 
CTAB-coated nanorods 
236 
Au nanorods Cellular uptake of Au nanorods can be truned from 
very high to very low by manipulating the surface 




Cationic nanoparticles are much more toxic than 
anionic particles of the same size 
238 




Species Functionalization dependent effects Sources 
Au nps Cationic and hydrophobic Au nps: penetrate into the 
circulatory system of the fish, lead to widespread 
distribution in the organs of the fish and cause fish 
mortality in less than 24 h; 
Hydrophilic surface: prevents accumulation, 
facilitates clearance and minimize environmental 
impact 
239 
Au nps  The acute cytotoxicity and genotoxicity of 
positively charged Au nps depend on the 
hydrophobicity of the ligands attached on their 
surface. Increasing the hydrophobicity of the 
particles increased their cytotoxicity.  
240 
Ag nps  Ag nps exhibited surface charge-dependent toxicity 
on the bacillus species: the more negative citrate 
coated Ag nps were the least toxic, whereas the 
positively charged BPEI coated Ag nps were the 
most toxic. 
241 
silica nps  Surface charge-dependent cellular uptake, positive 
surface charge enhances the uptake of nanoparticles  
242 
silica-titania 
hollow nps  
Cationic nanoparticles are the most toxic as 
compared to anionic and neutral nanoparticles. 
213 
HAP nps  Positively charged HAP nanoparticles are easily 
penetrated the cells as compared to negatively 
charged nanoparticles; 
Neutral HAP nanoparticles could not penetrate the 




Nanoceria with a positive or neutral charge enters 
most of the cell lines studied, while nanoceria with 
a negative charge internalizes mostly in the cancer 
cell lines. 
244 
ZnO nps The ability to reduce the cytotoxicity of ZnO 
nanoparticles: medium-soaked ≈ PMAA > OA; 
PMAA-coated ZnO had significant genotoxicity 
compared to uncoated ZnO and the other coated 
249 




Species Functionalization dependent effects Sources 
nanoparticles 
Ag NMs Human skin keratinocyte cells (HaCaT): 
Citrate coated silver nanopowder, toxic;  
PVP-coated nanoprism or nanopowder, nontoxic 
250 
Au nps Au nps cellular uptake is directly dependent on the 





uptake by the SK-BR-3 cells decreased in the 
following order: PAA > anti-HER2 > PEG 
209 
a PMAA = poly(methacrylic acid) , HAP = hydroxyapatite, OA = oleic acid, 
CTAB = cetyltrimethylammoniumbromide, PEG = polyethylene glycol , 
MHDA = mercaptohexadecanoic acid, BPEI = branched polyethyl-eneimine 
Moreover, the behavior and fate of nanomaterials in environment have 
attracted much concern due to the discard or run-off of nanomaterials into 
water sources, which may further contaminate our drinking water. The 
stability of nanoparticles in water can be heavily influenced by surface 
coatings.251 A dramatic difference between the behaviour of coated and 
uncoated nanoparticles in wastewater have been reported:251 surfactant-coated 
nanoparticles rapidly aggregated and sedimentated out to form part of the solid  
sewage sludge while uncoated nanoparticles remained dispersed in the sewage 
and therefore simply continue through the effluent stream.251 The aggregation 
of surfactant-coated nanoparticles could be attributed to interactions between 
the adsorbed surfactant molecules and organic matter in the sewage. 
Furthermore, dissolution and presence of other impurities could also affect the 
behavior and the fate of nanomaterials in living organism and environment.252 
The primary mechanism of Ag nanoparticle toxicity in aquatic lifeforms could 
be attributed to the release of silver ions in the exposure medium, as Ag nps 
have been reported to dissolve in a biological environment or in acidic 





1.10 Rationale and scope of the thesis  
As summarized in the earlier sections, the cytotoxicity of nanomaterials is 
dependent on several factors, such as surface functional groups, nanomaterial 
morphology and cell types. Ag and Au are two most commonly used metallic 
nanomaterials; however, no systematic study on their toxicity was done so far. 
Research reports on the adverse effects of Ag and Au NMs have focused 
mainly on spherical nanoparticles, but very few of these reports touch upon 
the cytotoxicity of nanomaterials with different shapes, especially for Ag and 
Au NMs. It should be noted that the toxicity of Ag and Au NMs with different 
shapes cannot simply be deduced from the existing data of the spher ical 
nanoparticles as slight differences in physical and chemical properties, such as 
surface functional group, particle size, surface charge and shapes, would 
largely affect the toxicity of such nanomaterials. This is important as more and 
more commercial products are available on the market, which may cause 
potential damage to human.  
Stem cells, either cancer stem cells or normal stem cells, which have the 
capability to self- renew and differentiated into different cell lines, have 
attracted much attention due to their vital roles in cancer therapy or tissue 
implanting. However, very few researches have reported on cytotoxic and 
genotoxic effects of metallic nanoparticles on these stem cells. Therefore, 
cytotoxicity of Ag and Au NMs on stem cells was investigated in detail here.  
The specific objectives of this study were to: 
1. Compare the toxicity of Ag nps with different functional groups, especially 
for those extracted from natural materials, some of which can even be used 
as traditional drugs; 
2. Investigate the cellular responses towards Ag NMs with different 
morphologies; 




3. Study the cytotoxicity of AuNPs with different shapes, such as triangle, 
hexagon, pentagon nanoplates; and 
4. Explore cytotoxicity and genotoxicity of Ag and Au nps on human stem 
cells. 
In this study, the cytotoxicity of Ag nps with different functional groups 
and that of Ag and Au NMs with different morphologies were investigated on 
human cells. The cellular responses were evaluated by cell viability, reactive 
oxygen species generation and alternation in cell cycle. The results in this 
project could provide guidelines for the use of nanomaterials in biomedical 
applications.  
To achieve the above objectives, the thesis will be divided into several 
sections accordingly. Chapter 2 of the thesis describes the materials and 
methods used in the present study. Cytotoxicity of Ag nps synthesized with 
different natural material extracts as both reducing agents and capping agents 
was explored in human cancer cells and the results were presented in chapter 3. 
Synthesis of Ag NMs with different morphologies such as nanocubes, 
truncated nanocubes or nanowires and their shape-dependent toxicity to 
human skin fibroblast cells are summarized in chapter 4. Chapter 5 describes 
cellular responses of AuNPs with different structures (hexagon, pentagon and 
triangle) in human breast cancer cells while chapter 6 discusses cytotoxicity 
and genotoxicity of Ag and Au nps on human colon cancer stem cells and 
embryonic stem cells at low doses.  
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MATERIALS AND METHODS 
  




2.1 Chemicals  
Nanoparticle synthesis was carried out using a standard procedure through 
reduction of silver or gold salt.1 All glasswares used for the synthesis were 
treated with piranha solution [30% hydrogen peroxide/concentrated sulphuric 
acid in 3:1 ratio] and washed thoroughly in ultrapure water (Millipore 
Corporation).  
The following chemicals were used as received from commercial 
suppliers. Silver nitrate (AgNO3), potassium gold (III) chloride (KAuCl4), 
ethylene glycol (EG, 99.8%) and polyvinylpyrrolidone (PVP, Mw = 40 000) 
were purchased from Sigma Ardrich. 1, 6-Hexanediol (+97%) were purchased 
from Tokyo Chemical Industry Company. Calcium chloride dihydrate 
(CaCl2·2H2O) was purchased from MERCK. All chemicals were used without 
further purification.  
Dry mint leaves and ginger rhizome were purchased from local Chinese 
traditional medicine shops, while pure soluble coffee (NESCAFE Gold), 100% 
freeze-dried soluble coffee (Nestle Korea Ltd.) was purchased from local 
supermarket in Singapore. Millipore water was used in all the preparations.  
2.2 Synthesis of nanomaterials 
2.2.1 Synthesis of Ag-mint, Ag-ginger and Ag-coffee nps  
The plant material extracts were used as both reducing agents and capping 
agents in this project and their selection was done based on their effects for 
enhancing the solubility and stability of Ag nps. The extracts could reduce 
silver nitrate into Ag nps at room temperature without adding other reducing 
agents.2,3  
Dried mint leaves (5 g) were washed triplicates with 200 mL Millipore 
water before boiling in 350 mL water until volume reduced to 150 mL, the 
final solution was filtered with filter paper. The dry powder of extracts was 




obtained by freeze drying process. The extracts were freeze at -20 °C 
overnight before dried with a vacuum pump for 2-3 days. No attempt was 
made to purify or isolate compounds in the extracts. Finally, the appropriate 
amount of mint extract powder was weighed and dissolved in millipore water 
to obtain a standard mint extract solution. Ag-mint nanoparticles were 
synthesized by reducing silver nitrate solution with mint extracts solution at 
the ratio of mAg/mmint = 1/5 under constant stirring at room temperature. The 
color of the solution was changed to yellowish brown with time, indicating 
nanoparticle formation. The mixture was stirred for an additional 2 h. Ag nps 
were purified using repeated centrifuging and washing with water to remove 
any traces of unbound mint extracts, dispersed in pure water and used for 
structural characterization.  
Ginger extracts was generated from dried ginger rhizome following the 
above procedures while pure soluble coffee (NESCAFE Gold) were used 
directly for coffee extracts. Ag-ginger nanoparticles and Ag-coffee 
nanoparticles were synthesized as described above for Ag-mint nanoparticles. 
All three Ag nps showed high dispersion and solubility at high concentrations 
during the cell viability studies.  
2.2.2 Synthesis of Ag nanocubes - Ag cube 1  
The silver nanocubes were synthesized by adopting a reported procedure.4 
Briefly, 5 ml of anhydrous ethylene glycol was heated at 160 °C for 1 h under 
nitrogen atmosphere. AgNO3 (0.127 g, 0.75 mmol) and PVP (0.125 g, 1.13 
mmol) were dissolved separately in ethylene glycol (each 3 mL) and 
simultaneously injected to the reaction flask by using two syringes at a rate of 
0.2 mL in 30 second interval. The reaction mixture was further heated at 
160 °C for another 45 min which showed the formation of gray color 
suspension, cooled to room temperature and diluted with Millipore water (50 
mL). SEM images of the reaction mixture showed nanocubes formation along 
with a few rods. The nanocubes were purified by centrifuging the solution and 




then washing with water for three times. At the last stage, the pellet was 
washed with acetone and dried under vacuum oven. 
2.2.3 Synthesis of Ag nanowires  
Synthesis of Ag nanowires was achieved using similar procedures as that 
of Ag nanocubes, however the AgNO3 and PVP were mixed together prior to 
addition in the reaction flask. Briefly, AgNO3 (0.127 g, 0.75 mmol ) and PVP 
(0.125 g, 1.13 mmol) were dissolved separately in ethylene glycol (each 3 mL) 
and mixed together at room temperature and kept for 45 min, after which the 
solution turned light yellow. A combined solution of PVP/AgNO3 (6 mL) was 
injected to the reaction flask, containing ethylene glycol (5 mL) preheated at 
160 °C for 1h, at a rate of 0.4 mL with 30 second interval. After the addition, 
the reaction was stirred for 45 min and the temperature was slowly raised to 
180 °C. A gray colored precipitate appeared and the reaction was stirred for 45 
min, cooled to room temperature and diluted with Millipore water (50 mL). 
The Ag nanowires were separated using centrifugation, washed and dried 
under vacuum. 
2.2.4 Synthesis of Ag truncated nanocubes - Ag cube 2  
The procedure of synthesis of Ag truncated nanocubes was through 
modifying the reported procedure for synthesis of silver nanocubes.5 In a 
typical synthesis, anhydrous ethylene glycol (5 mL) was heated at 160 °C for 
1.5 h; then separate solutions of AgNO3 (0.425 g, 2.50 mmol) and PVP (0.383 
g, 3.45 mmol) in ethylene glycol (each 3 mL) were simultaneously injected 
into the reaction flask by using a two-channel syringe pump at a rate of 500 
µL/min. The color of the reaction mixture was changed from colorless to 
reddish yellow, and to gray. The mixture was stirred at 160 °C for another 45 
minutes. Truncated cubes were purified by repeated centrifuge and filtration. 
The pellet obtained after the lyophilization (Freeze Dryer, Alpha 2-4 LD plus, 
Christ) was redispersed in ultrapure water through sonication to prepare the 





2.2.5 General procedure for the synthesis of shape-controlled Au 
nanoplates (AuNPs)  
Hexagon (HAuNPs), pentagon (PAuNPs) and triangle AuNPs (TAuNPs) 
were prepared using a modified alkanediol process.6 Stock solution of PVP 
(1.24 g) and KAuCl4 (0.075 mmol, 28.3 mg) were dissolved in 3 mL 1, 
6-HEXANEDIOL solution at 80 °C, separately, and kept warming until 
injection. Different concentrations of CaCl2 solutions were employed for 
controlling shape formation of AuNPs. Stock solutions of calcium chloride 
dihydrate at various concentrations of Au were prepared with Au/Ca ratio of 
200/1 (Au:Ca = 200:1), 400/1 and 800/1 in 1, 6-HEXANEDIOL solution. 
Solution of CaCl2 (0.15 mL) was added to 5.0 mL 1, 6-HEXANEDIOL 
solution at 220 °C. PVP (3.0 mL) and KAuCl4 (3.0 mL) stock solutions were 
alternatively injected every 30 seconds over 9 min under vigorous stirring. 
Note that simultaneous injection of both solutions or injection of KAuCl4 
stock solution to 8 mL PVP 1, 6-HEXANEDIOL solution changed the shape 
formation. After the injection, the resulting mixture was kept for 1 hour and 
cooled to room temperature. The nanoplates formed were washed with ethanol 
and water three times to remove excess amount of PVP and collected by 
centrifugation. All nanoplates were dried using lypholization and resuspended 
in an appropriate amount of ultrapure water to prepare a stock solution.  
2.2.6 Synthesis of Ag-PVP and Au-PVP nps  
Briefly, 2 ml of AgNO3 stock solution (0.1 M) and 400 mg PVP dissolved 
in 8 ml of ultrapure water were added to 188 ml of ultrapure water in a flask. 
Further, 40 mg of NaBH4 dissolved in 2 ml of ultrapure water were added 
dropwise to the resulting mixture while stirring. The color of the solution 
immediately changed to reddish-brown. The solution continued stirring for 24 
hours at room temperature to react completely. A similar procedure was 




carried out to synthesize Au nps by replacing 2 mL of AgNO3 stock solution 
(0.1 M) with 2mL of HAuCl4 stock solution (0.1 M) during the reaction.  
After synthesis, the nanoparticles solution was centrifuged and washed 
with ultrapure water several times to remove any unreacted or excess reagents. 
The pellet obtained was resuspended in ultrapure water and filtered through a 
0.2 µm filter to remove any aggregates. The nanoparticles solution was 
freeze-dried and the resulting powder was resuspended in ultrapure water for 
preparation of nanoparticles stock solution.  
2.3 Characterization of nanomaterials  
2.3.1 Transmission electron microscopy (TEM)  
The size and morphology of Ag-mint, Ag-coffee, Ag-ginger nanoparticles, 
Ag-PVP nanoparticles, Au-PVP nanoparticles and AuNPs were observed with 
JEOL 2010-F Field Emission Transmission Electron Microscope (FETEM). 
Briefly, aqueous solution of Ag NMs (10 µL) was dropped on the copper grids 
and left dried in air. Then the samples were imaged using TEM.  
2.3.2 Scanning electron microscope (SEM) 
The morphology of Ag cube1, cube 2 and nanowires were observed with 
JEOL JSM-6701F field emission scanning electron microscope (FESEM). For 
sample preparation, a dilute solution of Ag NMs was dispersed in ultrapure 
water, placed onto 12 mm cover glass (Marlenfeld GmbH) and left to dry in 
oven (70 °C) for overnight and used for SEM. 
2.3.3 Elemental analysis 
Elemental analysis of freeze-dried Ag-mint, Ag-ginger, Ag-coffee, 
Ag-PVP and Au-PVP nanoparticles was analyzed for their respective 
elemental composition. Presence of carbon, hydrogen and nitrogen content 
was detected using Elementar Vario Micro Cube. Inductively-coupled plasma 
(ICP) analysis (Dual-view Optima 5300 DV ICP-OES) was used for the 




determination silver level in digested solutions of Ag nps.  
2.3.4 X-ray diffraction 
X-ray diffraction (XRD) pattern of Ag and Au NMs were recorded using 
Bruker-AXS: D8 DISCOVER with GADDS Powder X-ray diffractometer 
with Cu-Kα (λ = 1.54 Å) at 40 kV and 40 mA over a range of 2θ angle from 5° 
to 90°. For sample preparation, Ag and Au NMs solutions were deposited onto 
cover glass (Marlenfeld GmbH) and dried in oven (70 °C). The process was 
repeated several times to get a thick layer suitable for XRD analysis.  
2.3.5 Surface plasmon resonance (SPR) properties 
The surface plasmon resonance properties of nanomaterials were 
evaluated by their ultraviolet–visible (UV-Vis) measurements. The absorption 
spectra of nanomaterials aqueous solution were recorded on either 
UV-Vis-NIR spectrophotometer (Shimadzu UV-3600PC) or UV-Vis 
spectrophotometer (Shimadzu UV-1601PC). The measurements were 
conducted at room temperature.  
2.3.6 Dynamic Light Scattering (DLS) 
Dynamic light scattering (DLS) of nanomaterials aqueous solution were 
done using Malvern Zetasizer Nano-ZS90 at room temperature.  
Colloidal stability of Ag NMs (Ag cube 1, cube 2 and nanowires) in different 
disperse solutions was measured. Ag NMs stock solution was diluted with 
water, Dulbecco’s modified eagles medium (DMEM, HyClone) and DMEM 
with fetal bovine serum (FBS, GIBCO) (10%) to a final concentration 25 and 
100 µg/mL and incubated for 24 hours before the analysis was performed. The 
DLS measurements were performed on Malvern Zetasizer Nano-ZS90. After a 
30 seconds equilibration step at 25 °C, each sample underwent three 
measurements. Intensity distribution data were considered for the analysis. 
Values were obtained by averaging the three measurements.  




For Ag-PVP and Au-PVP nanoparticles, the aggregation and 
hydrodynamic size of nanoparticles in different solutions were measured by 
DLS. Ag nps stock solution were diluted with water, phosphate buffered saline 
(PBS, Biological Industries), serum free medium and medium with serum to a 
final concentration 50 µg/mL and incubated for 24 hours before the analysis 
was performed. The DLS measurements were performed on Malvern Zetasizer 
Nano-ZS90. After a 30 seconds equilibration step at 25 °C, each sample 
underwent three measurements. Read number and duration for each 
measurement were set on ‘automatic’ on the Zetasizer control software. Only 
intensity distribution data were considered for the analysis. Values were 
obtained by averaging the three measurements.  
Colloidal stability of Ag NMs (Ag cube 1, cube 2 and nanowires) in 
different disperse solutions was measured by DLS. Ag NMs stock solution 
was diluted with water, DMEM and DMEM with FBS (10%) to a final 
concentration 25 and 100 µg/mL and incubated for 24 hours before the 
analysis was performed. The DLS measurements were performed on Malvern 
Zetasizer Nano-ZS90. After a 30 seconds equilibration step at 25 °C, each 
sample underwent three measurements. Intensity distribution data were 
considered for the analysis. Values were obtained by averaging the three 
measurements. 
2.3.7 Surface charge of nanomaterials 
Surface charge of nanomaterials was detected through zeta potential 
measurements performed on the Zetasizer Nano-ZS90 (Malvern Instruments).  
Surface charge of Ag NMs (Ag cube 1, cube 2 and nanowires) in different 
disperse solutions was measured. Ag NMs were prepared using the similar 
procedures described above in DLS part and detected in triplicates after a 2 
minutes equilibration step at 25 °C. 
For Ag-PVP and Au-PVP nanoparticles, nanoparticles stock solution was 




diluted with water, PBS, serum-free media and media with serum to a final 
concentration 50 µg/mL. The measurements were conducted in triplicates on 
the Zetasizer Nano-ZS90 (Malvern Instruments). The sample was equilibrated 
at 25 °C for 2 minutes, and underwent measurements using the automatic 
measurement protocols recommended by Malvern.  
For Ag NMs (Ag cube 1, cube 2 and nanowires), surface charge of Ag 
NMs in different solutions was checked using Malvern Zetasizer Nano-ZS90. 
Ag NMs stock solution was diluted with water, DMEM and DMEM with FBS 
(10%) to a final concentration 25 and 100 µg/mL and incubated for 24 hours 
before the analysis was performed. Ag NMs were detected in triplicates after a 
2 minutes equilibration step at 25 °C. 
2.3.8 Silver ions release from Ag NMs 
Ag NMs (Ag cube 1, cube 2 and nanowires) were dissolved in millipore 
water to prepare stock solution (2 mg/mL). Freshly prepared stock solutions 
(100 µL) were diluted with either water or cell culture medium (2 mL) to a 
final concentration (100 µg/mL). These solutions were kept at room 
temperature for 1 to 7 days. The resulting suspension was subjected to 
centrifugation at 10000 rpm for 1 h to remove the solid nanoparticles. The 
supernatant was filtered with Whatman filter, topped up to 10 mL with water 
before analysing silver content using ICP-OES (Dual-view Optima 5300 DV, 
PerkinElmer). The experiment for each group was performed in triplicates and 
average value is reported.   
2.4 Cell culture 
2.4.1 Human cancer cell line 
Human cancer cell lines HeLa, HepG2 and MCF7 were purchased from 
commercial sources, American Type Culture Collection, USA. Cells were 
maintained in DMEM (HyClone) supplemented with 10% FBS (GIBCO) and 
1% penicillin streptomycin (Gibco, Invitrogen). Cells were maintained in a 5% 




carbon dioxide (CO2) incubator at 37 °C.  
2.4.2 Human normal cell line 
Normal human skin fibroblast cells (Department of Surgery, Yong Loo 
Lin School of Medicine, National University of Singapore, Singapore) and 
human dermal fibroblast (HDF, Gibco, Life technologies) were used in the 
study. Human normal cells were cultured in minimum essential medium 
(MEM, Gibco, Life technologies) supplemented with 10% FBS (Hyclone), 1% 
penicillin streptomycin (PAN Biotech GmbH), 1% MEM non-essential amino 
acids (100X, Gibco, Life technologies) and 1% MEM vitamin solution (100X, 
Gibco, Life technologies) and maintained in an incubator containing 5% CO2 
at 37 °C. 
2.4.3 Human cancer stem cell line 
Human colon cancer stem cell line (colon CSCs) obtained from Celprogen. 
Cells were cultured in accordance with Celprogen specifications. In brief, cells 
were cultured in human colon cancer stem cell complete growth medium with 
the appropriate human colon cancer stem cell extra-cellular matrix (Celprogen) 
in a water-saturated atmosphere with 5% CO2 at 37 °C. 
2.4.4 Human embryonic stem cell line  
Human embryonic stem cells (HESCs) BG01V were obtained from 
American Type Culture Collection (ATCC, SCRC-2002), as a frozen stock. 
BG01V were cultured in a 6-well plate (Greiner Bio-One CELLSTAR) with 
mitomycin C-treated (mitomycin C, Sigma Aldrich) mouse embryonic 
fibroblasts (MEF) CF-1 (ATCC, SCRC-1040.2) feeder cells. Cells were 
cultured at 37°C, in a 5% CO2 atmosphere, in the HESC medium of 80% 
Dulbecco's Modified Eagle Medium : Nutrient Mixture F-12 (DMEM / F-12) 
(GIBCO, Life technologies), supplemented with 20% knockout serum 
replacement (GIBCO, Life technologies), 1% MEM non-essential amino acids 
(100X) (GIBCO, Invitrogen), 2 mmol·L-1 L-glutamine (GIBCO, Life 




technologies), 0.1 mmol·L-1 2-mercaptoethanol (GIBCO, Invitrogen) and 4 
ng·mL -1 basic fibroblast growth factor (FGF-basic-147, Cell guidance 
system). The cell medium were daily changed and cells were passaged every 
6-7 days using collagenase Type IV (200 Units/mL) (GIBCO, Invitrogen).  
2.4.5 Embryoid body (EB) formation 
HESCs in culture were removed from feeder cells using collagenase IV. 
hESC clusters were transferred to 12-well plate (sterile non-treated, NUNC) 
and cultured in medium of 80% Dulbecco's Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM / F-12), supplemented with 20% knockout serum 
replacement, 1% MEM non-essential amino acids (100X), 2 mmol·L-1 
L-glutamine and 0.1 mmol·L-1 2-mercaptoethanol. The medium was changed 
every second day. 
2.5 Preparation of stock solution and treatment  
Stock solutions of nanomaterials (1 or 2 mg/mL) were prepared in sterile 
millipore water and diluted to the required concentrations (Ag nps: 0, 10, 25, 
50 and 100 µg/mL; Ag cube1 cube 2 and nanowires: 0, 10, 25, 50, 100 and 
200 µg/mL; AuNPs: 0, 25, 50, 100, 200 and 400 µg/mL) using cell culture 
medium. Cells were cultured in either 24 well plates or 96 well plates 
overnight. Appropriate concentration of stock solution was added to each well 
to obtain respective concentration of nanomaterials and incubated for 24 h to 
72 h.  
2.6 Microscopy 
2.6.1 Light microscopy 
Cells were plated in cell culture plates and treated with different 
concentration of nanomaterials. After incubation, cells were photographed to 
study the morphology changes under an inverted microscope (Olympus 
1X71). 




2.6.2. TEM of AuNPs treated cells 
Ultrathin sections of the cells were analyzed using TEM to reveal the 
distribution of AuNPs. MCF7 cells (1.5 x 106 cells) were seeded in T25 flask 
(Griener Bio-one GmbH) with 5 mL medium overnight to allow cell 
proliferation. Thereafter cells were treated with AuNPs (50 µg/mL) in fresh 
medium for 24 h. At the end of the incubation period, cells were washed with 
PBS to remove excess unbound AuNPs. Cells were trypsinized, washed with 
PBS and fixed in 2.5% glutaraldehyde for 2 h. Fixed cells were washed with 
PBS and post- fixed with 1% osmium tetroxide for 1 h at room temperature. 
Cells were further washed, dehydrated using alcohol, treated with propylene 
oxide (30 min), propylene oxide-resin mixture (overnight) and pure resin 
(overnight) before embedding in beem capsules containing pure resin (70 °C 
for 2 days). Ultrathin sections were cut using Reichert Jung Ultracut, stained 
with 1% lead citrate and 0.5% uranyl acetate before analyzing with TEM 
(JEOL JEM 2010F). The presence of AuNPs inside the cells was confirmed 
using electron-dispersive x-ray analysis (EDX). 
2.6.3 SEM observation of Ag NMs treated cells  
For SEM imaging of Ag cube 1, cube 2 and nanowires treated cells, 
human skin fibroblast cells were seeded onto coverslips in a 24-well plate at a 
density of 10000/well and allowed to adhere and proliferate for 24 h. The cells 
were then treated with Ag NMs (100 µg/mL) and incubated for 24 h. 
Thereafter, the cells were washed with PBS several times and fixed in 
glutaraldehyde (5%) and formaldehyde (4%) in PBS buffer at 4 °C for 24 h. 
The fixed cells were washed 5 times in PBS and then dehydrated using 30%, 
50%, 70%, 80%, 90%, 95% and 100% (2X) ethanol. The coverslips were 
dried, coated with platinum and further analyzed using JEOL JSM 6701F 
SEM.  
 




2.6.4 Dark field microscopy 
The morphology changes of cells treated with coffee, ginger and mint 
extracts were observed with dark field microscopy (Cyto Viva optical 
microscopy). Cells were seeded onto coverslips (Marlenfeld GmbH) of a 
24-well plate (Greiner Bio-one, Cellstar) at a density of 6 x 103 cells per well 
and allowed to adhere and proliferate for 24 h. The coverslips were washed 
with 70% ethanol and soaked in sterile phosphate buffered saline (PBS, 
Vivantis) for 3-5 min before putting inside the 24-well plate. Spent media was 
removed the next day and replaced with fresh medium along with extracts (20 
µg/mL) for 24 h. Untreated cells (control) were treated with medium only. The 
coverslip was removed from each well, rinsed with sterile PBS solution and 
placed face-down onto a clean glass slide for observation.  
Changes in morphology of cells treated with Ag NMs (20 or 25 µg/mL) were 
checked with similar procedure as described above.  
2.6.5 Confocal microscopy 
The distribution of Ag NMs inside the cells was examined by Confocal 
microscope. Cells were seeded onto coverslips in a 24-well plate at a density 
of 10000 /well and allowed to adhere and proliferate for 24 h. The cells were 
then treated with Ag NMs at the concentration of 25 µg/mL and incubated for 
24 h. Thereafter, the cells were washed with PBS several times, stained with 
CellMask™ Deep Red plasma membrane stain (2.5 µg/mL, Invitrogen) for 5 
minute at 37 °C. The staining solution was removed and the cells were fixed 
with warm 3.75% formaldehyde in PBS at 37ºC for 10 minute. The fixed cells 
were washed with PBS for 3 times and stained with DAPI (300 nM, Sigma 
Aldrich) at room temperature for 15 minutes. Thereafter, the coverslip was 
removed from each well, rinsed with sterile PBS solution and placed 
face-down onto a clean glass slide for observation under a confocal 
microscope (Olympus FV1000).  




2.7 Cell viability assay  
2.7.1 Measurement of ATP content 
The viability of cells treated with Ag and Au NMs were measured using 
CellTiter-Glo luminescent cell viability assay (Promega) following 
manufacturer’s instructions. This assay determines the number of viable cells 
in a cell culture based on quantification of the adenosine-5'-triphosphate (ATP) 
present, which signals the presence of metabolically active cells.7 The assay is 
based on the conversion of luciferin to oxyluciferin by a recombinant 
luciferase in the presence of ATP. The observed luminescence is proportional 
to the quantity of ATP in cells.  
The experiments were performed in 96-well plates (Corning, Costar). For 
the ATP assay, cells were plated in each well and incubated in 100 µL medium 
overnight for the cells to adhere to the bottom of the well. Spent medium was 
removed the next day and replaced with fresh medium and the cells were 
treated with different concentrations of nanomaterials (0, 10, 25, 50 and 100 
µg/mL for Ag-coffee, Ag ginger and Ag-mint nanoparticles; 0, 10, 25, 50, 100 
and 200 µg/mL for Ag cube 1, cube 2 and nanowires; 0, 25, 50, 100, 200 and 
400 µg/mL for AuNPs) for 24 h or 24, 48 and 72 h. At respective time points, 
100 µL of CellTiter-Glo viability assay pre-warmed to room temperature was 
added into each well and mixed properly. After 15 min, luminescence readings 
were measured using Tecan Infinite F200 microplate reader or BioTek 
microplate reader (Synergy 4). The dependence of toxicity on Ag nps was 
studied using mint, ginger and coffee extract stock solutions. Cells were 
treated with mint, ginger and coffee extracts (100 µg/mL) in 96-well plates for 
different incubation periods (24 h, 48 h and 72h) and then followed by 
CellTiter-Glo analysis. 
The dependence of toxicity on purity of Ag NMs (Ag cube 1, cube 2 and 
nanowires) was studied using the supernatants from the centrifugation step. 




The supernatant (20 mL) obtained after removing the nanomaterial pellet was 
concentrated by lyophilization and re-constituted in 1 mL of sterile water. 
Different volumes of the stock solution (0, 2.5, 5, 10, 15 and 20 µL) were 
dispensed in to 100 µL of medium in 96-well plates, incubated for 24 h and 
then followed by CellTiter-Glo analysis. 
2.7.2 Mitochondrial function cell viability assay 
Mitochondrial activity of cells with nanomaterials treatment was detected 
by a fluorimetric cell viability assay, CellTiter-Blue (Promega). This assay was 
used to measure the metabolically active cells in a culture by reducing 
resazurin in the reagent. Resazurin was reduced by the mitochondrial and 
microsomal enzymes to resorufin, a highly fluorescent molecule. Cells were 
seeded in 96-well plates at a density of 5 x 103 cells per well and incubated 
overnight for the cell proliferation. After incubation, cells were treated with 
different concentrations of nanomaterials (0, 10, 25, 50, 100 and 200 µg/mL 
for Ag cube 1, cube 2 and nanowires; 0, 25, 50, 100, 200 and 400 µg/mL for 
AuNPs; 0, 0.1, 0.5, 1.0, 2.5, 5 and 10 µg/mL for Ag-PVP and Au-PVP 
nanoparticles). Comparison study was conducted by treated cells with Ag and 
Au ions with similar metal amount as the nanoparticles (PVP capped 
nanoparticles) were used in the experiment based on elemental analysis results. 
After incubation, 20 µL of CellTiter-Blue cell viability assay pre-warmed to 
room temperature was added into each well. Cells were incubated in the dark 
at 37 °C for 2 h before detecting fluorescence using Tecan Infinite F200 
microplate reader or BioTek microplate reader (Synergy 4) at 560/590 nm. 
2.8 Intracellular reactive oxygen species (ROS) production 
The generation of ROS was evaluated by employing 2', 7' - 
dichlorodihydrofluorescein diacetate (DCF-DA, Sigma Aldrich) staining.8,9 
During incubation, non-fluorescent and non-polar DCFH-DA could passively 
enter the cells and is deacetylated by cellular esterases to the non-fluorescent 




but polar 2’, 7’-diclorfluorescein (DCFH), which therefore trap inside the cells. 
In the presence of intracellular ROS, the non-fluorescent DCFH was converted 
to a highly florescent compound 2’,7’-dichlorfluorescein (DCF). The ROS 
assay was performed using supplier’s instructions. The ROS level can be 
measured through three different detection methods.  
2.8.1 BioTek microplate reader  
Approximately 5 x 103 cells incubated with Ag-coffee, Ag-ginger and 
Ag-mint nanoparticles (0, 10, 25, 50, and 100 µg/mL) for 24 h in 96-well plate 
were washed with PBS twice and incubated with 10 µM DCF-DA for 30 min 
at 37 °C in the dark. Then cells were washed twice with PBS and analyzed by 
microplate reader (BioTek, Synergy 4) at an excitation wavelength of 485 nm 
and an emission wavelength of 530 nm.10   
2.8.2 Olympus microscope 
Cells were seeded in 96-well plates at a density of 5 x 103 cells per well 
and incubated overnight to allow cells proliferation. After the cells were 
treated with nanomaterials at different concentrations (50 and 100  µg/mL for 
AuNPs; 0, 0.1, 1, and 10 µg/mL for Ag-PVP and Au-PVP nanoparticles) for 24 
h, cells were washed twice with phosphate buffered saline (PBS, Vivantis) 
followed by incubation with 10 µM DCFH-DA at 37 °C for 30 min. Cells 
were then washed twice with PBS to remove the free DCFH-DA that did not 
enter the cells before observing under the inverted microscope (Olympus 
1X71). 
2.8.3 Flow cytometry 
Approximately 4 x 105  cells were seeded in each well of a 6-well plate 
(Greiner Bio-one, Cellstar) and incubated with Ag NMs (25 µg/mL) for 24 h. 
Cells were washed twice with PBS followed by incubation with 10 µM 
DCF-DA for 30 min at 37 °C in dark. Cells were again washed twice with 
PBS to remove the free DCF-DA that did not enter the cells. Further 




fluorescence of the cells was analyzed by flow cytometry (Epics Altra, 
Beckman and Coulter) at excitation wavelength of 488 nm and an emission 
wavelength of 530 nm. Data collected for 10000 cells were analyzed using 
Summit V4.3.02 software. 
2.9 Cell cycle analysis 
Cell cycle analysis was performed by staining DNA with propidium 
iodide (PI, Sigma Aldrich). Approximately 1 x 105 cancer cells and 3 x 105 
skin fibroblast cells were seeded in each well of 6-well plate (Corning, Costar) 
and incubated at 37 °C overnight for cells to proliferate. Following cells 
treated with the nanomaterials at different concentrations (20 µg/mL for 
Ag-coffee, Ag-ginger, Ag-mint nanoparticles, 24h; 25 µg/mL for Ag cube1, 
cube 2 and nanowires, 24 h; 0, 0.1, 1 and 10 µg/mL for Ag-PVP and Au-PVP 
nanoparticles, 3 days), the cell medium was removed and stored. Cells were 
washed in PBS, trypsinized, harvested in the stored medium, and centrifuged. 
The pellet was washed twice in PBS, fixed in fresh prepared ice-cold ethanol 
(70%), and stored at -20 °C overnight. Thereafter, cells were washed in PBS, 
stained with PI in RNase (40 µg/mL PI and 100 µg/mL RNase A) at 37 °C for 
30 min and followed by incubation at 4 °C until analysis. Flow cytometry 
analysis was performed at an excitation wavelength of 488 nm and emission 
wavelength of 610 nm (Epics Altra, Beckman and Coulter). Data collected for 
1 x 104 cells for HepG2 cells and HeLa cells was analyzed using Summit 
V4.3.02 software.  
2.10 Cell death 
2.10.1 Morphological assessment of apoptotic cells by DAPI staining 
Apoptotic nuclei in cells with Ag and Au NMs treatment were detected by 
a DNA-binding dye, 4', 6-diamidino-2-phenylindole (DAPI, Sigma Aldrich). 
Cells were seeded in a 24 well plate (1×104 cells/well) for 24 h to allow the 
cells to adhere to the bottom of the well. Cells were then treated with 




nanomaterials at different concentrations (100 µg/mL for AuNPs; 0, 0.1, 1.0 
and 10 µg/mL for Ag-PVP and Au-PVP nanoparticles) for 24 h. After 
incubation, cells were fixed with 2% paraformaldehyde at 4 °C for 30 min and 
then treated with absolute ethanol for 5 minutes. After washing with PBS 
twice, cells were stained with DAPI and observed under a fluoresce 
microscope (Olympus 1X71). 
2.10.2 Annexin-V staining for apoptosis and necrosis 
Annexin-V staining was performed to distinguish apoptosis and necrotic 
cell death induced by nanomaterials. Annexin-V, a family of 
calcium-dependent phospholipid-binding proteins, has a high affinity for 
phosphotidyl serine (PS). Upon initiation of apoptosis, PS is translocated from 
the inner to the outer leaflet of the plasma membrane, thus exposing PS to the 
external cellular environment. Its conjugation with the fluorescent probe FITC 
facilitates measurement for cells undergoing apoptosis using flow cytometric 
analysis. Use of propidium iodide (PI) staining helps to differentiate between 
apoptosis and necrosis, which is attributed to difference in permeability of PI 
through the cell membranes of live and damaged cells. Approximately 2.5 x 
105 HepG2 and HeLa cells and 3 x 105 skin fibroblast cells were placed in 60 
x 15 mm tissue culture dish (Falcon, Franklin Lakes), and then treated with 
nanomaterials at different concentrations (20 µg/mL for Ag nps; 25 µg/mL for 
Ag cube 1, cube 2 and nanowires) for 24 h. Treated cells were harvested and 
washed twice in dulbecco’s phosphate buffered saline (DPBS, Sigma-Aldrich) 
and stained (annexin-V FITC apoptosis detection kit, Sigma-Aldrich) as 
manufacturer’s instruction before detecting with flow cytometry (Epics Altra, 
Beckman and Coulter). Data was collected for 1 x 104 gated cells and analyzed 
using Summit V4.3.02 software.  
2.11 Quantitation of cellular uptake of AuNPs 
The nanoparticle uptake by the cells was quantified using inductively coupled 




plasma-optical emission spectroscopy (ICP-OES, Perkin Elmer Optima 5300 
DV). Cells were seeded at a density of 1.5 × 105 cells in T-75 flask and treated 
with Au nanoplates to achieve a final concentration of 100 μg/mL. Following 
incubation period, medium was removed and flasks were washed 5 times with 
PBS. Cells were harvested using trypsin, washed 3-4 times in PBS and 
resuspended in 10 mL PBS. The cell number in all tubes was adjusted to 2 
million and one millilitre of the lysate was analysed after homogenization. 
Control, without silver nanoparticles treatment, was also sent for elemental 
analysis. 
2.12 Gene expression profile using real time-reverse transcriptase- 
polymerase chain reaction (RT-PCR) 
Colon CSCs (2 x 105 cells) were seeded in T25 flask for overnight and 
then treated with Ag and Au nps (0, 0.1, 1.0 and 10 µg/mL) for 3 days. The 
cells were washed once with PBS and the total RNAs were extracted from the 
cells using TRIzol® reagent (Life Technologies, Invitrogen) according to the 
manufacturer’s protocol. The extracted RNA was dissolved with 70 µL DEPC 
(diethylpyrocarbonate) treated water. To verify the purity of the RNA and to 
determine the concentration, the extracted RNA was analyzed by the 260nm 
absorbance and the 260/280nm absorbance ratio on NanoDrop 1000 (Thermo 
Scientific), respectively. The extracted RNA was stored at -80 °C. Afterwards, 
2 mg of the extracted mRNA was reverse transcribed into complementary 
DNA (cDNA) with EZ-first strand cDNA synthesis kit (Biological industries). 
The cDNA was then stored at −20 °C.  
Quantitative real- time polymerase chain reaction (RT-PCR) for cDNA 
was performed on an Applied Biosystems StepOnePlus™ Instrument using 
Taqman® Gene expression assays (Applied Biosystems, USA) according to 
the supplier’s instructions.  
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as 




control for normalization.  The final reaction volume was 20 µL, containing 
10 µL Taqman® Gene expression master mix (2X, Applied Biosystems, USA), 
1.0 µL Taqman® Gene expression assay (20X, Applied Biosystems, USA), 
1.0 µL cDNA template and 8 µL RNase-free water. Cycling conditions were 
as follows: a 2 min incubation at 50 °C step for optimal UDG enzyme activity, 
and a 95 °C AmpliTaq Gold® enzyme activation for 10 min, followed by 40 
cycles of 95 °C denaturation for 15 s and 60 °C anneal/extension for 1 min.  
Each measurement was conducted in triplicate, and negative controls with 
no cDNA template were included for each assay. After PCR, a dissociation 
curve analysis was done. Relative gene expression was calculated using the 
2−∆∆CT  method with pooled cDNA from all samples as a reference.11 
2.13 Statistical analysis 
Statistical analyses of data for all experiments are expressed as mean and 
standard deviation. The data were analyzed using Student’s t-test (Microsoft 
Excel, Microscoft Corporation). Differences were considered as statistically 
significant when P value <0.05. 
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3.1 Introduction  
Owing to the antimicrobial activity, silver (Ag) nanoparticles have been 
used in a wide range of consumer products ranging from cosmetics, household 
products and medical applications including imaging, drug delivery and 
disinfection. Ag nps impregnated catheters1 and wound dressings2 are used in 
therapeutic applications. However, previous studies have indicated that 
nanoparticles have a size-, time- and dose-dependent cytotoxicity, where 
smaller particles with longer exposure time at higher concentrations showed 
the highest toxicity.3,4 A possible mechanism of cytotoxicity of Ag nps 
involves disruption of the mitochondrial respiratory chain, increase of reactive 
oxygen species (ROS) production and interruption of 
adenosine-5'-triphosphate (ATP) synthesis, which in turn cause 
deoxyribonucleic acid (DNA) damage.4 An organic capping agent with 
functional groups is used to fine-tune solubility, stability, surface charges, and 
interactions of nanoparticles with other molecules. The nature of capping 
agent influences both the physicochemical properties and biological properties 
of nanoparticles.3,5-8 To our knowledge, little is known on the influence of 
capping agents on the bioactivity of Ag nps.9,10 Recently, there has been 
growing interests in developing environmentally friendly and multifunctional 
biomaterials as capping agents for nanoparticles to reduce toxicity.11-16  
Green approaches have been employed for the synthesis of nanoparticles 
where plant extracts were used as reducing agent and capping agent.17-21 Here, 
we use common ginger,22 mint and coffee23 extracts as reducing and capping 
agents to control the size and surface functional groups for the synthesis of 
water soluble Ag nps. Ag nps were characterized with multiple techniques and 
their cytotoxic effects in cell lines (hepatocellular liver carcinoma cells, 
HepG2 and human cervical cancer cells, HeLa) were investigated by using the 
following experimental methods which were described in detail in Chapter 2 
(Materials and Methods):  




1. Synthesis, purification and characterization of Ag-coffee, Ag-ginger and 
Ag-mint nanoparticles; 
2. Dark field microscopy (CytoViva) – cell morphology and Ag nps uptake; 
3. ATP assay (CellTiter-Glo) – cell viability; 
4. Cell cycle assay – cell proliferation; 
5. ROS production – mechanism of Ag nps cytotoxicity; 
6. Apoptosis assay – mechanism of cell death.  
3.2 Results and discussion  
The separation and identification of various components in coffee, ginger 
and mint extracts were reported in literature.22-30 The extracts from the above 
materials contain polyphenols,31-33 which can form complexes with silver ions 
in solution and reduce them to Ag nps.17 Some other compounds existed in the 
extracts may also help to stabilize Ag nps in solution, which include caffeine, 
sucrose and amino acids in coffee extract;34 ascorbic acid in both ginger and 
mint extracts.29,35 All Ag nps capped with plant extracts were synthesized at 
room temperature, purified by repeated centrifuging and washing. These Ag 
nps were stable at room temperature for long periods of 6 months or more. 
Ag-mint, Ag-ginger and Ag-coffee nanoparticles showed good solubility in 
water with bluish yellow, brownish yellow and light brownish yellow color, 
respectively (Figure 3.1A). From the elemental analysis of the lyophilized 
particles, it appears that Ag-mint has a slightly higher Ag content (48.76 wt%) 
than Ag-ginger (41.33 wt%) and Ag-coffee (41.46 wt%). Ag nps exhibit 
unique surface plasmon resonance (SPR) properties, which could be detected 
by UV-Vis spectroscopy (Figure 3.1B). A characteristic absorbance band of 
Ag nps is dependent on the size of nanoparticles. Ag-mint nanoparticles 
showed a maximum absorbance at 460 nm, while Ag-coffee nanoparticles and 
Ag-ginger nanoparticles showed absorption maxima at 442 nm and 424 nm, 
respectively (Table 3.1). 





Figure 3.1: Optical images (A) and UV-Vis spectra (B) of Ag-mint, Ag-coffee 
and Ag-ginger nanoparticles solution. The concentration of solution in (A) is 
0.1 mg/mL.  
3.2.1 TEM analysis of Ag nps   
TEM images showed that Ag nps are present in varying size formed by 
using different natural material extracts (Figure 3.2A-C). For Ag-mint 
nanoparticles, the size distribution was in the range of 5 to10 nm with a few 
larger nanoparticles with the size of 50 nm (Figure 3.2A); for Ag-ginger 
nanoparticles, nanoparticles were distributed in the range of 5 to10 nm along 
with some large particles range from 30 to 40 nm (Figure 3.2B); while for 
Ag-coffee nanoparticles, the majority was in the range of 30 to 40 nm (Figure 
3.2C). The calculated size distribution histograms are shown in Figure 
3.2D-F. 
The size of Ag nps depends on the efficiency of the reducing agent and 
the binding ability of the capping agent. Smaller Ag nps could be obtained 
through slow reduction,36 or in presence of strong capping agent.37 In our 
experiment, mint, ginger and coffee extracts were acted as both reducing agent 
and capping agent. Among the three Ag nps prepared under similar conditions, 
Ag-mint nanoparticles are smaller than both Ag-ginger and Ag-coffee 
nanoparticles (Figure 3.2), indicating that the mint extracts are more active 
towards reduction of Ag+ ions and capping to nanoparticles.  





Figure 3.2: Typical TEM image of Ag-mint (A), Ag-ginger (B) and Ag-coffee 
(C) nanoparticles and the size distribution histogram of Ag-mint (D), 
Ag-ginger (E) and Ag-coffee (F) generated using image (A-C) captured with 
JEOL JSM 2010F. 
3.2.2 DLS and zeta potential measurements  
The hydrodynamic diameter of the Ag nps was determined using Malvern 
Zetasizer Nano System. All Ag nps are dispersible in water owing to the 
hydrophilic capping agents which can prevent individual particle from 
aggregating. The histograms of hydrodynamic size distributions of Ag-mint. 
Ag-ginger and Ag-coffee nanoparticles were showed in Figure 3.3. DLS 
measurements showed that Ag-mint, Ag-ginger and Ag-coffee nanoparticles 
showed two major size distributions in the water solution, indicating the 
aggregation of Ag nps in the solution. TEM images gave the diameter of 
nanoparticles at dry state, while DLS offers the hydrodynamic size distribution 
which includes the core particle, its organic layers (capping agents) and the 
hydration shell.38 The zeta potential values of Ag-mint and Ag-ginger 
nanoparticles were at -10.1 mV and -10.2 mV while that of Ag-coffee 
nanoparticles was at -27.1 mV (Table 3.1). The high negative charge of 
Ag-coffee nanoparticles could enhance the stabilization, which led to smaller 
hydrodynamic diameters compared to the other two nanoparticles. 





Figure 3.3: Histograms of hydrodynamic size of Ag-coffee (A), Ag-ginger (B) 
and Ag-mint nps (C) detected by DLS measurement. 
 
Table 3.1: Chemical composition (in wt%), zeta potential and SPR peaks of 
Ag-mint, Ag-coffee and Ag-ginger nps.  
3.2.3 Elemental analysis 
As can be seen in Table 3.1, it is apparent that the ratio of capping agent 
to silver in Ag-coffee is high. On the contrary, lowest carbon content was 
observed for Ag-mint nanoparticles. Silver content (48.8%, 41.3% vs. 41.5%) 
of all three samples were comparable which enables a fair comparison 








Ag-mint   48.76 10.45 1.45 2.38 36.96 -10.1 460 
Ag-coffee   41.46 37.04 3.23 5.63 12.64 -27.1 442 
Ag-ginger   41.33 19.31 3.35 5.43 30.58 -10.2 424 




between these three nanoparticles in cell viability testing. Oxygen content of 
Ag-mint nanoparticles was found to be higher than expected due to its 
hygroscopic nature. 
3.2.4 Dark field microscopy 
The first readily noticeable effect seen after exposure of cells to toxic 
materials is the alteration in cell shape or morphology. The experiment was 
first performed by treating HepG2 cells with mint, coffee and ginger extracts 
alone for 24 h and compared with the untreated cells which served as control. 
As can be seen in Figure 3.4, the plasma membrane, nuclear envelopes, 
cellular contents and organelles of all the cells could be observed in dark field 
microscopy. However, untreated cells showed much clearer plasma membrane 
compared to those treated with mint, coffee and ginger extracts which become 
less distinct from each other, although they still appear to maintain their 
structural integrity as the membranes remained intact.  
 
Figure 3.4: Low magnification (40X) dark field images of HepG2 cells 
untreated (A) and treated with mint extracts (B), coffee extracts (C) and ginger 




extracts (D). Concentration of extracts = 20 µg/mL 
 
Figure 3.5: Low magnification (40X) dark field images of HepG2 cells 
untreated (A) and treated with Ag-mint (B), Ag-coffee (C) and Ag-ginger (D) 
nanoparticles. Concentration of Ag nps = 20 µg/mL. 
The morphology changes of HepG2 cells treated with Ag nps (20 µg/mL, 
24 h) were also compared with untreated cells (Figure 3.5). Low 
magnification dark image (40X) of HepG2 cells with Ag-mint treatment 
showed significant morphological changes as compared to untreated cells.  
Cells treated with Ag-ginger and Ag-mint nanoparticles showed that Ag nps 
were concentrated in cells. High magnification (100X) images were further 
captured by dark field microscopy to observe the detailed cell changes with Ag 
nps treatment (Figure 3.6). Images of treated cells showed distinct 
morphological changes indicating unhealthy cells, whereas the control cells 
appeared normal. Ag-mint nanoparticles treated cells appeared to be slightly 
elongated as compared to the untreated cells. This could be due to the 
disturbances in cytoskeletal framework as a consequence of nanoparticles 
treatment. Untreated cells showed a small number of bright, round shape of 
spots distributed throughout the cells. These bright specks (green arrows) 




could be transport vesicles (endosomes) or organelles which contain high 
concentrations of ions and proteins (Figure 3.6A). Such bright specks should 
not be mistaken for Ag nps aggregates (yellow arrows) which are 
randomly-shaped. Ag nps are so small that they could not be observed directly 
under an optical microscope. Therefore, the bright objects seen in these 
images should be considered as scattered light from nanoparticles. It is also 
clearly found that Ag nps entered the cytoplasm but not the nucleus, which is 
consistent with literature findings.39 Ag-mint treated cells showed more 
sparkling specks with visible cell morphology changes indicating that they 
could penetrate the cell membrane more efficiently (Figure 3.6B) owing to 
their smaller size. In contrast, cells treated with Ag-coffee nanoparticles and 
Ag-ginger nanoparticles showed no morphology changes along with sparking 
specks inside the cells (Figure 3.6C and 3.6D) which can be interpreted that 
such Ag nps are less toxic than Ag-mint nanoparticles. Similar results were 
also observed for Ag nps treated HeLa cells (Figure 3.7). 
 
Figure 3.6: High magnification (100X) dark field images of HepG2 cells 
untreated (A) and treated with Ag-mint (B), Ag-coffee (C) and Ag-ginger (D) 




nanoparticles. Concentration of Ag nps = 20 µg/mL. Green arrows point to 
cellular components such as endosomes and lysosomes, while yellow arrows 
point to big Ag nanoparticle aggregates. 
 
Figure 3.7: High magnification (100X) dark field images of HeLa cells 
untreated (A) and treated with Ag-mint (B), Ag-coffee (C) and Ag-ginger (D) 
nanoparticles. Concentration of Ag nps = 20 µg/mL. Green arrows point to 
cellular components such as endosomes and lysosomes, while yellow arrows 
point to big Ag nanoparticle aggregates. 
Many papers from different laboratories have reported that uptake of 
nanoparticles was size-dependent.3,40,41 It showed that optimal nanoparticle 
radius for endocytosis is in the order of 25–30 nm.40 Smaller particles (< 10 
nm) are known to pass through various pores on the cell membrane. The 
cellular uptake of nanoparticles was also dependent on the nature of the 
capping agent.5 Generally, the smaller water soluble nanoparticles with 
targeting groups (e.g. transferrin, folic acid, galactose) are absorbed faster into 
the cell as compared to those capped with nontargeting capping agents such as 
PVP and PEG.42-44 Dark filed images also shown that Au nps could be 
selectively delivered into the cell nucleus by using RGD 
(arginine-glycine-aspartic acid) and nuclear location sequence (NLS) peptides 




or the cytoplasm region using RGD alone, while the PEG conjugated Au nps 
did not enter into the cells.45 Further the cellular uptake of nanoparticles was 
also dependent on the cell lines.46 Recently, we have shown that platinum 
nanoparticles capped with PVP showed higher cellular uptake in HeLa cells 
than in MCF7 and IMR90 cells.44 The strong reflection from Ag nps observed 
in our study could be attributed to many factors, such as size or capping agents. 
Moreover, similar results were also found in Ag nps capped with tea extract.9 
Ag nps capped with epicatechin alone showed minimal interaction with human 
keratinocyte cells (HaCaT) while Ag nps capped with tea extract showed 
extensive interaction (at the 1:1 ratio of water to tea extract).9 Further, the 
interaction between cells with Ag nps decreased when decreasing 
concentrations of tea extract.  
3.2.5 Viability assay  
Viability assays are important for identifying toxicity that indicates the 
cellular response to a toxic chemical and gives information on cell death, 
survival and metabolic activities. A concentration- and time-dependent study 
was performed to find out the effect of Ag nps on cell viability. Commonly 
used viability assays such as MTT or MTS assay were used to study the 
viability and the proliferation of cells through monitoring the absorbance of a 
formazan product formed in living cells. However, nanomaterials which sho w 
similar optical properties of a formazan product caused errors during the 
quantitative analysis. In our experiments, Ag nps solution which showed 
distinct UV-Vis absorption peaks gave inaccurate results when MTT or MTS 
assays were used. Such absorbance-based methods are considered not suitable 
for Ag nps treated cells. The Cell Titer-Glo luminescent cell viability assay 
was used in our experiment which could monitor cytotoxicity as well as cell 
proliferation (Procedure details refer to Page 66, section 2.7.1). This assay 
measures the amount of ATP present in the culture medium, which is 
proportional to the number of viable cells. It is more sensitive with short 




waiting time (minutes) as compared to other assays such as resazurin assay 
and MTS (1 to 4 h or more).47  
 
Figure 3.8: Viability of HepG2 cells treated with Ag-coffee nanoparticles (A), 
Ag-ginger nanoparticles (B), Ag-mint nanoparticles (C) and HeLa cells treated 
with Ag-coffee (D), Ag-ginger (E), Ag-mint (F) nanoparticles at different 
concentrations, * represents P < 0.05. 
The viability trends of Ag-mint, Ag-ginger and Ag-coffee treated cells 
were similar across different cell types. Generally, the viability of cells 
decreased with an increase in the concentration of Ag nps and with exposure 
time from 24 h to 72 h (Figure 3.8). HepG2 cells showed high ATP content (> 
70%) when treated with all three Ag nps at a lower dosage (10 µg/mL), 
however, ATP level decreased more significantly for cells treated with higher 




concentration of Ag-mint nanoparticles than the others. HepG2 cells treated 
with Ag-mint nanoparticles showed low ATP content (20% or even less) at the 
dosage 25 µg/mL or higher. Ag-ginger treated cells showed ATP depletion 
nearly 0% at the concentration of 50 µg/mL or higher. However, for cells 
treated with Ag-coffee nanoparticles, ATP was nearly 50% and 30% at 
concentration of 50 µg/mL and 100 µg/mL, respectively. This observation 
suggests that among all the three nanoparticles screened, Ag-mint 
nanoparticles are found to be the most toxic, followed by Ag-ginger 
nanoparticles and Ag-coffee nanoparticles showed least toxicity. Compared to 
HepG2 cells, HeLa cells treated with Ag nps seem to have higher viability at 
the same concentration, indicating that Ag nps showed different toxicity to 
different cell lines.  
The cytotoxicity of Ag nps with different capping agents was also 
explored on human normal cell line: human dermal fibroblast (HDF, Gibco, 
Life Technologies) cells (Figure 3.9). Similar results were also observed in 
HDF cells. After exposure to Ag nps for 24 h, the toxicity of all three Ag nps 
to the cells was dependent on the dose. Furthermore, of all three Ag nps, 
Ag-mint nanoparticles were the most toxic, followed by Ag-ginger 
nanoparticles and then Ag-coffee nanoparticles. All data put together suggest 
that change in the capping agents of Ag nps not only produce change in the 
extent of toxicity in human cancer cells but also in normal cells. When plant 
material extracts alone were used as control, it showed no significant 
cytotoxicity in HepG2 cells even at high concentration (100 µg/mL, Figure 
3.10A). However, coffee and ginger extracts were relatively more toxic to 
HeLa cells at 72 h (Figure 3.10B). A low ATP value does not always represent 
cell death and it could be due to the inhibition of metabolic processes in cells. 
No significant cell death was observed in the presence of Ag nps at low 
concentrations. Absence of large number of floating cells in the culture 
medium implies a possibility for metabolic arrest. Hence, it is of great 




importance to analyze the cell cycle to interpret the viability data fully.  
 
Figure 3.9: Viability of HDF cells treated with Ag-coffee, Ag-ginger and 
Ag-mint nanoparticles at different concentrations for 24h, * represents P < 
0.05. 
 
Figure 3.10: Comparison of viability of HepG2 (A) and HeLa (B) cells 
treated with coffee, ginger and mint extracts (100 µg/mL), * represents P < 
0.05. 
3.2.6 Intracellular ROS level  
Oxidative stress was reported to play an important role in nanoparticle 
toxicity.48 It is known that a small size and large surface area of nanoparticles 
could generate ROS. Oxidative stress represents an imbalance between the 
production and manifestation of ROS, which has specific effects in the cells 
such as oxidative damage to protein, lipids and DNA.49 All three extracts used 
in our experiments were reported to have antioxidant components.28,50,51 The 
antioxidant components of coffee extracts were polyphenols and 




melanoidins.52 The major constituents of mint leaves extract include terpenes 
(α-menthol, neomenthol) and flavonoids (quercetin, eugenol).53 Similarly, the 
ginger extracts contain gingerols, shogaols and some related phenolic ketone 
derivatives.50 Ginger extracts is reported to possess antioxidant characteristics 
and known to scavenge superoxide anion and hydroxyl radicals.54 To check 
the effect of capping agents on the surface of Ag nps in the production of ROS, 
DCF-DA staining methods were conducted in HepG2 and HeLa cells  
(Procedure details, refer to Page 68, section 2.8). In the presence of ROS, 
DCF-DA is promptly oxidized to 2′-, 7′- dichlorodihydrofluorescein (DCF), 
which is highly fluorescent.4 However, no significant increase was observed 
when cells were treated with different Ag nps (Figure 3.11). On the contrary, 
the analysis showed a decrease of ROS in both cell lines, which is proportional 
to concentration of Ag nps. Even at a low concentration of 10 µg/mL, the ROS 
level was less than 20% as compared to the control cells for all three Ag nps. 
For Ag-mint and Ag-ginger treated cells, the ROS level decreased drastically 
as the concentration of nanoparticles increased. For Ag-mint nanoparticles 
(100 µg/mL) treated cells, the ROS concentration of HepG2 cells was less 
than 20% while 30% of ROS was observed in HeLa cells. For Ag-ginger 
nanoparticles (100 µg/mL) treated cells, an approximately 60% reduction of 
ROS was observed in both cell lines.  
 
Figure 3.11: ROS production from DCF-DA staining of HepG2 (A) and HeLa 
(B) cells treated with Ag-coffee, Ag-ginger and Ag-mint nanoparticles for 24 h. 
Untreated cells were negative control. All the data are significance different 




from the control, as all the P < 0.05.  
The ROS data shows that Ag-mint nanoparticles have highest antioxidant 
capacity, followed by Ag-ginger nanoparticles. ROS production was reported 
to be dependent on the nanoparticles surface functionalization.55 Ag nps with 
other capping agents such as PVP, starch, citrate or tannic acid were reported 
to induce cytotoxicity through ROS production.4,56-59 The decreased ROS in 
cells treated with our Ag nps could be attributed to antioxidant effect of the 
capping agents. 
3.2.7 Mechanism of toxicity   
The differences in toxicity of Ag-mint, Ag-ginger and Ag-coffee 
nanoparticles could be due to many factors such as size of nanoparticles, silver 
content and nature of capping agent. Small nanoparticles showed high toxicity 
due to enhanced uptake into the cells and large surface area for interaction 
with biological molecules60 or generation of ROS.61 Majority of Ag-mint and 
Ag-ginger nanoparticles are in the range of 5 to 10 nm while Ag-coffee 
nanoparticles are in the range of 30 to 40 nm. The silver content of Ag-mint is 
higher (49%) as compared to that in Ag-coffee (42%) and Ag-ginger (41%). 
Under slightly acidic conditions, Ag⁰ can be converted to Ag+, which is 
believed to be responsible for ROS production and cause of the cell 
damage.58,62  
ROS was reported to have the potential to inhibit or promote cell 
proliferation by modulating the cell signaling pathways.63 ROS is produced in 
response to variety of extracellular and intracellular stimuli, whose reactivity 
and regulation could be controlled by antioxidants.64 Zhang et al.65 has 
reported that apoferritin-encapsulated platinum nanoparticles can improve the 
viability of the cells by decreasing the H2O2-induced intracellular ROS level. 
However, ROS is also a normal product of cellular metabolism, which is an 
indispensible component in cell signaling and homeostasis.66 The cell 
signaling pathways can be disturbed at low levels of ROS, which in turn cause 




the cell damage and ultimately to cell death.66 In our study, the ROS level 
decreased drastically when cells were treated with all three Ag nps, especially 
for Ag-ginger and Ag-mint nanoparticles. The viability data is consistent with 
the decreased ROS levels in cells, which is attributed to the antioxidant effect 
of the capping agents. 
3.2.8 Apoptosis and necrosis 
Apoptosis and necrosis, the most preferred responses for cell death among 
various mechanisms,41,67 are investigated to access the extent and mode of cell 
death upon exposure to Ag nps. Annexin V-FITC was used as a marker for 
apoptosis while PI was utilized to detect plasma membrane integrity to 
recognize necrotic cell death. Statistical data were acquired from the dot plots, 
based on the percentages of unstained cells (viable cells), and those stained 
with PI (necrotic cells), FITC (apoptotic cells), and dual stained cells (late 
apoptosis).  
 
Figure 3.12: Dot plots from Annexin- FITC staining of HepG2 cells. 
Untreated cells (A) are used to calculate % of change in population. Cells 
accumulating at lower left window represent live cells. (B) shows necrosis 
positive controls (H2O2 treated) which accumulate on upper left window for 




red fluorescent cells.(C) shows apoptosis positive controls (Staurosporine 
treated) accumulating on lower right window. Late apoptotic cells will 
accumulate in upper right window. (D) shows cell population for cells treated 
with Ag-mint (E) represents cells treated with Ag-ginger and (F) represents 
cells treated with Ag-coffee NPs (20 µg/mL). The % of cells under each 
category (live, early and late apoptosis, necrosis) is represented in respective 
windows. 
The above mentioned results of HepG2 cells with Ag nps treatment are 
shown in Figure 3.12. For Ag-ginger and Ag-coffee nanoparticles treated 
HepG2 cells, a decrease in the percentage of viable cells (3-8%) and early 
apoptosis cells (3-4%) was observed as compared to control cells. Moreover, 
7-12% increase was found in the percentage of late apoptosis cells, indicating 
that Ag-ginger and Ag-coffee nanoparticles were only slightly toxic to HepG2 
cells at a concentration of 20 µg/mL. However, a significant decrease in the 
percentage of live cells (42%) was observed for Ag-mint nanoparticles treated 
cells, accompanied by an increase in both early apoptosis (17%) and late 
apoptosis (25%) stages. It confirmed that Ag-mint nanoparticles are the most 
toxic, which is consistent with cell viability results.  
 
Figure 3.13: Dot plots from Annexin- FITC staining of HeLa cells. Untreated 
cells (A) are used to calculate % of change in population. Cells accumulating 




at lower left window represent live cells. (B) shows necrosis positive controls  
(H2O2 treated) which accumulate on upper left window for red fluorescent 
cells.(C) shows apoptosis positive controls (Staurosporine treated) 
accumulating on lower right window. Late apoptotic cells will accumulate in 
upper right window. (D) shows cell population for cells treated with Ag-mint 
(E) represents cells treated with Ag-ginger and (F) represents cells treated with 
Ag-coffee NPs (20 µg/mL). The % of cells under each category (live, early 
and late apoptosis, necrosis) is represented in respective windows. 
The response of HeLa cells to Ag nps was quite similar to HepG2 cells 
(Figure 3.13). Decrease in the percentage of live cells along with increase in 
the percentage of apoptosis cells was observed for all three Ag nps treated 
HeLa cells. Only small changes were observed on both Ag-ginger and 
Ag-coffee nanoparticles treated cells, indicating that these two nanoparticles 
were less toxic at low concentrations. Around 2% increase in late apoptosis 
cells along with 6% decrease in live cells were observed for Ag-mint 
nanoparticles treated cells, which indicate that Ag-mint nanoparticles were 
toxic to cells at a low concentration. Significant increase of necrotic cells (5%) 
was observed in Ag-mint treated HeLa cell.  
 
Figure 3.14: Apoptosis and necrosis mode of HepG2 and HeLa cells with 
ginger, coffee or mint extracts treatment (100 µg/mL, 24 h) by using Annexin-  
FITC staining. The percentage of cells stained with PI alone is represented as 
necrotic cells, whereas percentage of cells stained with FITC alone represents 
early apoptosis. Cells at final stages of apoptosis take up both stains. The 
percentage of cells under each area was generated using Summit V4.3.02 





 To check the cellular response of plant extracts on cells, HepG2 and HeLa 
cells, were treated with plant extracts (100 µg/mL, 24 h) and investigated the 
response. As can be seen from Figure 3.14, plant extracts treated cells did not 
induce significant cell death from neither apoptosis nor necrosis.  
Necrosis is usually related to loss of lysosomal membrane integrity and 
uncontrolled release of inflammatory cellular contents,68 while apoptosis is 
associated with the generation of ROS and JNK activation,69 mitochondrial 
fusion/fission machinery,70 caspase activation,71 calcium overload72 or caused 
by death- inducing signals.73 Oh et al.41 reported that the apoptosis and necrosis 
observed among silica-titania hollow nanoparticles internalized macrophages 
were size-dependent and surface functionality-dependent, which agrees with 
other experimental results.61 Small changes in particle size and functional 
groups on the surface affect the mechanism of cell death. Furthermore, these 
factors may also have significant influence on the nanoparticle and membrane 
interaction, nanoparticle internalization and degradation within cells.  
3.2.9 Effects of Ag nps on cell cycle 
Earlier reports have emphasized a bidirectional effect of ROS on genomic 
stability.74 High intracellular ROS levels in CTAB-coated Au nanorods treated 
cells induced mitochondrial damage which led to changes of cell cycle and 
increased apoptosis.75 Intracellular ROS levels can be decreased dramatically 
by the addition of high-dose of antioxidants. Furthermore, DNA damage from 
low level ROS in stem cells treated with antioxidants was reported to be 
concentration dependent.74 Moreover, the early effect of DNA damage was 
seen in cell cycle progression. Cells with damaged DNA accumulated in gap1 
(G1), DNA synthesis (S), or in gap2/mitosis (G2/M) phase while cells with 
irreversible damage accumulated in subG1 phase.76 By detecting parameters 
such as apoptosis, cell cycle arrest and evidence of DNA damage, the toxicity 
of Ag nps on the cells is established. 





Figure 3.15: Cell cycle graph (A) and data (B) of HeLa and HepG2 treated 
with 20 µg/mL Ag nps for 24h to detect the DNA damage of cells. Markers 
were set at regions of interest (sub G1, G1, S, and G2/M), and the percent of 
cells (events) under each area was generated using Summit V4.3.02 software 
through Figure 3.16.  
The influence of Ag nps on the percentage of cells in each phase of the 
cell cycle was analyzed (Figure 3.15). Both HeLa and HepG2 cell lines 
showed a decrease in G1 phase. Ag nps treated HepG2 cells showed 
significant increase in both S and G2/M stages, while Ag-mint treated HepG2 
cells also showed significant increase in subG1 stage. For Ag nps treated HeLa 
cells, Ag-coffee induced significant increase in both S and G2/M stages and 
Ag-ginger induced only G2/M arrest. However, Ag-mint nps caused a 
significant increase in both subG1 and S stages. The significant increase in 
subG1 stage for Ag-mint treated cells indicated that cells were seriously 




damaged as a result of an irreversible DNA damage while G2/M or S arrest 
revealed reversible DNA damage. Only small increases in subG1 stage of 
HepG2 cells with Ag-ginger and Ag-coffee treatment were observed while no 
changes were found in HeLa cells. The absence of changes in number of cells 
in subG1 of HeLa cells indicates no significant cell death via apoptosis 
occurred when cells were treated with Ag-ginger or Ag-coffee nps. In other 
words, both Ag-ginger and Ag-coffee treated cells only showed reversible 
DNA damage with G2/M and S arrest.  
 
Figure 3.16: Histograms representing cell cycle analysis of HepG2 (A-D) and 
HeLa (E-H) cells. The control showed normal distribution of sub G1, G1, S 
and G2/M (A and E). The ce lls treated with 20 μg/mL Ag mint (B and F), 
Ag-ginger (C and G) and Ag-coffee (D and H) showed increases in S/G2 
population indicating S/G2 arrest while the presence subG1 population of cells 
treated Ag mint (B and F) indicates cell death through apoptosis. Markers 
were drawn on regions of interest (R1-subG1, R2-G1, R3-S and R4-G2/M) to 
generate statistics of cells under each region. Corresponding statistics were 
generated using Summit V4.3.02 software. 
Several reports suggest that Ag nps could induce cell cycle arrest in G2/M 
phase and enhance apoptosis.4,77,78 Absence of massive apoptosis and necrosis 
for Ag-ginger and Ag-coffee nanoparticles treated cells accompanied by G2/M 
arrest (Figure 3.15) indicates a retarded cell proliferation, allowing cells extra 
time to repair DNA damage prior to segregation of chromosomes. However, 
the DNA repair could be affected by the reduction of ATP content (Figure 3.8) 
after Ag nps treatment, as ATP played multiple roles in the repair of DNA 




damage.79-81 Excessive ROS production was reported to be harmful to DNA, 
while low levels of ROS affect cell signaling particularly at the level of redox 
modulation.82 Relatively low level of ROS was observed to promote cell 
proliferation rather than cell degeneration or death.65,83 Low levels of ROS 
was also reported to induce DNA damage in cells74 and similar results were 
observed in our study.  
3.3 Conclusion  
In this study, a green synthesis of Ag nps using mint, ginger, and coffee 
extracts as a reducing and capping agents was explored. The cellular uptake 
and toxicity of Ag nps was determined using the changes in cell morphology,  
cell viability and oxidative stress. Ag-mint, Ag-ginger and Ag coffee 
nanoparticles were found to be more toxic to HepG2 than to HeLa cells. 
Among all the Ag nps, Ag-mint were the most toxic, followed by Ag-ginger 
and Ag-coffee were the least toxic. Morphology changes and cellular uptake 
observed among Ag nps treated cells were considered as the first indication of 
toxicity. Significant decrease in cell viability was observed as a result of 
reduction in ATP. Surprisingly, bioextracts capped Ag nps did not increase but 
decreased the production of ROS in a dose dependent manner, which can be 
attributed to the antioxidant activity of biomaterial extracts on the surface. The 
low levels of ROS are believed to be the trigger for DNA damage. No massive 
apoptosis or necrosis and G2/M arrested cells were observed for the cells 
exposed with Ag-ginger and Ag-coffee nanoparticles, suggesting an active 
DNA repair pathway operating inside the damaged cells. On the other hand, 
significant increase in apoptosis and arrest in subG1 stage was observed for 
Ag-mint nanoparticles treated cells, indicating an irreversible DNA damage. 
The higher toxicity of Ag-mint nanoparticles to cancer cells could be further 
explored for evaluating their potential use in cancer therapy.  
In summary, the results indicate that cytotoxicity of Ag nps was strongly 
related to their compositions and capping agents. Among three Ag nps 




investigated, Ag-mint nanoparticles were much more toxic compared to 
Ag-ginger and Ag-coffee nanoparticles. Exposure of cells to Ag nps led to low 
levels of ROS which caused DNA damage followed by cell arrest in G2/M 
stage and eventually cell death through apoptosis. However, complete 
elimination of toxicity, especially at higher concentration is not yet achieved 
and need further studies.    
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4.1 Introduction  
In the last few decades, many consumer products incorporated with 
nanomaterials have reached the market and nanomaterials have already been 
employed to create new analytical tools or imaging agents for biotechnology 
and life sciences.1,2 Notably, silver nanomaterials (Ag NMs) are at the 
forefront in terms of commercialization due to their antibacterial and wound 
healing properties.3 Recently, Ag NMs have also attracted much attention for 
their use in biomedical imaging and photothermal therapy owing to their 
surface plasmon resonances (SPR) in the visible spectral range.4 Further, the 
plasmon properties of Ag NMs can be tailored with great versatility by 
controlling their shapes during synthesis.5-7 Comparison of plasmonic 
properties of Ag and gold (Au) nanorods revealed that Ag nanorods showed 
two times higher sensitivity in the spectral range of 600 - 700 nm and about 10 
to 20% in 700 - 900 nm region than Au nanorods.8 Ag NMs also have the 
lowest plasmonic losses among other metallic nanomaterials in the UV-visible 
spectrum.9 Furthermore, a rich variety of dipolar and higher order plasmon 
resonances have been illustrated for nanocubes and nanoparallelepipeds of Ag, 
in contrast to the simple dipolar modes found on Ag nanospheres or 
nanorods,10 and they seems to be more toxic to surrounding healthy 
tissues.11-13 However, toxicity of Ag NMs could be reduced through surface 
modifications.9,14,15 Until now, there are limited studies on the cytotoxicity of 
Ag NMs with different morphologies, such as nanocubes and nanowires.16 
Therefore, it is important to evaluate the potential biological impact of 
different morphologies of Ag NMs to understand the shape sensitive 
interaction of such NMs with living organisms.  
Toxicity of spherical Ag NMs has been established by many research 
groups using various models which also include results published from our 
lab.17-19 In this chapter, response of human skin fibroblast cells on exposure to 
Ag nanocubes (Ag cube 1), truncated nanocubes (cube 2) and nanowires was 




investigated. The experimental methods were described in detail in Chapter 2 
(Materials and Methods): 
1. Synthesis and purification of Ag cube1, cube 2 and nanowires; 
2. Characterization of Ag cube1, cube 2 and nanowires – SEM, DLS, XRD 
and UV-Vis spectroscopy; 
3. Dark field microscope, SEM and confocal microscope of Ag NMs treated 
cells – cell morphology and uptake of Ag NMs; 
4. ATP production and metabolic activity – cell viability; 
5. ROS production – mechanism of cytotoxicity; 
6. Cell cycle analysis – cell proliferation; 
7. Apoptosis and necrosis – cell death. 
4.2 Results and discussion  
Ag NMs with different shapes were synthesized through a 
polymer-mediated polyol process and characterized using a range of 
techniques.20 Different morphologies were obtained by changing the 
experimental parameters such as the sequence of adding reagents (e.g. AgNO3 
and PVP) and reaction time. Synthesized nanocubes, truncated nanocubes and 
nanowires of Ag were characterized using SEM. Ag nanocubes and Ag 
truncated nanocubes were referred as Ag cube 1 and Ag cube 2, respectively, 
throughout the manuscript. SEM images revealed that Ag cube 1 showed 
regular cubic morphology with an average edge size of around 152 ± 15 nm 
whereas Ag cube 2 showed truncated cubic structures with etched corners of a 
regular cubes with an edge size 176 ± 27 nm (Figure 4.1). Interestingly, the 
Ag nanowires showed different lengths (7.5 ±4.1µm) with diameter 272 ± 
78 nm. Low magnification SEM images (Figure 4.2) of Ag NMs suggested 
that more than 95% of nanoparticles were with the desired shapes. Based on 
these images, the size distribution histograms of Ag NMs were generated 






Figure 4.1: SEM images of cube 1 (A), cube 2 (B) and nanowires (C), UV-Vis 
spectra (D) and XRD patterns (E)of different Ag NMs. 
 
Figure 4.2: Low magnification SEM images of Ag cube 1(A), cube 2 (B) and 
nanowires. 
The hydrodynamic size of Ag NMs in different media was measured using 
DLS to examine the stability with time. Ag NMs with desired concentrations 
(25 µg/mL and 100 µg/mL) were prepared in water, MEM or in cell medium 
and kept for 24 h at room temperature before measurement. The 
hydrodynamic size of Ag cube 1 was 214 ± 2 nm in water and 212 ± 1 nm in 
cell medium. However, their size significantly increased to 634 ± 104 nm in 
MEM medium (Table 4.1). Similar results were also observed for cube 2 in 




different solvents (water: 317 ± 8 nm; cell medium: 290 ± 17 nm and MEM: 
1564 ± 686 nm). Secondly, when increasing the concentrations of Ag NMs 
(cube 1 and cube 2) from 25 µg/mL to 100 µg/mL, no significant changes 
were observed in their hydrodynamic size (Table 4.1).  
 
Figure 4.3: The size distribution histogram of Ag cube 1 (A), cube 2 (B), 
diameter (C) and length of Ag nanowires (D) generated using images captured 
with JEOL JSM 2010F (Figure 4.2). 
 
Table 4.1: Hydrodynamic size of Ag NMs with different concentrations in 
different disperse solvents (water, MEM and cell medium).a  
 SEM 
 side length 
nm 
Hydrodynamic size nm 










































D: 272 ± 78 














aEach sample was detected in triplicates and the values were presented with 
mean ± standard deviation (SD).  The large errors observed for Ag nanowires 
could be due to its high aspect ratio, as DLS is commonly used to detect the 
hydrodynamic size of spherical nanoparticles. The large errors for Ag cube1 
and cube 2 in MEM medium could be attributed to their aggregation in this 






Table 4.2: Zeta pontential of Ag NMs with different concentrations in 
different disperse solvents (water, MEM and cell medium).a  
 
Zeta mV 
Water MEM Cell medium 
25 µg/mL 100 µg/mL 25 µg/mL 100 µg/mL 25 µg/mL 100 µg/mL 
Ag cube 1 -26.7 ± 0.6 -26.7 ± 0.7 -13.5 ± 0.8 -9.9 ± 0.9 -9.5 ± 0.2 -10.7 ± 1.0 
Ag cube 2 -37.3 ± 0.5 -36.5 ± 0.6 -11.9 ± 0.7 -9.8 ± 1.3 -8.8 ± 0.2 -9.8 ± 0.3 
Ag 
nanowires -34.7 ± 1.4 -31.7 ± 2.2 -12.1 ± 0.9 -10.3 ± 0.2 -8.6 ± 1.1 -9.8 ± 0.7 
aEach sample was detected in triplicates and the values were presented with 
mean ± standard deviation (SD).  
 
Table 4.3: Ag ions release of Ag NMs in different disperse solvents (water and 
completed cell medium) at the concentration 100 µg/mL.a  
 
H2O 100 µg/mL ( Ag
+
, ppm) Cell medium 100 µg/mL (Ag
+
, ppm) 
1 day 7 days 1 day 7 days 
Ag cube 1 
0.363 ± 
0.021 0.383 ± 0.015 0.640 ± 0.017 2.790 ± 0.062 
Ag cube 2 < 0.10 0.276 ± 0.005 0.187 ± 0.006 0.687 ± 0.021 
Ag 
nanowires < 0.10 0.113 ± 0.011 0.123 ± 0.015 0.160 ± 0.010 
aEvery experiment was performed in triplicates and the values were presented 
with mean ± standard deviation (SD).  
Overall, the results indicate that the colloidal stability of Ag NMs was 
independent on their concentrations, but closely related to the nature of the 
medium. There is significant interaction between Ag NMs and components of 
MEM medium (without FBS) while the addition of FBS significantly 
enhanced the colloidal stability of Ag NMs in cell medium. The observed 
differences in size from SEM and DLS measurements are attributed to the 
state of the dry sample (SEM) and solvated sample (DLS) used for 
measurements.21,22 The apparent high and somewhat inaccurate hydrodynamic 




diameter of Ag nanowires is attributed to their long aspect ratios (Table 4.1). 
The surface charge of Ag NMs in different solvents was measured by zeta 
potential measurements and the results were summarized in Table 4.2. The 
zeta potential of Ag cube 1 (25 µg/mL) was -26.7 ± 0.6 mV in water, -13.5 ± 
0.8 mV in MEM and -9.5 ± 0.2 mV in completed cell medium, which 
indicates that surface charge of Ag cube 1 were strongly dependent on their 
disperse solvent. Further, slight changes were observed when increasing the 
concentration of Ag cube 1 from 25 µg/mL to 100 µg/mL, indicating that 
concentration of the particles is also a factor in determining the final surface 
charge. Similar results were also found for Ag cube 2 and Ag nanowires in 
different solvents at different concentrations. Overall, the results indicate that 
the nature and composition of the solvents are the dominant factor for 
determining the surface charge of Ag NMs in solutions. 
Silver ion (Ag+) release form Ag NMs is one of the important factors 
which affect the toxic effects of Ag NMs to cells. Freshly prepared Ag NMs 
purified by centrifuge were suspend in water and cell medium(MEM with FBS) 
and kept in room temperature for 1 day and 7 days before performing the 
elemental analysis measurements. The experiments were performed in 
triplicates and the results were summarized in Table 4.3. After 24 h, Ag+ in Ag 
cube 1 water solutions showed 0.363 ± 0.021 ppm (part per million) while 
both Ag cube 2 and Ag nanowires water solutions showed minimal release of 
Ag+ with less than 0.10 ppm. However, increased release of Ag+ from Ag NMs 
in cell medium was observed after 24 h. Ag+ in Ag cube 1 showed 0.640 ± 
0.017 ppm while those in Ag cube 2 and Ag nanowires were 0.187 ± 0.006 
ppm and 0.123 ± 0.015 ppm, respectively. The results indicates that the release 
of Ag+ from Ag NMs were dependent on both the morphology of Ag NMs and 
their disperse solvent. The release of Ag+ was the fastest for Ag cube 1 in cell 
medium. Further, significant increase of Ag+ from Ag NMs were observed in 
both water solution and cell medium after 7 days, indicating that the release of 




Ag+ was also strongly time-dependent.  
Surface plasmon resonance (SPR) properties of Ag NMs with different 
morphologies were measured by UV-Vis-NIR spectrophotometer. The 
UV-visible absorption spectra of three aqueous dispersions that contained Ag 
cube 1, Ag cube 2, and Ag nanowires are shown in Figure 4.1D. The number 
of SPR peaks is dependent on the symmetry of particles: spherical particles 
showed one peak, while multiple peaks are often observed for cubic or 
triangular nanoparticles.20 Ag cube 1 displayed three SPR peaks located at 352, 
420, and 550 nm and can be attributed to the possibility of several distinct 
symmetries for dipole resonance.23,24 Ag cube 2 exhibited two SPR peaks at 
432 and 665 nm, which is in accordance with the reported values.24,25 
McLellan et al.25 reported that Ag nanocubes with large size (100 nm) 
exhibited much broader SPR bands with a red-shift as compared to those with 
smaller size (60 nm), similar results were also observed for truncated Ag 
nanocubes. The extremely broad peaks observed in our study could be 
attributed to their large size distribution (150-180 nm). Ag nanowires showed 
two absorption peaks at 352 and 392 nm, which should be attributed to the 
out-of-plane quadrupole resonance and out-of-plane dipole resonance of the 
Ag nanowires, respectively.9,26,27 The longitudinal mode of the Ag nanowires 
is absent here probably due to the high aspect ratio.28  
In order to examine the crystalline structure of the resulting Ag NMs, 
XRD measurements were carried out (Figure 4.1E). Strong intensity of the 
(200) peak of Ag cube 1 in the XRD pattern indicated a predominance of 
oriented (100) facets.6,29 A slight increase in intensity of the (111) peak of Ag 
cube 2 suggests the etching edge of sharp corner of nanocube.30 Ag nanowires 
showed three strong peaks which were assigned to the diffraction of (111), 
(200) and (222) planes of metallic silver, which are in agreement with standard 
value for the face-centered cubic (fcc) structure of silver lattice (JCPDS card 
no. 04-0783).9,31  




4.2.1 Cellular uptake of Ag NMs  
As commented earlier, the purpose of preparation Ag NMs in this study 
was to check their shape-dependent bioactivity to human skin dermal 
fibroblast cells. The changes in cell morphology and cellular uptake of Ag 
cube 1, Ag cube 2 and Ag nanowires were measured by dark field optical 
microscopy. After cells were exposed to Ag NMs for 24 h, no significant 
increase in the number of floating cells was observed (Figure 4.4), indicating 
that absence of massive cell death through apoptosis or necrosis. Intact cell 
membrane and clear nucleus could be observed in untreated cells (Figure 
4.5A), while cellular uptake of Ag cube 1, cube 2 and nanowires were clearly 
observed in the cells (Figure 4.5B-D).  
 
Figure 4.4: Dark field optical images of human skin fibroblast cells untreated 
(A) and treated with Ag nanocubes (B), Ag truncated nanocubes (C) and Ag 
nanowires (D). Concentration of Ag NMs = 25 µg/mL and Scale bar= 10 µm 





Figure 4.5: High magnification optical microscope images of cells (Passage 7) 
untreated (A) and treated with cube 1 (B), cube 2 (C) and nanowires (D) of Ag 
NMs. Concentration of Ag NMs = 25 µg/mL, scale bar is 10 µm 
To confirm whether Ag NMs were only attached on the surface of cell 
membrane or penetrate inside the cells, human skin dermal fibroblast cells 
with Ag NMs (25 µg/mL, 24 h) treatment were analyzed using SEM. In order 
to remove the unattached Ag NMs, cells were washed several times with PBS 
solution before fixation. No significant morphology changes were observed 
while bright dots/wires were found on the cell surface for cells treated with Ag 
NMs (Figure 4.6). High magnification SEM images were taken to confirm the 
presence of Ag NMs on the cell surface (Figure 4.7). Ag cube 1 and Ag cube 2 
were found to be displayed both on the surface of cell membrane and inside 
the cells (Figure 4.7B and 4.7C). Owing to the high aspect ratio, the Ag 
nanowires were observed to partially penetrate the cells (Figure 4.7D).  





Figure 4.6: Low magnification SEM images of human skin fibroblast cells 
untreated (A) and treated with Ag nanocubes (B), Ag truncated nanocubes (C) 
and Ag nanowires (D). Concentration of Ag NMs = 25 µg/mL 
 
Figure 4.7: High magnification SEM images of cells untreated (A) and treated 
with Ag cube 1 (B), Ag cube 2 (C) and Ag nanowires (D). Concentration of Ag 
NMs = 25 µg/mL 




In order to further establish the presence of Ag NMs inside the cells, 
energy-dispersive X-ray spectroscopy (EDX) analysis was performed. Cells 
treated with Ag cube 1 were chosen as an example for EDX analysis. The gray 
spots were selected to provide comprehensive evidence on the presence of Ag 
NMs underneath the cell membrane (Figure 4.8). Gray spots displayed on the 
cells (Figure 4.8A) were analyzed and the Ag peaks shown in EDX analysis 
confirmed the presence of silver (Figure 4.8B). Similar data were obtained 
from other gray spots on the surface. As a control, the dark area on the cell 
membrane (Figure 4.8C) was also analyzed. The EDX pattern was different 
from gray spots and did not show any Ag peaks (Figure 4.8D). 
 
 
Figure 4.8: SEM images and EDS analysis at marked places on cells (Passage 
7) treated with Ag cube 1 to confirm the cellular uptake. The images in the  
right panel correspond to the analysis of the marked places in the images on 
the left panel. Concentration of Ag cube 1 = 25 µg/mL 
 





Figure 4.9: Confocal microscope images of cells stained with Cellmask deep 
red and DAPI. Cellmask stained the cell membrane showed red color while 
DAPI stained cells showed blue nucleus. Due to their SPR effect, Ag cube 1, 
cube 2 and nanowires exhibited both blue and green color in the images. 
Images A are untreated cells, B cells with Ag cube 1 treatment, C with Ag 
cube 2 treatment and D are cells with Ag nanowires treatment. Concentration 
of Ag NMs = 25µg/mL 
The distribution of Ag NMs inside the cells was also examined using a 
confocal microscope (Figure 4.9). After treatment with Ag NMs (25 µg/mL, 
24 h), cells were stained with both Cellmask Deep Red (Invitrogen) and 
4',6-diamidino-2-phenylindole (DAPI, Sigma Aldrich) to distinguish the cell 
membrane and nucleus. Owing to their small size and special SPR effects, Ag 
cube 1, cube 2 and nanowires exhibited photoluminescence after excitation at 
405 and 473 nm. Klein et al. reported that Au nps with the size from 15 to 80 
nm exhibited similar effects after excitation with light at 543 and 633 nm.32 As 




seen in Figure 4.9, clear cell membrane (Red) and nucleus (Blue) were 
observed in control cells (untreated cells). Ag NMs treated cells showed both 
blue and green fluorescence in the confocal images (Figure 4.9), confirming 
their presence inside the cells after treatment. Z-stack images captured by 
confocal microscope (Figure 4.10) suggest that Ag NMs were not only present 
on the surface of cell membrane but also penetrated inside the cells, which is 
consistent with earlier reports.33 
 
Figure 4.10: Z-stack confocal images of untreated cells (A), Ag nanocubes 
(B), truncated nanocubes (C) and nanowires (D) exposed cells are given. A, B, 
C and D are merge images of cells treated with Cellmask (A) and Cellmask 
plus Ag NMs (B-D). The cell membrane showed red color and green dots 
represent the Ag NMs (25 µg/mL, 24 h).  
 




4.2.2 Cellular responses of Ag NMs 
The cellular responses of Ag NMs were further explored using viability 
assays, which were designed to measure activities related to cellular growth 
and viability. Normally, viability assays include monitoring the level of 
metabolic biomarkers such as mitochondrial reductase potential and ATP.34  
Since the viability of cells could be measured by detecting reduced 
potential in mitochondria, resazurin, one of the most commonly used assays, 
was chosen to detect the metabolic activity of the Ag NMs treated cells.35 The 
metabolic activity decreased for cells treated with Ag cube 1 with an increase 
in the concentration of nanomaterials (Figure 4.11), indicating a 
dose-dependent toxicity. Unlike the cells treated with Ag cube 1, metabolic 
activity of cells exposed to Ag cube 2 and Ag nanowires treatment were less 
affected and no significant decrease was observed even at high concentrations 
200 µg/mL (Figure 4.11).  
 
Figure 4.11: Mitochondrial activity of cells (Passage 7-9) after exposure to 
various concentrations of Ag cube 1, Ag cube 2 and Ag nanowires for 24 h. 
The y-axis represents the percentage of metabolically active cells which relates 
to viable cells present in the treated sample after 24 h and the x-axis represents 
the concentrations of Ag NMs. The values represent the mean ± standard 
deviation of three independent experiments; * denotes P < 0.05 with respect to 




untreated cells using Student’s t test.  
The viability of cells was further detected using a widely accepted, rapid 
and sensitive ATP assay.36-38 ATP contents of cells treated with Ag NMs were 
less affected at low concentrations whereas significant decrease was shown at 
high concentrations (Figure 4.12), indicating a concentration dependent 
toxicity. Among all three Ag NMs, Ag cube 1 was the most toxic, followed by 
Ag cube 2 and Ag nanowires. Higher ATP content was observed in cells 
treated with Ag nanowires as compared to that treated with Ag cube 1 or Ag 
cube 2 at high concentrations (100 and 200 µg/mL). To check the presence of 
any toxic materials left over from the synthesis, toxicity studies were done 
using the supernatant liquid obtained after centrifugation of Ag NMs solution, 
which is expected to contain excess of reagents, if any. Our results showed no 
evidence of toxicity for this supernatant liquid (Figure 4.13). The cell viability 
in all the wells was comparable to that of control. 
 
Figure 4.12: ATP content of cells (Passage 7-9) after exposure to various 
concentrations of Ag cube 1, Ag cube 2 and Ag nanowires for 24 h. The y-axis 
represents the percentage of ATP content which relates to viable cells present 
in the treated sample after 24 h whereas the x-axis represents Ag NMs with 
different concentrations. The values represent the mean ± standard deviation 
of three independent experiments; * denotes P < 0.05 with respect to untreated 
cells using Student’s t test.  





Figure 4.13: Toxicity studies of the supernatant liquid obtained after 
centrifugation of Ag NMs solution were investigated using ATP assay. ATP 
content of cells exposed to various volumes (0, 2.5, 5, 10, 15 and 20 µL) of 
centrifuge supernatant liquid of Ag cube 1, Ag cube 2 and Ag nanowires for 
24 h. The values represent the mean ± standard deviation of three independent 
experiments. 
The viability data suggested that Ag cube 1 nanoparticles seems to be 
more toxic, while Ag cube 2 and Ag nanowires were relatively less toxic.  
Toxicity of nanomaterials is believed to be multifactorial, where size, 
morphology, composition, surface charge, surface functionalization, 
concentration and potential to release the corresponding metal ions could play 
significant roles in living systems.2,39-43 Earlier reports showed that spherical 
Ag nanoparticels exhibited size-dependent toxicity.16 Nanoparticles with 
smaller size are reported to be more toxic than those with the larger size due to 
their higher penetration rate into cells and increase in reactive surface area for 
interaction with biomolecules.16,39,44,45 PVP coated Ag nps were more toxic to 
zebrafish embryos than citrate coated ones at the same particle core size (110 
nm).46 Cytotoxicity studies of Ag spherical nanoparticles (100 - 200 nm) 
showed they could induce cell damage at very low concentrations 10 µg/mL, 
or even less (5 µg/mL).47-50 In our study, Ag NMs with different morphologies 
were less toxic as compared to reported Ag sphere nanoparticles. Ag 
nanocubes caused mitochondrial damage at a concentration of 25 µg/mL, 




while Ag truncated nanocubes and nanowires induced ATP decrease at a 
higher concentration (100 µg/mL) and showed no mitochondrial damage even 
at 200 µg/mL. The relationship of morphology and toxicity of Ag NMs were 
explored, as our Ag NMs are all PVP-capped. The different toxicities of Ag 
NMs could be explained using several factors. First, the size of Ag cube 1 was  
the smallest (150 nm), while Ag cube 2 (180 nm) and Ag nanowires (2 -10 µm) 
were slightly larger. Second, different morphologies are expected to induce 
different degree of toxicities to cells.51,52 Relatively sharp edges of Ag cube 1 
may lead to instability of NMs due their high chemical potential, which enable 
particles to penetrate cell membrane and then decompose inside cells much 
more easily, as compared to the other two Ag NMs.  
4.2.3 Mechanism of cytotoxicity  
Oxidative stress has been reported to play an important role in the NMs 
toxicity, which could induce oxidative damage to protein and DNA.53-56 To 
explore the role of oxidative stress toward toxicity of Ag NMs, reactive 
oxygen species (ROS) production of cells with Ag NMs treatment were 
measured by 2', 7' - dichlorohydrofluorescein diacetate (DCF-DA, Invitrogen) 
staining. After exposure to the cell, DCF-DA was first deacetylated by cellular 
esterases to a non-fluorescent compound. In the presence of ROS, it could be 
oxidized into a highly fluorescent compound 2', 7' - dichlorofluorescin (DCF). 
Fluorescent intensity of the cells treated with Ag NMs and stained with 
DCFH-DA was increased. Unstained cells were used as a negative control to 
detect the autofluorescence from cells. Untreated cells (control) were used as 
standards to calculate the extent of ROS production in Ag NMs treated cells 
by measuring the percentage increase in fluorescence intensity (Figure 4.14). 
Cells treated with Ag NMs (25 µg/mL) showed increase in percentage of gated 
cells with high ROS production as compared to control cells. Cells treated 
with Ag NMs showed increase in fluorescent intensity – Ag nanowires (9.7%); 
Ag cube 2 (12.6%) and Ag cube 1 (17.6%).  





Figure 4.14: The graphs of ROS production in cells without (A and B) or with 
Ag cube 1 (C), cube 2 (D) and nanowires (E) treatment (25 µg/mL, 24h) by 
flow cytometry. The graph represents the percentage of gated cells among the 
Ag NMs exposed cells. Untreated cells were considered as control (B). Cells 
without DCF-DA staining (negative control) were used to detect the 
autofluorescence of cells (A). The percentage of cells with high fluorescent 
intensity (FITC ≥ 102) was considered as gated cells and totally 10000 cells 
were calculated in each graph.  
The early sign of the DNA damage inside the cells caused by NMs could 
be seen in the cell progression. Cells with reversible DNA damage will 
accumulate in gap1 (G1), DNA synthesis (S) or in gap2/mitosis (G2/M) phase, 
while cells with irreversible DNA damage will undergo apoptosis, and then 
accumulate in subG1 phase. Thus toxicity studies of Ag NMs were further 
extended to cell cycle analysis through detecting parameters such as apoptosis 




and cell cycle arrest to confirm DNA damage. The influence of Ag NMs on 
the cell cycle was analyzed by detecting DNA content using a fluorescent 
DNA-selective dye PI, which exhibits emission signals proportional to the 
content of DNA. Compared to untreated cells (control), an increase of cell 
population in G2/M phase (9% for Ag cube 1, 7% for Ag cube 2 and 11% for 
Ag nanowires, respectively) was observed (Figure 4.15), indicating that all Ag 
NMs could induce G2 arrest. For control cells, major cell population was 
observed in G1 phase, whereas in cells treated with Ag cube 1, a decrease in 
G1 population was observed which was accompanied by an increase in G2/M 
and S population. For the cells treated with Ag cube 2 and Ag nanowires, the 
proportion of cells in S phase was less affected as compared to the G2/M 
population. Absence of cells in subG1 was observed for all Ag NMs treated 
cells, indicating that no significant apoptosis or necrosis had occurred.  
 
Figure 4.15: Ag cube 1 treated cells showed an increase in the S/G2 
population, and Ag cube 2 and Ag nanowires treated cells showed G2/M arrest. 
Markers were set at regions of interest (subG0, G1, S, and G2/M), and the 
percentage of cells (events) under each area was generated using Summit 
V4.3.02 software; * represents P < 0.05. Histograms are included in Figure 
4.16. 





Figure 4.16: Histograms represent cell cycle analysis of human skin fibroblast 
cells. The control showed normal distribution of sub G1, G1, S and G2/M (A). 
The cells treated with 25 μg/mL Ag nanocubes (B), truncated nanocubes (C) 
and nanowires (D) showed increases in S/G2 population indicating S/G2 arrest. 
Markers were drawn on regions of interest (subG1, G1, S and G2/M) to 
generate statistics of cells under each region. Corresponding statistics were 
generated using Summit V4.3.02 software.  
Mechanism of cytotoxicity of Ag NMs was explored by investigating the 
relationships of ATP content, mitochondrial activity, oxidative stress and DNA 
damage. The decreased cellular ATP content could  be caused by the damage of 
the mitochondrial respiratory chain. The mitochondrial dysfunction and 
damage could be attributed to two possible reasons: oxidative stress induced 
by ROS production and mechanical injury caused by nanoparticle depositions 
in mitochondria. Oxidative stress is considered as a common mechanism for 
cell damage induced by nanomaterials.53 Deposition of nanomaterials inside 
mitochondria can induce mitochondrial dysfunction by disrupting electron 
transport chain and ultimately result in increase of ROS, low ATP yield and 
even apoptosis.17,57 Many nanomaterials such as titanium dioxide, zinc oxide, 
silicon dioxide and multi-wall carbon nanotubes were known to exert toxicity 
through oxidative stress.58-60 ROS is also believed to be the major reason of 




spontaneous damage to DNA and genotoxicity observed among cells treated 
with metal oxide nanoparticles.58 In eukaryotic cells, DNA damage causes cell 
cycle arrest at the G2/M and/or S boundary, allowing cells extra time to repair 
damages before replication.61 The reduction in ATP content after Ag NMs 
treatment could affect the DNA repair, as ATP is required in the repair 
process.62,63 Cell cycle data indicates reversible DNA damage, as cells arrested 
in the G2/M and S phase after exposure to Ag NMs, which enable them to 
have enough time for the cells to repair the damaged DNA. The level of cell 
cycle arrest is dependent on the shape of NMs where a drastic increase in cell 
population was observed in the G2/M and S phase for Ag cube 1.  
 
Figure 4.17: Apoptosis and necrosis of cells with Ag nanocubes, truncated 
nanocubes and nanowires treatement. Ag nanocubes treated cells showed an 
increase of cell population in both apoptosis (early and late) and necrosis death 
mode, while Ag truncated nanocubes and nanowires induced cell death mainly 
through apoptosis. The percentage of cells under each area was generated 
using Summit V4.3.02 software * represents P < 0.05. 





Figure 4.18: Dot plots from Annexin-FITC staining of human skin fibroblast 
cells. Untreated cells (A) are used to calculate % of change in population. 
Cells accumulating at lower left window represent live cells. Apoptosis 
positive controls (Staurosporine treated) accumulating on lower right window 
(B). Necrosis positive controls (H2O2 treated) which accumulate on upper left 
window for red fluorescent cells (C). Late apoptotic cells will accumulate in 
upper right window. (D) shows cell population for cells treated with Ag 
nanocubes, (E) represents cells treated with truncated nanocubes and (F) 
represents cells treated with Ag nanowires (25 µg/mL). The % of cells under 
each category (live, early and late apoptosis, necrosis) is represented in 
respective windows. 
4.2.4 Apoptosis and necrosis 
Apoptosis and necrosis are two general modes of cell death.64 Flow cytometry 
and Annexin V assays were used to study both processes using cells treated 
with Ag NMs (Figure 4.17). Statistical data were acquired from the dot plots 
(Figure 4.18). Viable cells are negative for both PI and Annexin staining 




whereas necrotic cells are PI positive and Annexin negative. Early apoptotic 
cells are PI negative and Annexin positive, whereas later apoptotic cells are 
positive for both PI and Annexin V staining. For untreated cells (control), no 
significant cell death (late apoptosis) was observed, and major cell population 
remained viable (Figure 4.17). Compared to untreated cells, a significant 
increase in early apoptosis was observed among Ag NMs treated cells. Cells 
treated with Ag cube 1, cube 2 and nanowires showed a small increase in 
necrosis; however, apoptosis was the dominant process. Ag cube 1 induced a 
significant increase of cell population in late apoptosis (20%) and a slightly 
increase in early apoptosis stage (16%). However, Ag cube 2 and nanowires 
caused significant increases of cell population in early apoptosis (cube 2: 22% 
and nanowires: 20%) other than late apoptosis (cube 2: 15% and nanowires: 
12%). The results demonstrated that cells treated with Ag cube  1 became 
unhealthier as compared to those treated with cube 2 and nanowires. 
4.3 Conclusion 
Ag NMs with different morphologies showed interesting optical 
properties, which offer opportunities for potential applications. Furthermore, 
they also showed different levels of toxicity to cells. Among three Ag NMs 
discussed in the paper, Ag cube 1 was the most toxic, while Ag cube 2 and Ag 
nanowires were relatively less toxic. Cellular uptake revealed that all Ag NMs 
could penetrate inside the cells, irrespective of their shapes. Oxidative stress 
was believed to be the reason for toxicity, which could induce DNA damage 
shown by cell cycle arrest. Cells exposed to Ag NMs showed G2/M or S stage 
cell cycle arrest, indicating a reversible DNA damage, which could either be 
repaired in cell cycle or undergone apoptosis. O nly Ag cube 1 treated cells 
showed a significant increase in later apoptosis, which is consistent with 
viability data. In viability test, Ag cube 1 treated skin fibroblast cells showed 
mitochondrial damage (25 µg/ml), while Ag cube 2 and nanowires caused ATP 
decrease (100 µg/ml) in cells and showed no mitochondrial damage even at 




200 µg/ml. The low toxicity of Ag cube 2 and Ag nanowires make them 
potential candidates for applications in drug delivery or bioimaging in the 
future.  
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5.1 Introduction  
Gold nanomaterials (Au NMs) have been explored in a wide range of 
applications including catalysis,1,2 photoelectronic devices,3,4 biosensing5,6 and 
nanomedicines7-9 owing to their unique chemical and physical properties that 
are distinctly different from bulk materials.10 The rapid increase of Au NMs 
applications has attracted researchers’ attention on their health and 
environmental safety concerns. However, until now, no conclusive information 
on Au NMs cytotoxicity is available. A recent review summarized that cellular 
uptake and toxicity of Au NMs were very complex, which were affected by 
many factors such as size, surface functionalization, animal and cell models, 
doses applied, the type of Au NMs administration, time of examination and 
assays for evaluating Au NMs toxicity.11 Au NMs were reported to show a 
size-dependent toxicity as size of Au NMs is an important physical parameter 
that controls endocytosis effectiveness.11 Furthermore, the toxicity of Au NMs 
was also dependent on their concentrations and surface functionalizations, and 
Au NMs were more toxic at higher concentrations or with toxic capping 
agents such as cetyltrimethylammonium bromide (CTAB).11 However, very 
few studies have examined the shape effect of Au NMs on their toxic 
responses. Shape of nanoparticles is expected to play a significant role towards 
interaction with biomacromolecules such as proteins and therefore influence 
the final outcome of exposure. Small nanoparticles enter  the cells through 
endocytosis or via pores in the cell membrane. The shape of the particle may 
play significant roles in both nanoparticles endocytosis and transport through 
pores. In addition, interaction and complexation of nanoparticles with different 
proteins may also depend on shape. This is the main reason for the shape 
sensitive toxicity and more investigations are needed to understand the 
mechanism in detail.  
Recently metallic nanoplates have attracted great interests as they could 




exhibit a strong plasmon band in the near- infrared region (NIR),12 which could 
be used in cell imaging and photothermal therapy. Gold nanoplates (AuNPs) 
were reported to show an intensive and enhanced Raman scattering during 
surface-enhanced Raman scattering study.13-15 Au nanoplate surfaces exhibit 
unique electro-catalytic activities which could be used for oxygen reduction 
and glucose oxidation.16 Triangle nanoplates showed higher catalytic 
efficiency in the oxidation of small organic substrates as compared to 
nanospheres or nanowires from the same metal.17 
Although a number of studies have examined the cellular and toxicity of 
Au NMs, very few concentrated specifically on their shape effect on cellular 
uptake and cytotoxicity of Au NMs. Since Au NMs are being extensively used 
in various biomedical applications,18 there is still a need for a more detailed 
evaluation of their toxic effect. The current study aims to explore the shape, 
dose and incubation time effects of AuNPs on their cellular uptake and toxicity 
in human breast cancer cell line (MCF7). Au hexagon nanoplates (HAuNPs), 
pentagon nanoplates (PAuNPs) and triangle nanoplates (TAuNPs) were 
synthesized in the presence of calcium ions and fully characterized with 
multiple techniques. Cellular responses of such AuNPs on MCF7 cell lines 
were evaluated by cell viability and reactive oxygen species (ROS) generation. 
Cellular uptake and biodistribution of AuNPs were investigated using 
transmission electron microscopy (TEM). The details of experimental methods 
are described in Chapter 2 (Materials and Methods).  
1. Synthesis, purification and characterization of HAuNPs, PAuNPs and 
TAuNPs; 
2. Light microscopy – cell morphology changes with AuNPs treatment; 
3. ATP production – cell viability;  
4. ROS production – mechanism of cytotoxicity; 
5. DAPI staining of apoptotic nuclei – cell death; 




6. Cell cycle analysis;  
7. TEM of AuNPs treated cells – cellular uptake and biodistribution of 
AuNPs. 
5.2 Results  
5.2.1 Synthesis and characterization of AuNPs 
A one pot synthesis of AuNPs was developed in this study. Calcium ions 
were used to facilitate the growth of nanoplates.  Different morphologies could 
be obtained by changing the gold to calcium ion concentration ratios during 
the synthesis. As the calcium concentration decreases, the morphology 
changes from hexagon to pentagon and to triangles. TEM images showed clear 
morphologies of Au hexagons, pentagons and triangles (Figure 5.1). 
 
Figure 5.1: TEM images of AuNPs grown in the presence of different 
concentrations of Ca2+ ions: HAuNPs (A), PAuNPs (B) and TAuNPs (C). 
 
Figure 5.2: Low magnification TEM images of HAuNPs (A), PAuNPs (B) 
and TAuNPs (C). SEM images of AuNPs were present in the right corner of 
each TEM image.  
The relation between the morphology of AuNPs and the change in 




concentrations of Au/Ca cations are summarized in Table 5.1. Low 
magnification TEM images indicated that Au hexagons, pentagons and 
triangles were monodispersed (Figure 5.2). The shape distribution of AuNPs 
was showed in Table 5.2. More than 85% of the desired nanoplate shape was 
observed, and these nanoplates were further used to for the toxicology studies. 
Table 5.1: Characterization of shape-dependent AuNPs*  
AuNPs Concentration 
of Au/Ca 










HAuNPS 200/1 Hexagon 60 - 65 3.0 x 10
4 
2.2 x 105 
PAuNPs 400/1 Pentagon 50 - 55 1.5 x 10
4
 9.5 x 104 
TAuNPs 800/1 Triangle 120 - 130 2.1 x 10
4
 1.4 x 105 
*Additional SEM images of AuNPs are included in Figure 5.2. 
 
Table 5.2: Ratio of the calcium and Au salt concentrations and observed 
percentage of compositions based on low magnification TEM images.  
  
 
Concentration of Au/Ca 
200/1 400/1 800/1 
Shape 
Hexagon 85% 
Truncated triangle 10% 
Polyhedron 5% 
Pentagon 80% 





The average surface area and volume of AuNPs were calculated based on 
shape, side length and thickness of AuNPs and summarized in Table 5.3. As 
expected, the average volume and surface area are different based on their size, 
shape and edge length. The hydrodynamic sizes of HAuNPs, PAuNPs and 
TAuNPs in water were 156 nm, 106 nm and 94 nm, respectively, which 
indicate the size of hydrated nanoplates (Table 5.3). The core size of AuNPs 
was determined by TEM and their hydrodynamic size distribution was 
investigated by DLS. The hydrodynamic size of AuNPs includes its solid 
cores, its organic layers (capping agents) and the hydration shell.19,20 
  




Table 5.3: Surface charge and aggregate state of AuNPs in water and cell 
exposure media (100 µg/mL) for 24 h* 
 
AuNPs 
H2O (100 µg/mL) Cell medium (100 µg/mL) 
Size (nm) Zeta (mV) Size (nm) Zeta (mV) 
HAuNPS 156.0 ± 3.1 -34.5 ± 0.4 176.9 ± 4.2 -8.3 ± 0.2 
PAuNPs 106.4 ± 0.7 -25.0 ± 0.5 121.0 ± 1.1 -6.0 ± 0.4 
TAuNPs 94.3 ± 0.3 -25.0 ± 1.1 103.5 ± 0.6 -7.0 ± 0.7 
*Hydrodynamic size and zeta potential results were measured after 24 hrs of 
incubation in corresponding solvents in triplicates and the average values are 
presented with mean ± standard deviation (SD).  
Aggregation of AuNPs was checked by dispersing nanoplates in cell 
exposure media for 24 h. The hydrodynamic size of nanoplates did not change 
significantly in cell medium as compared to water, which indicated that 
AuNPs were stable in cell culture media and did not aggregate. The 
differences in size of nanoplates in disperse media can be attributed to the 
different thicknesses of their hydration shells due to potential adsorption of 
various components of cell medium on nanoplate surface and not due to 
aggregation. In addition, HAuNPs, PAuNPs and TAuNPs showed high 
negative surface charges in water, which decreased in cell exposure media 
owing to high ionic strength. Decrease in surface charges in cell medium also 
highlights the adsorption of ions from the medium to the nanoplate surface.  
Similar results were reported for neutral and hydrophilic polymer PVP 
stabilized AuNPs.21  





Figure 5.3: UV-Vis absorption spectra (A) of HAuNPs, PAuNPs and TAuNPs 
in aqueous solution and their XRD patterns (B).  
Surface plasmon resonance (SPR) properties of AuNPs were examined by 
UV-Vis spectroscopy (Figure 5.3A). The maximum absorption wavelength 
showed a red shift as the number of edges in the AuNPs increased from 3 to 6 
(Triangle to Hexagon). The SPR peaks gradually shifted from 574 nm for 
TAuNPs to 585 nm for PAuNPs and 620 nm for HAuNPs, indicating that 
AuNPs exhibit shape-dependent optical properties. The crystalline structures 
of AuNPs were examined using XRD measurements (Figure 5.3B). The XRD 
patterns of HAuNPs, PAuNPs and TAuNPs are all dominated by the (111) and 
(222) peaks, indicating that all AuNPs are mainly bound by the (111) planes, 
which are consistent with earlier reports.22 
5.2.2 Morphology changes of cells with AuNPs treatment 
Morphological changes of cells treated with AuNPs were considered as 
the first noticeable phenomenon of cellular responses. Cell morphology of 
AuNPs treated cells was observed under an optical microscope and compared 
with untreated cells, which served as a control. Microscopic observations of 




AuNPs treated cells showed dose dependent morphological changes indicating 
unhealthy cells, whereas the control cells appeared normal. Only small 
changes in cell morphologies were observed in cells exposed to HAuNPs and 
PAuNPs at a concentration of 50 μg/mL (Figure 5.4B and 5.4C). Moreover, 
TAuNPs treated cells showed significant number of spherical cells with 
restricted proliferation (Figure 5.4D). HAuNPs did not induce significant 
morphological changes to cells even at a higher concentration of 100 µg/mL 
(Figure 5.4F). However, PAuNPs and TAuNPs treated cells became 
unhealthier at higher concentration (100 µg/mL), and majority (80%) of the 
cells showed spherical morphologies (Figure 5.4G and 5.4H). Even after 
repeated washings, dark orange patches were seen on the cell surface of 
AuNPs treated cells, which is due to the penetration of nanoplates into the 
cells. Moreover, very few floating cells or cellular debris were observed under 
the microscope (Figure 5.4), indicating that no widespread cell death occurred 
through necrosis owing to the treatment.  





Figure 5.4: Optical images of cell morphology of MCF7 cells with or without 
AuNPs treatment: untreated cells (A, E), MCF7 cells exposed with 50 µg/mL 
of HAuNPs (B), PAuNPs (C), TAuNPs (D) treatment and MCF7 cells exposed 
with 100 µg/mL of HAuNPs (F), PAuNPs (G), TAuNPs (H) treatment. Scale 
bar = 50 µm 
 




5.2.3 Cell viability with AuNPs treatment 
Viability assays are vital steps to explain the cellular response to 
nanomaterials. In addition, they also give information on cell death, survival, 
and metabolic activities. The effect of AuNPs on MCF7 cells was studied by 
using both luminescence-based assay and fluorescent based assay. ATP 
assessment of toxicity of AuNPs (Figure 5.5) showed a 
concentration-dependent drop in luminescence intensity in MCF7 cells, 
signifying a dose-dependent toxicity. No significant changes in ATP content 
of cells in the presence of AuNPs were observed with an increase in exposure 
time from 24 h to 72 h, indicating that cell damage caused by AuNPs occurred 
within 24 h. At the same concentration and incubation time, TAuNPs were the 
most toxic, followed by PAuNPs and HAuNPs.  
 
Figure 5.5: Cell viability assays of MCF7 after exposure to various 
concentrations of HAuNPs, PAuNPs and TAuNPs after 24, 48 and 72 h using 
CellTiter-Glo assay. The y-axis represents the percentage of ATP content 
which relates to viable cells present in the treated sample after a certain time 
and the x-axis represents AuNPs with different exposure time. The values 
represent the mean ± standard deviation of three independent experiments; * 
denotes P < 0.05 with respect to the control group using Student’s t test.  
To check the presence of any toxic materials left over from the AuNPs 




synthesis, toxicity studies were done using the supernatant liquid obtained 
after centrifugation of AuNPs solution. The results showed no evidence of 
toxicity for supernatant liquid (Figure 5.6). The viability of cells exposed to 
supernatant liquid was comparable to that of control.  
 
Figure 5.6: Intracellular ATP content of MCF7 cells treated with supernatant 
solution of AuNPs (0, 2.5, 5, 10, 15 and 20 µL). The data show no toxicity 
after 24 h incubation. 
 
Figure 5.7: Cell viability assays of MCF7 after exposure to HAuNPs, PAuNPs 
and TAuNPs with various concentrations after 24 h of exposure using 
CellTiter-Blue assay. The values represent the mean ± standard deviation of 
three independent experiments; * denotes P < 0.05 with respect to the control 
group using Student’s t test.  
No significant cell death was observed after exposing to AuNPs. Since the 




cell damage was caused by AuNPs within the first 24 h, the metabolic activity 
studies were conducted using CTB assay. The results from CTB assay were 
similar to ATP content analysis, a small drop (15%) in mitochondrial activity 
was observed with increase in concentration of AuNPs to 50 µg/mL (Figure 
5.7). However, the effect of AuNPs to mitochondrial activity was not as 
significant as to ATP depletion at a high concentration (400 μg/mL).  
5.2.4 Detection of cellular oxidative stress 
Intracellular ROS production induced by AuNPs was detected by applying 
the fluorescent DCFH-DA assay as a measure for oxidative stress. DCFH-DA, 
a cellular membrane permeable non-fluorescent probe, can be irreversibly 
oxidized by intracellular ROS into a green fluorescent molecule,  
dichlorofluorescein (DCF).23,24 It is clearly shown that AuNPs induced 
intracellular ROS generation in a dose-dependent fashion (Figure 5.8). 
Untreated cells (control) showed low fluorescence while green fluorescent 
cells were observed under the microscope when exposed to AuNPs (50 and 
100 µg/mL), indicating increase in ROS production in the AuNPs treated cells.  
 
Figure 5.8: Fluorescence images (DCF-DA staining) of MCF7 cells with or 
without AuNPs treatment: untreated cells (A and E), MCF7 cells exposed with 
50 µg/mL of HAuNPs (B), PAuNPs (C), TAuNPs (D) and MCF7 cells 
exposed with 100 µg/mL of HAuNPs (F), PAuNPs (G), TAuNPs (H). Scale 
bar = 50 µm 
5.2.5 Morphological changes in cell nucleus 
Morphological assessment of apoptotic cells induced by AuNPs was 




detected by DAPI staining of cell nucleus. Cell shrinkage or nuclear 
fragmentation with condensed chromatin indicates cells undergoing 
apoptosis.25,26 Moreover, chromosomes remain condensed throughout mitosis. 
Under a fluorescent microscope, control cells were stained uniformly with 
blue and few condensed or fragmented nuclei were observed (Figure 5.9A). 
However, cells treated with HAuNPs, PAuNPs and TAuNPs for 24 h, 
significant numbers of condensed or fragmented nuclei were observed (Figure 
5.9B, 5.9C and 5.9D, yellow arrows). Morphological changes in cell nucleus 
indicated that all three AuNPs either induced cell apoptosis or arrested in cell 
division. In addition, more condensed or fragmented nuclei were observed in 
cells exposed to TAuNPs, as compared to cells treated with HAuNPs and 
PAuNPs.  
 
Figure 5.9: DAPI staining of untreated MCF7 cells (A) and cells exposed to 
HAuNPs (B), PAuNPs (C) and TAuNPs (D). Concentration of AuNPs = 100 
µg/mL, yellow arrows represent condensed or fragmented nuclei.  
 




5.2.6 Cell cycle arrest   
Cell cycle analysis was further conducted to examine DNA damage inside 
cells caused by AuNPs in the cell progression. Cells with reversible DNA 
damage will accumulate in gap1 (G1), DNA synthesis (S) or in gap2/mitosis 
(G2/M) phase, while cells with irreversible DNA damage will undergo 
apoptosis, and then accumulate in subG1 phase.  Thus toxicity studies of 
AuNPs were further extended to cell cycle analysis through detecting 
parameters such as apoptosis and cell cycle arrest to confirm DNA damage. 
 
Figure 5.10: Cell cycle arrest of MCF7 cells with HAuNPs, PAuNPs and 
TAuNPs treatment. AuNPs treated cells showed a significant increase in the 
G2/M population as compared to the control cells. Markers were set at regions 
of interest (subG0, G1, S, and G2/M), and the percentage of cells (events) 
under each area was generated using Summit V4.3.02 software. The red line 
represents the percentage of cells in the G2/M stage for control cells.  
 
The influence of AuNPs on the cell cycle was analyzed by detecting DNA 
content using a fluorescent DNA-selective dye PI, which exhibits emission 
signals proportional to the concentration of DNA. As compared to control, an 
increase of cell population in G2/M phase (5% for HAuNPs, 6% for PAuNPs 
and 5% for TAuNPs) was observed (Figure 5.10), indicating that all AuNPs 
induced a reversible DNA damage with G2/M arrest. For control cells, major 
cell population was observed in G1 phase. No significant increase of cell 




population in the SubG1 stage was observed in cells exposed to AuNPs. This 
implies that AuNPs did not induce significant cell death. Therefore, the 
condensed or fragmented nuclei in DAPI staining represented that cells were 
arrested in the cell division stage rather than dying through apoptosis.  
5.2.7 Cellular uptake of AuNPs  
The extent of AuNPs uptake and cellular distribution within MCF7 cells 
was explored through TEM images of ultrathin sections of cells. 
Representative images illustrated that AuNPs were readily internalized 
following 24 h cellular exposure (Figure 5.11). Any morphological 
abnormalities of cells exposed to AuNPs were compared with controls. 
Untreated MCF7 cells (control) displayed circular nuclei, a prominent 
nucleolus (Figure 5.11A) while AuNPs treated cells exhibit relatively small 
oblong nuclei (Figure 5.11B, 5.11E and 5.11H). Small agglomerates of Au 
hexagon were observed at low magnification within both cytoplasmic 
vacuoles and nuclei of MCF7 (Figure 5.11B). High magnification images 
confirmed the presence of HAuNPs, and some were still maintaining the 
hexagonal shape while others showed slight round shape or large aggregate 
(Figure 5.11C and 5.11D). Similarly, PAuNPs were seen in small 
agglomerates within vacuoles along the periphery of the nucleus (Figure 
5.11E). High magnification images confirmed numerous PAuNPs aggregate 
within the vacuoles and some maintained their pentagonal shapes (Figure 
5.11F). Furthermore, a small percentage of PAuNPs had already penetrated 
into the nuclei within 24 h (Figure 5.11G). Majority of TAuNPs were 
degraded into small nanoparticles and distributed evenly inside the cells, 
including the nuclei (Figure 5.11H). Only a small percentage of TAuNPs 
were still maintaining their shapes (Figure 5.11I). EDX of the cells exposed to 
AuNPs showed high concentration of gold inside the cells (Figure 11A). 
Quantitation of cellular uptake of AuNPs in MCF7 cells was conducted by 




ICP-OES (Figure 11B). MCF7 cells not exposed to AuNPs were used as 
control, which showed no gold inside the cells. The highest amount of gold 
content was observed in TAuNPs treated cells (0.40 ppm) while the least 
amount was found in HAuNPs treated cells (0.29 ppm).  
 
Figure 5.11: TEM images of untreated MCF7 cells (A) and MCF7 exposed 
with 50 µg/ml AuNPs for 24 h: MCF7 cells treated with HAuNPs (B – low 
magnification), magnified image of particles in nucleus (C), and cytoplasm 
(D); PAuNPs exposed cells – (E – low magnification), high magnification 
image of particles in cytoplasm (F), inside nucleus (G) and TAuNPs exposed 
cells with low magnification (H) and high magnification (I) images. The 
symbol n represents nuclei while c represents cytoplasm. 





Figure 5.12: EDX of TAuNPs treated cells (A) and concentration of gold in 
cells with AuNPs treatment (B) estimated using ICP-OES. Cells were treated 
with HAuNPs, PAuNPs and TAuNPs at the concentrations 100 µg/mL for 24 h, 
before ICP-OES measurement. The values represent the mean ± standard 
deviation of three independent experiments. The amount of gold concentration 
in control cells without AuNPs treatment was undetectable.  
5.3 Discussion  
Au NMs have been widely used in medical field such as drug delivery, 
bioimaging or phototherapy owing to low toxicity, easy surface modifications 
and interesting optical properties.7 A deeper understanding of the cytotoxicity 
of Au NMs including the mechanism is essential before extending their use in 
different biomedical sectors. The toxicity of Au NMs could be influenced by 
many factors such as size,9,27 shape,28 surface charge and functionalization.29-31 
However, majority of the published reports were focused on either spherical 
nanoparticles or rods with different aspect ratios.32-34 The current study 
establishes the shape sensitivity of AuNPs on cellular toxicity. The 
cytotoxicity of Au nanospheres was dependent on their size; smaller 
nanoparticles (< 10 nm) were more toxic than larger nanoparticles (> 50 




nm).27, 35 Further, the cellular uptake and cytotoxicity of Au nanospheres were 
influenced by their surface functionalization,36 charge30 and the 
hydrophobicity.31 In addition, the cytotoxicity of Au NMs were also affected 
by their shapes – Au nanorods induced apoptosis in human keratinocyte cell 
line (HaCaT) while Au nanospheres did not show such detrimental effects to 
cells.28 Detailed studies of shape effects on cytotoxicity of AuNPs in MCF7 
cells were explored in this study. AuNPs exhibited a dose- and 
shape-dependent toxicity to MCF7 cells with a reduction in ATP content and 
mitochondrial damages inside the cells. When the concentration of AuNPs 
with different shapes was increased from 25 µg/mL to 400 µg/mL, ATP 
amount inside the cell was significantly decreased (HAuNPs: from 88% to 
40%; PAuNPs: 76% to 12% and TAuNPs: 60% to 8%). TAuNPs showed the 
highest toxicity to MCF7 cells, followed by PAuNPs and then HAuNPs. 
Further, toxicity of AuNPs did not show any changes with increase in the 
incubation time from 24 h to 48 h, or 72 h. This indicates that toxicity 
response of AuNPs occurs within 24 h. Oxidative stress has been reported to 
be reason for toxicity of Au nanospheres, which could cause oxidative damage 
to protein and DNA.37, 38 Since ROS plays an important role in various 
pathogenic processes, it has been recognized as an early indicator for cytotoxic 
events and cellular disorders. Early studies indicated that exposure to Au nps 
induced the endogenous ROS production.31 This oxidative stress could initiate 
the autophagic process to protect the cells,39 which then destroys foreign 
molecules.31 Since Au nps are not easy to be digested or removed from cells, a 
dose-dependent oxidative stress (Figure 5.8), inside the cells lead to DNA 
damage. Condensed or fragmented nuclei were observed in DAPI stained cells 
treated with AuNPs (Figure 5.9). G2/M arrest induced by AuNPs in the cell 
cycle analysis showed a reversible DNA damage (Figure 5.10), indicating 
retarded cell proliferation. It allowed cells extra time to repair DNA damage 
prior to segregation of chromosomes. However, the reduction of ATP content 
(Figure 5.5) induced by AuNPs may affect the DNA repair, as ATP plays 




multiple roles in the repair of DNA damage.40,41  
 
Figure 5.13: Interior angles and stability of AuNPs with different shapes. 
Interior angles of TAuNPs, PAuNPs and HAuNPs are 60°, 108° and 120°, 
respectively. The sharper of the angles, the higher surface energy of the 
vertices’ atoms, as it interact with less number Au atoms. Instability of Au 
atoms at the vertices inside the cells: Triangle > Pentagon ≈ Hexagon. TEM 
images of ultrathin sections of TAuNPs treated cells confirmed their 
degradation inside the cytoplasm. Only individual or aggregate of AuNPs were 
observed inside the cells with HAuNPs and PAuNPs treatment. Symbol n 
represent nucleus and c represents cytoplasm. 
The stability of AuNPs also plays significant effect in their physical 
translocation inside the cell and cytotxoic effects. Interior angles of TAuNPs, 
PAuNPs and HAuNPs are 60°, 108° and 120°, respectively (Figure 5.13). The 
number of Au atoms exist at the vertices is proportional to the sharpness of 
edges and value of interior angles of Au nanoplates. The atoms at the edges 
have minimum interaction with those in the lattice of the particles and thus 
show higher reactivity. TEM images of cells with Au nanoplates treatment 
showed that both HAuNPs and PAuNPs were remained in their original shape 
(Figure 5.11). However, TAuNPs were degraded into small nanoparticles 
(Figure 5.11) which were evidenced from EDX data (Figure 5.12A). 
Moreover, the sharper angle of Au nanoplates, the easier for them to penetrate 
inside the cells. ICP-OES data of cells with Au nanoplates treatment indicated 
that TAuNPs showed the maximum cell permeability within 24 h (Figure 




5.12B), which amplifies the toxicity. All data presented in this paper suggest 
that the cytotoxicity of Au nanoplates was shape - and dose - dependent. A 
recent study showed that spherical Au nps affected the epidermal growth 
factor signal transduction in human epithelial cells even at a nontoxic dose (5 
and 25µg/ml).42 Therefore, further studies are necessary to explain a complete 
mechanism of cell damage caused by AuNPs before applying them in future 
applications.   
5.4 Conclusion  
Three AuNPs (HAuNPs, PAuNPs and TAuNPs) were synthesized using 
alkaline earth cations (Ca2+), characterized with various techniques and 
evaluated for their cellular responses using a commercial cancer cell line  
MCF7. This study demonstrated that Au NMs exhibited a dose- and 
shape-dependent toxicity to MCF7 cells, which could be resulted from 
oxidative stress caused by ROS production with AuNPs treatment. The shape 
effects of AuNPs on their toxicity are closely related to the sharp angle and the 
high cell permeability of nanoplates. Therefore, TAuNPs with sharp angle 
(60°) showed the most toxicity as compared to PAuNPs and HAuNPs. Similar 
results were also observed in human dermal fibroblast cells. Therefore, special 
attention should be given and further studies are needed to perform to explore 
the cellular responses of AuNPs more deeply before incorporating them into 
bioapplications. 
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Nanotechnology nanomaterials have been used in many areas such as 
electronics, engineering, pollutant remediation, therapeutics, diagnostic 
devices and personal care products.1-5 Cancer, including colon cancer, has 
been widely accepted by the scientific community as a “stem cell disease”. 6-9 
Cancer stem cells (CSCs), isolated from a variety of tumor types, are the cell 
populations responsible for the development of tumor and have important role 
in cancer recurrences. Therefore, these cells are of particular importance to 
explore innovative cancer therapies.10 
The mechanism of toxicity of the nanomaterials is not yet fully elucidated, 
previous studies have indicated that the physico-chemical properties of 
nanomaterials (size, shape, surface charge, chemical composition and 
solubility) play vital roles in the induced biological responses.13-19 Earlier 
studies have indicated that silver nanoparticles (Ag nps) could cause 
morphological changes, damage to cell membrane, disruption of the 
mitochondrial respiratory chain, interruption of ATP synthesis, reactive 
oxygen species (ROS) generation, and further induce cell cycle arrest and cell 
apoptosis.20,21 A recent review reported that toxic effects of Au nps  are 
dependent on both cell types and capping agents used for stabilizing the 
nanoparticles.22 The formation of ROS within cells exposed to nanoparticles is 
considered to be a major contributor to their toxicological effects.23-25 Even at 
nontoxic doses, Ag and Au nps reduced cathepsin activity in Vero cells,26 
indicating their potential to impact a host's immune system. In addition, the 
introduction of Ag and Au nps (at low doses) within the human epithelial cells 
(A-431) was reported to impair their epidermal growth factor s ignal 
transduction.4 However, few studies have been explored for the potential 
disturbance induced by Ag and Au nps at low doses to colon CSCs with no 
toxic response. 




Normal stem cells, including embryonic stem cells (ESCs) and adult stem 
cells, have attracted particular attention in the field of regenerative medicine 
because of their pluripotency. Several groups have already explored the 
possibilities of using embryonic and fetal stem cells to produce dopaminergic 
cells for curing Parkinson’s disease.27 Mesenchymal stem cells could be 
implanted locally to promote or augment repair or regeneration of a fractured 
or osteoporotic bone.28 Skin stem cells can not only provide hope for the 
functional repair of the skin itself but also offer a potential source of adult 
stem cells for the cell-based therapy of injuries and diseases throughout the 
body.29 Various reports have shown that nano based materials can facilitate 
stem cell therapy for bone engineering30 and wound healing.31 Directed 
differentiation of stem cells into certain types of cells is one of the most 
important issues in ESCs research, which represent not only theoretical 
interest, but also show potential application on cell or tissue therapy for curing 
serious human diseases.32 Human ESCs (HESCs) can differentiate into 
cardiomyocytes under low serum concentration supplemented with bone 
morphogenetic protein-2,33 otherwise they may differentiate into hepatic cells 
in serum-free medium with both fibroblast growth factor-4 and bone 
morphogenetic protein-2.34 Besides growth factors and specific genes, 
numerous microenvironmental cues such as soluble chemicals and adhesive 
contexts can also affect physiologically relevant differentiation responses of 
stem cells. Au nps can promote the differentiation of mesenchymal stem cells 
toward osteoblast cells over adipocyte cells through p38 MAPK Pathway.35 
Furthermore, Laura A. Smith et al.36 proposed that nano-fibrous architecture 
could enhance the osteogenic differentiation of the HESCs compared to more 
traditional scaffolding architectures. Even C. Greulich et al.37 found that Ag 
nps exert cytotoxic effects on human mesenchymal stem cells at high 
concentrations but also induce cell activation (as analyzed by the release of 
IL-8) at high but nontoxic concentrations of nanosilver. Both in vitro and in 
vivo, studies have already unveiled evidences of significant toxicity associated 




with Ag nps.38,39 However, until now, little is understood about the effects and 
mechanisms of Ag nps on HESCs. 
The first part of the present study investigates the cellular responses of Ag 
and Au nps with similar size and morphology, but with different composition, 
to colon CSCs. The study was carried out with special emphasis on the 
toxicological effects of nanoparticles at relative low doses and their effects on 
gene expressions. Moreover, nanoparticles were characterized using electron 
microscopy (TEM), dynamic light scattering (DLS), element analysis, UV-Vis 
absorption and X-ray diffraction (XRD). The cellular responses of colon CSCs 
treated with Ag and Au nps at low doses are evaluated by changes in viability, 
ROS generation, morphological changes of nuclei, cell cycle arrest and 
changes in gene expression. The second part of the study focuses on the effect 
of Ag nps to undifferentiated HESCs and the embryoid body (EB, 
differentiation state) at relatively low doses.  
6.2 Results and discussion  
6.2.1 Characteristics of Ag and Au nps 
Synthesized Ag and Au nps were characterized with a combination of 
analytical techniques in order to measure their primary physical and chemical 
properties. TEM images revealed that Ag and Au nps form homogeneous 
colloids in water with no signs of agglomeration (Figure 6.1). The size of Ag 
nps is in the range of 6 to 18 nm, while that of Au nps was in a narrower range 
from 2 to 14 nm. Both Ag and Au are water dispersible owing to their 
hydrophilic capping agents. PVP was selected as the capping agent also due to 
its high compatibility with biological systems.40 





Figure 6.1: TEM images of Ag (A) and Au (B) nanoparticles and the 
histogram of size distribution of these two nanoparticles based on their TEM 
images. 
The hydrodynamic size of Ag and Au nps suspensions in water, PBS, 
serum free media and media with serum were detected to check their 
agglomeration in different dispersants (Table 6.1). DLS measurements showed 
that the average hydrodynamic diameters of Ag (109.8 nm) and Au nps (86.7 
nm) in water were larger than their TEM size. This could be attributed to the 
fact that the hydrodynamic size of nanoparticles includes not only the core 
particles but also their organic layers and the hydration shell.41 The average 
hydrodynamic size of Ag and Au nps in PBS is 82.7 nm and 93.7 nm, which 
are similar to the size in water. Significant increase of hydrodynamic size of 
Ag (1083.7 nm) and Au nps (3399.5 nm) were observed in serum free media 
indicating pronounced agglomeration of Ag and Ag nps. The dispersal of 
nanoparticles in media was improved by the addition of serum, the average 
hydrodynamic size of Ag (50.8 nm) and Au (32.7 nm) nanoparticles in media 
with serum decreased. The surface charge of these nanoparticles was 
determined by measurement of their zeta potential (Table 6.1), indicating that 
the surface charge of nanoparticles were dependent on their dispersant. The 
negative surface charge of Ag nps (-24.5 mV) decreased when dispersed them 
in media with or without serum (-11.3 and -10.1 mV), similar results were also 
found for Au nps. 
 




Table 6.1: Hydrodynamic diameter size and zeta potential of Ag and Au nps in 
H2O, PBS, serum free media and media with serum* 
 
 Hydrodynamic diameter nm 
H2O PBS serum free media media with serum 
Ag nps 109.8 ± 1.4 82.7 ± 1.9 1083.7 ± 6.7 50.8 ± 1.9 
Au nps 86.7 ± 3.3 93.7 ± 8.4 3399.5 ± 202.9 32.7 ± 8.4 
 
Zeta potential mV 
H2O PBS serum free media media with serum 
Ag nps -24.5 ± 0.3 -9.2 ± 0.8 -11.3 ± 0.8 -10.1 ± 0.2 
Au nps -29.0 ± 1.1 -12.2 ± 1.4 -8.7 ± 0.8 -8.3 ± 0.6 
*The average hydrodynamic size and zeta potential of Ag and Au nps 
suspended in water, PBS, media without serum and media with serum. The 
working concentration of nanoparticles suspensions were prepared by mixing 
20 µl of the original nanoaprticles solution (stock concentration of 1 mg/mL) 
to 1 mL of water, PBS or media with/without serum and kept at room 
temperature overnight. All measurements were done in triplicates, and the 
values were shown in average ± SD. 
 
Table 6.2: Chemical composition (in wt%) of Ag and Au nps. 
Element C wt% H wt% N wt% M wt% 
O wt% 
(estimate) 
C/Ag or C/Au 
atom  ratio 
Ag nps 7.95 1.24 2.33 Ag 52.88 35.60 1.35 
Au nps 7.07 1.05 1.66 Au 65.74 24.48 1.76 
The chemical composition of Ag and Au nps were measured using 
elemental analysis, the summarized data were shown in Table 6.2. It is clearly 
showed that the ratio of capping agent to gold in Au nps is high (high carbon 
to gold ratio 1.76). On the contrary, low carbon to silver was observed for Ag 
nps (1.35). Oxygen contents of both Ag and Au nps were found to be higher 
than expected due to their hygroscopic nature.  
The crystalline structure of Ag and Au nps were detected by XRD. The 
XRD peaks of Ag nps at 2θ degrees of 38°, 44°, 64°, 77°and 81° can be 
attributed to the 111, 200, 220, 311 and 222 crystalline planes of the face 
centered cubic (fcc) structure of silver (JCPDS file No. 00–004–0783).42 
Similarly, the XRD peaks of Au nps can also be attributed to 111, 200, 220 and 




311 crystalline structure of the face centered cubic (fcc) structure of gold 
(JCPDS file No. 00–004–0784). Surface plasmon resonance (SPR) properties 
of Ag and Au nps in water were characterized using UV-Vis-NIR 
spectrophotometer. The number of SPR peaks of nanoparticles was dependent 
on their symmetry: spherical nanoparticles showed one peak while multiple 
peaks were often observed for cubic structures or triangular nanoplates.43 
Single SPR peaks of Ag (400 nm) and Au (550 nm) nanoparticles confirmed 
their spherical shape (Figure 6.2).  
 
Figure 6.2: XRD (A) pattern and UV-Vis absorption (B) of Ag and Au nps. 
6.2.2 Ag and Au nps to colon CSCs 
6.2.2.1 Viability 
The viability of colon CSCs treated with Ag and Au nps at low 
concentrations were measured with resaruzin assay (Figure 6.3A). No toxicity 
of Ag nps were found at the concentration 2.5 µg/mL or less, and viability of 
cell was around 90% for cells treated with fresh prepared Ag nps at 5 and 10 
µg/mL, indicating Ag nps showed high biocompatibility at low concentrations. 
Similar results were observed in colon CSCs treated with Au nps. Au nps 
showed no toxicity to colon CSCs at 5 µg/mL or less, and caused 10% cell 
death at a concentration of 10 µg/mL. Further we also examined the toxic 
effect Ag and Au ions with similar amount of metal as nanoparticles used 
based on their elemental analysis results (Ag: 52.88 wt%; Au: 65.74 wt%). It 




is clearly showed that Ag ions were more toxic than Ag nps (Figure 6.3B). Ag 
ions killed almost 90% cells at the concentration 2.6 and 5.3µg/mL (equal to 5 
and 10 µg/mL for Ag nps). On the contrary, Au ions showed low toxicity to 
cells at a concentration of 6.6 µg/mL (equal to 10 µg/mL for Au nps) with 
around 90% viability (Figure 6.3C).  
 
Figure 6.3: Viability of colon CSCs treated with Ag and Au nps (A), Ag ions 
(B) and Au ions (C) at different concentrations for 3 days. The concentrations 
for Ag and Au nps were 0, 0.1, 0.25, 0.5, 1, 2.5, 5, 10 µg/mL. And the 
concentration of Ag and Au ions used in this experiment were calculated based 
on their elemental analysis results.  
6.2.2.2 Intracellular ROS generation  
The introduction of ROS was generally used as a measure for oxidative 




stress.44 The intracellular ROS production induced by Ag and Au nps in colon 
CSCs was detected by applying the fluorescent DCF-DA assay (Figure 6.4). 
After 24 h incubation, no morphology changes could be observed from optical 
microscope images. Further, no green fluorescence was observed in control 
(untreated cells) while green fluorescence was observed in Ag and Au nps 
treated cells. The images also indicated a dose-dependent increase in ROS 
production. Both Ag and Au nps were found to significantly induce ROS 
production in concentrations ≥ 0.1 mg/ml. The fluorescence intensity of cells 
increased as the concentration of nanoparticles increased from 0.1 µg/mL to 
10 µg/mL. Moreover, ROS production of cells treated with Ag nps is more 
sensitive as compared to Au nps treated ones. Almost all cells treated with Ag 
nps showed fluorescence at a concentration of 0.1 µg/mL, while very few cells 
showed fluorescence with Au treatment at the same concentration (0.1 
µg/mL). 
 
Figure 6.4: Phase contrast images (A and C) and DCF-DA staining (B and D) 
images of colon CSCs treated with Ag and Au nps at different concentrations 
(0, 0.1, 1, and 10 µg/mL) for 24 h. 




6.2.2.3 Cell cycle analysis 
To check DNA damage of colon CSCs treated with Ag and Au nps, cell 
cycle analysis was performed using fluorescence PI staining. Cells with 
reversible DNA damage usually accumulate in gap1 (G1), DNA synthesis (S), 
or in gap2/mitosis (G2/M) phase while cells with irreversible DNA damage 
will accumulate in subG1 phase. Our cell cycle analysis showed that Ag and 
Au nps exert little influence on the cell cycle progression at low 
concentrations (0.1, 1 and 10 µg/mL) during a period of 3 days (Figure 6.5). 
 
Figure 6.5: Cell cycle of colon CSCs untreated (A) and treated with Ag nps 
0.1 µg/mL (B), 1 µg/mL (C), 10 µg/mL (D) and Au nps 0.1 µg/mL (E), 1 
µg/mL (F) and 10 µg/mL (G) for 3 days. Cell cycle analysis was divided into 
four phases: SubG1 (R1), G1 (R2), S (R3) and G2/M (R4).  
6.2.2.4 DAPI staining  
Morphological changes of cell nuclei induced by nanoparticles were 
detected by DAPI staining (Figure 6.6). Cell shrinkage, fragmented or 
condensed nuclei indicates cells either undergoing apoptosis or arrest in cell 
division.45,46 Majority of control cells showed uniformly stained nuclei. A 




small increase in condensed or fragmented nuclei was observed for Ag and Au 
nps treated cells at concentrations of 0.1 and 1 µg/mL. However, more 
condensed and fragmented nuclei were observed in cells treated with higher 
concentrations (10 µg/mL) of Ag and Au nps.  
 
Figure 6.6: Nanoparticles induced nuclear morphology changes in colon 
CSCs stained with DAPI: A and E control cells (untreated cells), B Ag nps (0.1 
µg/mL), C Ag nps (1 µg/mL), D Ag nps (10 µg/mL), F Au nps (0.1 µg/mL), G 
Au nps (1 µg/mL) and H Au nps (10 µg/mL). 
6.2.2.5 Real-time RT-PCR analysis 
To investigate the impact of Ag and Au nps exposure to colon CSCs at 
lower concentrations (0.1, 1 and 10 µg/mL), gene expression changes of cell 
treated with nanoparticles for 3 days were analyzed by real-time PCR. Several 
key members of the MAPK-Jnk pathway (MAPK9, NFATC3, and TP53), 
which are known to be induced by stress and often leads to cellular apoptosis, 
were detected in our experiments. The epidermal growth factor receptor 
(EGFR) signaling pathway is one of the most important pathways which 
regulate growth, survival, proliferation, and differentiation in mammalian 
cells.47 Changes on EGFR and EPS8 gene were also analyzed after Ag and Au 
nps treatment. The activation of EGFR could induce a specific pathway for the 
Ras/Erk cascades, several genes (BRAF, an upstream kinase of Erk; DUSP1 
and DUSP6, the negative regulation of the Ras/Erk cascade) were further 
examined in our study. As can be seen in Table 6.3, Ag and Au nps induced 
changes in gene expression at a low concentration of 1 µg/mL and no 




interference of gene expression was observed at extremely low concentration 
(0.1 µg/mL). Up-regulated MAPK9 together with down-regulated NFATC3 
observed with Ag nps treatment (10 µg/mL) were antagonized by a concurrent 
decrease in TP53, indicating low cell apoptosis response. Further, the 
up-regulated DUSP1 and DUSP6 together with down-regulated EGFR, and 
EPS8 suggest a suppression of Ras/Erk cascade by Ag nps. Interestingly, Au 
nps attempted to enhance cellular proliferation evidenced by the gene 
expression data. Au nps induced down-regulation of MAPK9 and NFATC3, 
suggesting that Au nps showed a tendency toward enhanced cell survival. 
Moreover, the down-regulated DUSP6 induced by Au nps treatment may 
antagonize the negative effects on Ras/Erk cascade caused by the decreased 
B-Raf, EGFR and EPS8. 
Table 6.3: Gene expression changes of colon CSCs treated with Ag and Au 
nps. 























MAPK that induces 
apoptosis 




downstream of Jnk 
- -1.27 *  -1.28 *   - -1.71* -3.41* 
TP53 
inhibit pro liferat ion, 
cause apoptosis 
- - -1.32 *   - - - 
BRAF 
proto-oncogene 
involved in Ras/Erk 
signaling 













- - -1.28 *   - -1.43* -3.19* 





part of the EGFR 
pathway with 
unknown role  
- -1.30 *  -1.67 *   - - -3.35* 
aGenes checked in our experiments. “*” denotes p< 0.05 and“-”indicates that 
no statistically significant change occurred.  
Ag and Au nps are two of the most commonly used nanomaterials 
incorporated into commercial products. For in vitro studies, researches were 
focus on various cell lines which include both cancer and normal cell lines. 
However, limited work has done on cancer stem cells (CSCs) which exhibit 
vital importance in exploring innovative cancer therapies.9,10 Ag and Au nps 
used in this study showed varied colloid stability in different solvent. 
Agglomeration of nanoparticles was observed in serum free media with a 24 h 
incubation period. Addition of serum in the cell media enhances the stability 
of Ag and Au nps which exhibited remarkable stability in the cell media. No 
agglomeration and precipitation were observed throughout the test period. 
Nanoparticle stability is a major concern in nanotoxicology, which may affect 
the test interpretations as unstable nanoparticles precipitate to metal clumps 
during experiments. In the case of water-insoluble nanoparticles the carrier 
solvents may cause toxic effects to cells. Therefore, it would be ideal to use 
water as a carrier solvent to test nanoparticle toxicity. The water- insoluble 
nanoparticles might be less affective to cells due to phase separation. PVP is a 
biocompatible agent which possesses the advantages of being non-toxic and 
good water-soluble stabilizing agents for nanoparticles. 
Our results suggest that Ag and Au nps showed a concentration-dependent 
toxicity to colon CSCs, they were nontoxic at low concentrations (≤ 2.5 
µg/mL) and started to cause cell damage at higher concentrations (5 and 10 
µg/mL). Indication of toxicity was observed by the drop in cell viability. As 
compared to Ag nps, Ag ions were much more toxic which caused cell death at 
much lower concentration (0.53 µg/mL, which contains same amount of silver 
equals to 1 µg/mL for Ag nps) and killed almost all the cells at 2.64 µg/mL 
(equals to 5 µg/mL for Ag nps). However, similar toxic effects were observed 




for both Au ions and Au nps at concentrations which contained same amount 
of gold. An earlier report showed that the toxicity of Ag nps increased during 
long storage due to slow dissolution under release of Ag ions,48 so freshly 
prepared Ag and Au nps were used in our experiments. Due to their low 
toxicity at low concentrations, no significant cell cycle arrest was observed for 
cells with Ag and Au nps treatment. Intracellular ROS production showed that 
nanoparticles induced oxidative stress to cells even at low concentrations. 
Earlier reports showed that oxidative stress induced by nanoparticles was 
considered as the trigger for DNA damage which may further induce cell 
apoptosis.49-51 TiO2 nanoparticles induced significant oxidative DNA damage 
and caused apoptosis in HepG2 cells at very low concentrations (1 µg/mL).3 
DAPI staining results in our study indicates that Ag and Au nps exhibited 
cell-dependent morphological changes of cell nuclei, which is consistent with 
our viability data. RT-PCR results showed that they also affected the gene 
expressions at low concentrations. Slight impact on gene transcription was 
observed in cells with Ag nps treatment indicates that it may not the leading 
cause for silver nanotoxicity, but it may work in conjunction with ROS 
production to increase cell damage. Gene interference was also observed for 
Au nps at low concentrations, which may attract much more concerns. Over 
the past decades, Au nps have been extensively studied for biological and 
medical applications such as drug delivery,52 cancer imaging53 and cancer 
therapies.54 Careful design and synthesis of Au nps and their implementation 
in gene expression might be useful in the development of cancer therapy.  
6.2.3 Ag nps effects to HESCs 
6.2.3.1 Viability of HESCs with Ag nps treatment 
The toxic effects of Ag nps to undifferentiated HESCs cells or embryoid 
body (EB) were detected with rezarurin assay. Undifferentiated HESCs cells 
and EB were prepared, treated with Ag nps with different concentrations (0, 
0.1, 1 and 10 µg/mL) of Ag nps and incubated at 37 °C for 3 days. Ag nps did 




not cause any toxic effect to the undifferentiated HESCs at low concentrations 
(Figure 6.7A). Similar results were observed in EB with Ag nps treatment 
(Figure 6.7B). 
 
Figure 6.7: Viability of undifferentiated HESCs and EB treated with Ag nps 
(0, 0.1, 0.5, 1, 2.5, 5 and 10 µg/mL) for 3 days. 
6.2.3.2 Morphological changes of HESCs treated with Ag nps  
As we already known that Ag nps did not cause any damage to the HESCs 
at low concentrations, their effect to HESCs cell morphological changes was 
further investigated. Morphological changes of undifferentiated HESCs treated 
with Ag nps (0, 1 and 10 µg/mL) were observed under an inverted microscope 
at different incubation time (1 day, 3 days and 5 days). As can be seen from 
Figure 6.8, slight differences of HESCs colony were only observed to cells 
treated with relatively high concentration of Ag nps (10 µg/mL) for 1 day. 
When the incubation time increases, significant differences were clearly 
shown indicating the effect of Ag nps to HESCs at the concentration 10 µg/mL. 
After 5 days treatment, slight differences were also found in HESCs colony 
with Ag nps at 1 µg/mL. 





Figure 6.8: Morphological changes of undifferentiated HESCs colony treated 
with Ag nps (0, 1 and 10 µg/mL) for 1 day, 3 days and 5 days. 
6.2.3.3 Morphological changes of EB treated with Ag nps 
Morphological changes of EB with Ag nps treatment were further 
examined by the inverted microscope. EB were prepared through culture 
HESCs colony in untreated cell culture plates to form 3 dimensional cell 
colonies. EB were treated with different concentrations (0, 1 and 10 µg/mL) of 
Ag nps and incubated for different periods. As can be seen from Figure 6.9, 
Ag nps caused the morphology changes of EBs as compared to untreated cells. 
The higher the concentration of Ag nps and the longer incubation time, the 
more significant morphological cell changes were observed in the images. 
Moreover, the black dots and objectives observed in EBs with 10 µg/ml Ag 
nps treatment were considered as the aggregate of Ag nps.   





Figure 6.9: Morphological changes of EB treated with Ag nps (0, 1 and 10 
µg/mL) for 1 day, 3 days and 5 days. 
The cellular responses of HESCs to Ag nps were investigated and the 
results showed Ag nps did not cause much adverse effect to both the 
undifferentiated and differentiated HESCs cells at low concentrations. 
Moreover, the cell morphological changes were observed in cells with Ag nps 
treatment. The higher the concentration of Ag nps and the longer the 
incubation time, the higher morphological differences by Ag nps were 
observed. HESCs have the ability to differentiate into different cell lines, 
which plays significant roles in stem cell therapies and tissue implanting. The 
effect of Ag nps to the differentiation of HESCs was planed to expolore 
through the gene expressions. The whole human genome of HESCs with Ag 
nps treatment is examined through microarray analysis by Origen Lab (Origen 
Laboratories Pte Ltd, Singapore). The microarray data analysis is in process 
and the results will be discussed in our future work.   
6.3 Conclusion 
The present study investigates the cytotoxicity and genotoxicity of Ag and 
Au nps on human colon cancer stem cells (CSCs). The size and shape of both 
Ag and Au nps were kept the same throughout the study. The viability results 




suggest that both Ag and Au nps were relatively nontoxic to colon CSCs and 
more than 80% cells were still alive even at the concentration 10 µg/mL. 
Although the intracellular ROS generation suggests that Ag and Au nps 
induced oxidative stress to CSCs, no interference on cell cycle progression 
was observed with Ag and Au nps treatment, even at the high concentration 
(10 µg/mL). Gene expression interference observed in the RT-PCR results 
clearly showed that both Ag and Au nps induced genotoxicity on CSCs even at 
relatively low doses (1 and 10 µg/mL). Future studies on their effects on 
whole human genome are still needed to fully understand their potential 
toxicity to humans due to the increasingly prevalence of Ag and Au nps in 
everyday products and medical procedures.  
The cellular responses of Ag nps to HESCs were also examined in our 
study. Ag nps exhibited induced cell morphological changes to HESCs at low 
concentrations without causing any adverse effect to the cell viability. 
Carefully design to control the differentiation of HESCs into special cell lines 
will play vital roles in stem cell therapies and tissue implanting in the future.  
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The primary objectives of this study were to investigate cytotoxicity of Ag 
and Au NMs with different surface functional groups and shapes. It was found 
that nanomaterials with different characteristics showed diverse toxicity to 
cells. The toxicity results indicate that the toxicity of novel nanomaterials with 
different properties could not be deduced from earlier knowledge and results, 
as a very small difference of the properties of nanomaterials could induce huge 
changes in toxicity. Further, cell cycle and gene expression of cells, the 
mechanism of nanotoxicity of Ag and Au NMs was explored through the 
examination of changes of mitochondria activity. 
Cytotoxicity of Ag nps with different functional groups was examined 
(Chapter 3), especially for those with plant extracts as functional groups. 
Among three plant extracts capped Ag nps, Ag-mint were the most toxic, 
followed by Ag-ginger, and then by Ag-coffee. In addition, it was found that 
the toxicity of Ag nps was not caused by oxidative stress, as the ROS of Ag 
nps treated cells did not increase but actually decreased. This can be 
adequately explained by the high antioxidant activity of plant extracts. 
Moreover, the cell cycle study showed that Ag-ginger and Ag-coffee nps 
induced cell arrest in S and G2/M stage, indicating a reversible DNA damage. 
However, Ag-mint nps were believed to cause cell death through apoptosis, 
which was confirmed by cell arrest in Sub G1 stage. In conclusion, the results 
demonstrated that Ag nps with different capping agents induced different 
toxicities in human tumor cells. 
Cytotoxicity of Ag and Au NMs with different morphologies was 
discussed in Chapter 4 and 5. Nanomaterials with different morphologies 
showed different properties, which may further cause different toxicities to 
cells. Among the three Ag NMs (Ag nanocube, Ag truncated nanocube and Ag 
nanowire), Ag nanocubes were the most toxic, which could be attributed to 
their relatively sharp edges and high instability. The high dissolution effect of 
Ag nanocubes was confirmed by the silver ion release experiment. Similarly, 




among the three AuNPs (HAuNPs, PAuNPs and TAuNPs), TAuNPs were the 
most toxic. The relatively sharp angles and high surface potential energy of 
TAuNPs enabled them to penetrate cell membrane and degrade inside the cells 
more easily. Furthermore, cellular uptake of Ag NMs examined by SEM and 
confocal microscope showed that Ag NMs were only penetrated inside the 
cytoplasm but not the nucleus of cells. Nevertheless, cellular uptake of Au 
NMs examined by TEM showed that Au NMs could penetrate and be 
distributed in both cytoplasm and nucleus part of cells.  This is especially for 
the case of TAuNPs, as TAuNPs were evenly distributed throughout the whole 
area of cells. The ROS resulted indicate that oxidative stress could be the 
possible reason to cause cell toxicity, which further induced DNA damage. All 
the data put together indicated that the toxicity of nanomaterials is very 
sensitive, which could be influenced by many factors such as the components, 
the surface group, the size, the shape and the chemical potential energy of 
nanomaterials. The results also showed that the level of ROS which was either 
too high or too low could induce DNA damage and then cause cell damage.  
Last but not the least, cytotoxicity and genotoxicity of Ag and Au nps on 
stem cells were reported in Chapter 6. The results of cell morphology changes 
and cell viability showed that Ag and Au nps did not cause cytotoxicity to 
colon cancer stem cells at low concentrations. However, gene expression 
interference observed in the RT-PCR results clearly showed that Ag and Au 
nps induced genotoxicity to CSCs even at relatively low doses (1 and 10  
µg/mL). Moreover, Ag nps exhibited induced cell morphological changes to 
HESCs at low concentrations without causing any adverse effect to the cell 
viability. HESCs have the ability to differentiate into different cell lines, which 
plays significant roles in stem cell therapies and tissue implanting. The effect 
of Ag nps to the differtiation of HESCs is planed to explore and report in the 
near future. At the meantime, long-term chronic toxicity of Ag NMs will also 
need to be carefully investigated in the future.  
